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vPrefACe
The monographs contained in this volume were prepared at the eightieth meeting of the 
Joint Food and Agriculture Organization of the United Nations (FAO)/World Health Organiza-
tion (WHO) Expert Committee on Food Additives (JECFA), which met at FAO headquarters in 
Rome, Italy, on 16–25 June 2015. These monographs summarize the data on selected food 
additives reviewed by the Committee. Monographs on two contaminant groups discussed 
at the meeting will be published as separate supplements in the WHO Food Additives series.
 The eightieth report of JECFA will be published by WHO in the WHO Technical Report 
series. Reports and other documents resulting from previous meetings of JECFA are listed in 
Annex 1. The participants in the meeting are listed in Annex 3 of the present publication. A 
summary of the conclusions of the Committee with respect to the food additives discussed 
at the meeting is given in Annex 4.
 JECFA serves as a scientific advisory body to FAO, WHO, their Member States and 
the Codex Alimentarius Commission, primarily through the Codex Committee on Food Addi-
tives, the Codex Committee on Contaminants in Food and the Codex Committee on Residues 
of Veterinary Drugs in Foods, regarding the safety of food additives, residues of veterinary 
drugs, naturally occurring toxicants and contaminants in food. Committees accomplish this 
task by preparing reports of their meetings and publishing specifications or residue mono-
graphs and dietary exposure and toxicological monographs, such as those contained in this 
volume, on substances that they have considered.
 The monographs contained in this volume are based on working papers that were 
prepared by WHO experts. A special acknowledgement is given at the beginning of each 
monograph to those who prepared these working papers. The monographs were edited by 
M. Sheffer, Ottawa, Canada.
 The designations employed and the presentation of the material in this publica-
tion do not imply the expression of any opinion whatsoever on the part of the organizations 
participating in WHO concerning the legal status of any country, territory, city or area or its 
authorities, or concerning the delimitation of its frontiers or boundaries. The mention of spe-
cific companies or of certain manufacturers’ products does not imply that they are endorsed 
or recommended by the organizations in preference to others of a similar nature that are not 
mentioned.
 Any comments or new information on the biological or toxicological properties of 
or dietary exposure to the compounds evaluated in this publication should be addressed to: 
WHO Joint Secretary of the Joint FAO/WHO Expert Committee on Food Additives, Depart-
ment of Food Safety and Zoonoses, World Health Organization, 20 Avenue Appia, 1211 Gene-
va 27, Switzerland.

1sPeCIfIC fooD ADDItIVes 

3Benzoates: dietary exposure assessment 
first draft prepared by 
Hae Jung Yoon1 and Michael Dinovi2
1 Food Contaminants Division, Food Safety Evaluation Department, Ministry of Food and 
Drug Safety, Cheongwon-gun, Chungcheongbuk-do, Republic of Korea 
2  Office of Food Additive Safety, Center for Food Safety and Applied Nutrition, Food and 
Drug Administration, College Park, Maryland, United States of America (USA)
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1.  explanation
At the request of the Codex Committee on Food Additives (CCFA) at its Forty-
sixth Session (FAO/WHO, 2014), the Committee evaluated dietary exposure 
to benzoic acid salts (benzoates). The Twenty-seventh Session of the Codex 
Alimentarius Commission (FAO/WHO, 2004) adopted the maximum level of 
benzoates (600 mg/kg) in Codex General Standard for Food Additives (GSFA) 
food category 14.1.4 on an interim basis with the understanding that a review 
would be conducted within 3 years. The safety of benzoates had been reviewed at 
the forty-sixth meeting of the Committee (Annex 1, reference 122), and the group 
was assigned an acceptable daily intake (ADI) of 0–5 mg/kg body weight (bw), 
expressed as benzoic acid.
 The fifty-first meeting of the Committee (Annex 1, reference 137) 
assessed dietary exposure to benzoates from all categories of food based on 
maximum limits specified in national standards and in the GSFA. The estimates 
of national exposures for consumers at the mean, based on national maximum 
limits, were below the upper bound of the ADI, ranging from 0.18 mg/kg bw per 
day (in Japan) to 2.3 mg/kg bw per day (in the USA). The estimated exposures at 
higher percentiles, based on food additive levels in national standards, exceeded 
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the upper bound of the ADI in some cases (7.3 mg/kg bw per day, 150% of the 
upper bound of the ADI, in the USA; or 14 mg/kg bw per day, 280% of the upper 
bound of the ADI, in China). The Committee stated, “Because diets differ among 
countries, the foods that contribute most to benzoate intake would be expected 
to vary” (the present Committee noted that varying use levels in similar products 
across countries would also affect the order of importance of their contribution 
to dietary exposure to benzoates). For Australia, France, New Zealand, the United 
Kingdom and the USA, the GSFA food category that contributed the most to 
dietary exposure to benzoates was carbonated water-based flavoured drinks 
(GSFA food category 14.1.4.1). In Finland, 40% of the benzoates used in food 
was in soft drinks. Soya sauce was the main source in China and the second most 
important source in Japan.
2. Data submitted or available to the Committee
Maximum use levels of benzoates in 59 food categories from the GSFA have been 
adopted. Although all data necessary for an assessment of dietary exposure to 
benzoates were requested, only benzoate use levels reported from industries for 
non-alcoholic beverages (seven subcategories of GSFA food category 14.1) were 
submitted for this assessment. A total of 796 individual branded products from six 
countries – Australia (n = 18), Brazil (n = 284), China (n = 33), Mexico (n = 152), 
South Africa (n = 42) and the USA (n = 267) – were submitted by the International 
Council of Beverages Associations (ICBA). Table 1 summarizes the submitted 
data. Use levels of “0” were reported when there was no use of benzoates; the use 
level of benzoates in GSFA food category 14.1.5 (Coffee, coffee substitutes, tea, 
herbal infusions, and other hot cereal and grain beverages, excluding cocoa) was 
reported to be “0” by all six countries. The use level of benzoates in GSFA food 
category 14.1.3.4 (Concentrates for vegetable nectar) from Mexico was reported 
as “0”; the remaining countries did not submit any data for this food category. The 
“average typical” and “maximum” reported use levels of benzoates for GSFA food 
category 14.1.2.1 (fruit juice) were reported only from the USA – 126 mg/L and 
229 mg/L, respectively. The average typical and maximum reported use levels of 
benzoates for GSFA food category 14.1.4 (water-based flavoured drinks) ranged 
from 83 to 209 mg/L and from 173 to 627 mg/L, respectively. 
 Norway submitted use level information for 86 products: soft drinks 
(weighted average 132.4 mg/L, maximum reported 148 mg/L), saft (a concentrate 
produced from fruit juice; weighted average 121.7 mg/L, maximum reported 173 
mg/L) and flavoured water (weighted average 109 mg/L, maximum reported 131 
mg/L). The data from Norway are also summarized in Table 1.
5Benzoates: dietary exposure assessment 
Country GSFA food category
Number of 
entries
Average typical 
reported use  
level (mg/L)
Maximum  
reported use  
level (mg/L)
Australia 14.1.2.1 Fruit juice
14.1.2.3 Concentrates for fruit juice
14.1.3.1 Fruit nectar
14.1.3.3 Concentrates for fruit nectar
14.1.3.4 Concentrates for vegetable nectar
 14.1.4 Water-based flavoured drinks, including “sport”,   
  “energy”, or “electrolyte” drinks and particulated drinks
 14.1.5 Coffee, coffee substitutes, tea, herbal infusions, and  
  other hot cereal and grain beverages, excluding cocoa
0
0
0
0
0
18
0
NA
NA
NA
NA
NA
103
NA
NA
NA
NA
NA
NA
173
NA
Brazil 14.1.2.1 Fruit juice
14.1.2.3 Concentrates for fruit juice
14.1.3.1 Fruit nectar
14.1.3.3 Concentrates for fruit nectar
14.1.3.4 Concentrates for vegetable nectar
14.1.4 Water-based flavoured drinks, including “sport”, 
“energy”, or “electrolyte” drinks and particulated drinks
14.1.5 Coffee, coffee substitutes, tea, herbal infusions, and 
other hot cereal and grain beverages, excluding cocoa
0
0
101
0
0
179
4
NA
NA
17
NA
NA
209
0
NA
NA
339
NA
NA
371
0
China 14.1.2.1 Fruit juice
14.1.2.3 Concentrates for fruit juice
14.1.3.1 Fruit nectar
14.1.3.3 Concentrates for fruit nectar
14.1.3.4 Concentrates for vegetable nectar
14.1.4 Water-based flavoured drinks, including “sport”, 
“energy”, or “electrolyte” drinks and particulated drinks
14.1.5 Coffee, coffee substitutes, tea, herbal infusions, and 
other hot cereal and grain beverages, excluding cocoa
0
0
1
0
0
28
4
NA
NA
0
NA
NA
83
0
NA
NA
0
NA
NA
175
0
Mexico 14.1.2.1 Fruit juice
14.1.2.3 Concentrates for fruit juice
14.1.3.1 Fruit nectar
14.1.3.3 Concentrates for fruit nectar
14.1.3.4 Concentrates for vegetable nectar
14.1.4 Water-based flavoured drinks, including “sport”, 
“energy”, or “electrolyte” drinks and particulated drinks
14.1.5 Coffee, coffee substitutes, tea, herbal infusions, and 
other hot cereal and grain beverages, excluding cocoa
2
0
1
0
4
144
1
0
NA
0
NA
0
148
0
0
NA
0
NA
0
368
0
Table 1
reported benzoate use levels submitted by ICBA and norway
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 The Global Environment Monitoring System – Food Contamination 
Monitoring and Assessment Programme (GEMS/Food) database contains 68 
measurements of benzoates in food category 14.1.2.1 (fruit juice, not detected 
[nd] – 580 mg/L), two measurements of benzoates in GSFA food category 14.1.3.1 
(fruit nectar, nd) and 74 measurements of benzoates in GSFA food category 14.1.4 
(water-based flavoured drinks, nd–150 mg/L), as provided by the Hong Kong 
Special Administrative Region (SAR) of China (see Appendix 1). Analytically 
determined average concentrations of benzoates in non-alcoholic beverages have 
been reported in the literature to range from 63.1 to 259 mg/L: Brazil (259 mg/L; 
Tfouni & Toledo, 2002), France (71.2 mg/L; Bemrah, Leblanc & Volatier, 2008), 
Lebanon (120 mg/L from 10 samples; Soubra et al., 2007) and New Zealand (63.1 
Country GSFA food category
Number of 
entries
Average typical 
reported use  
level (mg/L)
Maximum  
reported use  
level (mg/L)
South Africa 14.1.2.1 Fruit juice
14.1.2.3 Concentrates for fruit juice
14.1.3.1 Fruit nectar
14.1.3.3 Concentrates for fruit nectar
14.1.3.4 Concentrates for vegetable nectar
14.1.4 Water-based flavoured drinks, including “sport”, 
“energy”, or “electrolyte” drinks and particulated drinks
14.1.5 Coffee, coffee substitutes, tea, herbal infusions, and 
other hot cereal and grain beverages, excluding cocoa
2
0
1
0
0
38
1
0
NA
0
NA
NA
97
0
0
NA
0
NA
NA
352
0
USA 14.1.2.1 Fruit juice
14.1.2.3 Concentrates for fruit juice
14.1.3.1 Fruit nectar
14.1.3.3 Concentrates for fruit nectar
14.1.3.4 Concentrates for vegetable nectar
14.1.4 Water-based flavoured drinks, including “sport”, 
“energy”, or “electrolyte” drinks and particulated drinks
14.1.5 Coffee, coffee substitutes, tea, herbal infusions, and 
other hot cereal and grain beverages, excluding cocoa
10
2
2
1
0
250
2
126
64
0
0
NA
194
0
229
168
0
0
NA
627
0
Norway 14.1.4  Soft drink, sugar
Saft, sugar
Soft drink, sweetener
Saft, sweetener
Nectar, sweetener
Flavoured water
27
17
15
15
0
12
127a
110a
142a
135a
0a
109a
147
173
148
173
0
131
Table 1 (continued)
GSFA: Codex General Standard for Food Additives; ICBA: International Council of Beverages Associations; NA: not available
a Weighted average (mg/L).
7Benzoates: dietary exposure assessment 
mg/L in soft drinks; Cressey & Jones, 2009). Australia also measured benzoate 
concentrations in 18 soft drinks (nine cola and nine non-cola) in the 21st 
Australian Total Diet Study: 0–150 mg/L (average 17 mg/L) and 145–350 mg/L 
(average 220 mg/L), respectively (FSANZ, 2005).
 Overall, from the review of submitted data and the literature, the 
Committee noted that out of the 59 food categories for which maximum benzoate 
use levels were adopted by CCFA in the GSFA, non-alcoholic beverages (GSFA 
food category 14.1) provide the primary source of dietary exposure to benzoates. 
Moreover, the Committee noted that the available data set (reported use levels 
from industries, analytical measurements from countries) reviewed at the meeting 
shows good consistency between the average concentrations of benzoates when 
they are used in the GSFA food category of water-based flavoured drinks (category 
14.1.4) and in overall non-alcoholic beverages. The average typical reported 
concentrations from industries ranged from 83 to 209 mg/L (category 14.1.4); 
the published analytically quantified measurements for non-alcoholic beverages 
from various countries ranged from 63 to 259 mg/L. These concentrations were 
much lower than national maximum limits (150–400 mg/L) or limits for GSFA 
food category 14.1.4 (600 mg/L).
3. Assessment of dietary exposure 
3.1 Dietary exposure to benzoates from non-alcoholic beverages 
The Committee reviewed dietary exposure estimates submitted by the ICBA 
for four countries (Brazil, Mexico, South Africa and the USA), performed by 
combining individual consumption data with maximum reported use levels or 
national maximum permitted levels for non-alcoholic beverages. The Committee 
concluded that the information would not be appropriate for this assessment 
because maximum reported use levels or national maximum permitted levels 
were used in place of measured or average typical use levels. However, the 
Committee decided to make its own exposure estimates for these countries using 
consumption figures from the submitted data combined with average typical use 
levels.
 Norway also submitted estimates of exposure to benzoates from soft 
drinks, saft and flavoured water. The consumption data on soft drinks, saft and 
flavoured water from two national food consumption surveys, Smabarnskost 
2007 and Norkost 3, were combined with the weighted average benzoate use 
levels derived using Norwegian sales volumes to estimate benzoate exposure. The 
estimates of benzoate exposure for the general population were 0.73–1.1 mg/kg 
bw per day. The 95th percentile exposure estimates for children up to 2 years of 
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age were up to 3.4 mg/kg bw per day, whereas those for adult males reached 2.0 
mg/kg bw per day.
 The Committee also prepared international estimates of dietary exposure to 
benzoates using non-alcoholic beverage consumption levels from the FAO/WHO 
Chronic Individual Food Consumption Data – Summary statistics (CIFOCOss) 
database and information on average typical reported use levels of benzoates in 
water-based flavoured drinks (as non-alcoholic beverages in CIFOCOss consist 
primarily of water-based flavoured drinks) from various countries (83–209 mg/L). 
A total of 131 consumption data from 25 countries belonging to 10 GEMS/Food 
clusters were used, according to age/class in CIFOCOss. The weighted mean 
and the consumers-only weighted mean consumptions for beverages at FoodEx 
level 3 (European Food Safety Authority consolidated food consumption survey, 
classification for non-alcoholic beverages, not elsewhere specified) were estimated 
if several level 3 codes were presented from the same survey. The Committee was 
not able to take into account disparity in exposure estimates when different foods 
(beverages) were represented in the surveys that make up the FoodEx system. The 
Committee concluded that any differences would be small, as different beverages 
are generally consumed in similar volumes (e.g. lemonade versus carbonated 
beverages).
 Table 2 summarizes the exposure estimates. None of the mean exposure 
estimates for consumers of non-alcoholic (“soft”) beverages exceeded the upper 
bound of the ADI: 0.3–4.1 mg/kg bw per day for toddlers and young children, 
0.2–2.7 mg/kg bw per day for other children, including adolescents, and 0.1–1.7 
mg/kg bw per day for adults (see also Appendix 2). However, the Committee 
noted that the 95th percentile exposures for consumers-only reached or exceeded 
the upper bound of the ADI in some cases: up to 10.9 mg/kg bw per day for 
toddlers and young children and up to 7.0 mg/kg bw per day for other children, 
including adolescents. 
3.2 Total dietary exposure to benzoates
The Committee conducted a review of the literature published since 2000 to obtain 
estimates of total dietary exposure to benzoates in 15 countries where benzoate 
use is legally permitted. The details are given in Appendix 3, and the estimates 
are summarized in Table 3. The Committee noted that the comparison of dietary 
exposures between studies is difficult because of differences in the methodologies 
used and assumptions made in the exposure assessments. The estimates were 
made by combining mean analytically measured levels (Australia, Austria, 
Belgium, Brazil, China, Denmark, Lebanon, New Zealand, the Republic of Korea, 
Saudi Arabia and Serbia) or means from use level surveys (France, Ireland, Italy 
and the United Kingdom) of benzoates in food with their consumption levels 
9Benzoates: dietary exposure assessment 
Age group Mean exposure (mg/kg bw per day) 95th percentile exposure (mg/kg bw per day)
Toddlers and young children (1–7 years) 0.3–4.1 1.7–10.9a
Other children, including adolescents  
(8–17 years)
0.2–2.7 0.5–7.0
Adults (18+ years) 0.1–1.7 0.2–4.2
Table 2
Benzoate exposure for consumers of non-alcoholic (“soft”) beverages (CIfoCoss data plus 
Committee-prepared estimates)
bw: body weight; CIFOCOss: FAO/WHO Chronic Individual Food Consumption Data – Summary statistics
a 97.5th percentile exposure from South Africa.
from national consumption surveys (24-hour recall or intake record and/or food 
frequency questionnaire). Dietary exposure estimates from Austria were based 
on food consumption by consumers-only.
 Most of the reported estimates for mean and high percentile exposures 
for the general population were below the upper bound of the ADI. Average 
analytically measured concentrations in samples with benzoate concentrations 
above the limit of quantification were used for exposure estimates, assuming 
that consumers only consume foods that could contain benzoates. Average 
concentrations of benzoates in all analysed samples were used for exposure 
estimates when assuming that consumers randomly consume foods that may or 
may not contain benzoates. 
 The estimated exposures to benzoates were below the upper bound of the 
ADI for preschool children (1.6 mg/kg bw per day, 31.8% of the upper bound of 
the ADI), males (1.6 mg/kg bw per day, 31.4% of the upper bound of the ADI) 
and females (1.8 mg/kg bw per day, 35.6% of the upper bound of the ADI) when 
assuming that consumers randomly consume foods that may contain benzoates. 
The estimated exposures to benzoates exceeded the upper bound of the ADI for 
General population exposure  
(mg/kg bw per day)
Consumers-only exposure  
(mg/kg bw per day)
Age group Mean 95th percentile Mean 95th percentile
Toddlers and young children (1–7 years) 1.5 3.9 0.9–6.8 2.0–9
Other children, including adolescents  
(8–17 years)
0.1–1.0 0.4–2.6 0.2–4 1.1–8
Adults (18+ years) 0.04–1.3 0.2–2.9 0.1–6.2 0.7–5.5
Table 3
Literature-derived dietary exposure estimates for benzoates from all foods (including non-
beverage uses)
bw: body weight
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preschool children (6.8 mg/kg bw per day, 136% of the upper bound of the ADI), 
males (5.9 mg/kg bw per day, 118% of the upper bound of the ADI) and females 
(6.2 mg/kg bw per day, 124% of the upper bound of the ADI) when assuming that 
consumers only consume foods that could contain benzoates. Denmark reported 
similar results: exposures for 90th percentile consumers who always consume 
foods that contain benzoates exceeded the upper bound of the ADI, with the 
highest value of 9 mg/kg bw per day for boys aged 4–6 years. The Committee 
noted that the results are likely overestimates, because consumers do not select 
foods that contain benzoates all of the time.
 Saudi Arabia had no national food consumption data, but estimated 
consumption was based on a quantitative frequency questionnaire completed by 
100 students aged 18–25 years who recorded their food consumption during a 
week. The Committee noted that the exposures from Saudi Arabia exceeded the 
upper bound of the ADI because of a high-level consumption of non-alcoholic 
drinks (5.3 mg/kg bw per day) and yogurt rice dressing (5.2 mg/kg bw per day). 
More intake estimations, using a wide range of population groups and more 
food items, are needed in order to ascertain whether the exposure of the broader 
population is also above the upper bound of the ADI. 
 The largest contributor to estimated dietary exposure to benzoates was 
non-alcoholic beverages (up to 80% for the general population of Brazil) for 
most countries, but fish products (42.6–68.1%, Austria), meat products (68%, 
Italy, adults), soups and sauces (57%, United Kingdom), ketchup and tomato 
products (36.1%, Serbia) and seasoning (31.8%, China, 3- to 6-year-old female 
children) were also reported to be important contributors. China (Hong Kong 
SAR) also reported that soft drinks contributed to about 80% of dietary exposure 
to benzoates for children consuming the beverages and high beverage consumers 
(Ma et al., 2009). Therefore, the Committee noted that regional differences 
between diets should be taken into consideration, as well as different age groups 
with high consumption patterns.
 Overall, from the literature review, the Committee noted that most of the 
reported estimates of dietary exposure to benzoates for the general population 
did not exceed the upper bound of the ADI. However, the dietary exposure for 
the consumers-only group reached or even exceeded the upper bound of the ADI, 
with dietary exposure of high percentile young consumers up to 9 mg/kg bw per 
day, owing primarily to their consumption of non-alcoholic beverages. For some 
adults, exceedance of the upper bound of the ADI in mean consumers (dietary 
exposure up to 6.2 mg/kg bw per day) was also noted, owing to the consumption 
of fish products, fruit and vegetable juices, and yogurt rice dressing.
11
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4. Comments
4.1 Data submitted or available to the Committee
The Committee received data on “average typical” levels of benzoates in foods 
(796 individual branded products) for seven subcategories of GSFA food category 
14.1 from six countries – Australia, Brazil, China, Mexico, South Africa and the 
USA – through the ICBA as well as use level data for 86 products from Norway. 
The average typical and maximum reported use levels of benzoates in GSFA food 
category 14.1.4 (water-based flavoured drinks) ranged from 83 to 209 mg/L and 
from 131 to 627 mg/L, respectively.
 The Committee additionally evaluated published data on dietary 
exposures to benzoates from all foods at a national level. Information published 
since 2000 from 15 countries was considered. The estimates were made by 
combining mean analytically measured levels (Australia, Austria, Belgium, Brazil, 
China, Denmark, Lebanon, New Zealand, the Republic of Korea, Saudi Arabia 
and Serbia) or means from use level surveys (France, Ireland, Italy and the United 
Kingdom) of benzoates in food with their consumption levels from national 
consumption surveys (24-hour recall or intake record and/or food frequency 
questionnaire). Norway also submitted an estimate of benzoate exposure from 
soft drinks, saft (a concentrate produced from fruit juice) and flavoured water.
4.2 Assessment of dietary exposure 
The Committee reviewed dietary exposure estimates submitted by the ICBA 
for four countries (Brazil, Mexico, South Africa and the USA), performed by 
combining individual consumption data with maximum reported use levels or 
national maximum permitted levels for non-alcoholic beverages. The Committee 
concluded that the information would not be appropriate for this assessment 
because maximum reported use levels or national maximum permitted levels 
were used in place of measured or average typical use levels. However, the 
Committee decided to make its own exposure estimates for these countries using 
consumption figures from the submitted data combined with average typical use 
levels. The Committee also prepared exposure estimates using food consumption 
data for non-alcoholic beverages from the CIFOCOss database. These estimates 
are summarized in Table 2 (see section 3.1). A total of 131 consumption data 
from 25 countries belonging to 10 GEMS/Food clusters were used. Additionally, 
as previously noted, the Committee also evaluated published estimates of 
total dietary exposure to benzoates (including non-beverage uses). These are 
summarized in Table 3 (see section 3.2).
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 Overall, the largest contributions to total estimated dietary exposure 
to benzoates were from non-alcoholic beverages (up to 80% for the general 
population of Brazil) for most countries.
5. evaluation
Based on the available data set (reported use levels from industries and analytical 
measurements from the literature), the Committee noted that there is consistency 
in the average typical range of concentrations for benzoates used in the GSFA food 
subcategory for non-alcoholic (“soft”) beverages (GSFA food category 14.1). For 
example, typical reported concentrations from industries ranged from 83 to 209 
mg/L for water-based flavoured drinks (food category 14.1.4), and analytically 
quantified measurements ranged from 63 to 259 mg/L for non-alcoholic 
beverages (food category 14.1). These levels are lower than national maximum 
limits (150–400 mg/L) or limits for GSFA food category 14.1.4 (600 mg/L). The 
Committee also noted that most of the reported estimates for mean and high 
percentile per capita benzoate exposure were below the upper bound of the ADI, 
despite different methodologies and assumptions applied in the preparation of 
the exposure estimates.
 None of the mean exposure estimates for consumers of non-alcoholic 
(“soft”) beverages exceeded the upper bound of the ADI: 0.3–4.1 mg/kg bw per 
day for toddlers and young children, 0.2–2.7 mg/kg bw per day for other children, 
including adolescents, and 0.1–1.7 mg/kg bw per day for adults. However, the 
Committee noted that the 95th percentile exposures for the consumers-only 
group exceeded the upper bound of the ADI in some cases: up to 10.9 mg/kg 
bw per day for toddlers and young children and up to 7.0 mg/kg bw per day 
for other children, including adolescents. Additionally, the Committee noted 
that in some countries, the overall dietary exposure to benzoates for toddlers, 
young children and adolescents also exceeds the upper bound of the ADI at the 
high percentiles. Reduction of those exposures exceeding the upper bound of the 
ADI would require consideration of dietary patterns for both beverage and non-
beverage foods containing benzoates and typical/allowed benzoate use levels in 
those countries.
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Food category Food name Food code Local food name Result Units LOD LOQ
Non-alcoholic beverages (excluding 
milk, fruit and vegetable juice, water and 
stimulants)
Soft drinks 14.1.4 Malted soya milk; 
prepackaged
ND mg/kg 5 10
Non-alcoholic beverages (excluding 
milk, fruit and vegetable juice, water and 
stimulants)
Soft drinks 14.1.4 Soya milk; prepackaged ND mg/kg 5 10
Non-alcoholic beverages (excluding 
milk, fruit and vegetable juice, water and 
stimulants)
Soft drinks 14.1.4 Soya milk; prepackaged ND mg/kg 5 10
Fruit and vegetable juices Fruit juice 14.1.2.1 Grape juice; prepackaged 580 mg/kg 5 10
Non-alcoholic beverages (excluding 
milk, fruit and vegetable juice, water and 
stimulants)
Soft drinks 14.1.4 Soya milk; prepackaged ND mg/kg 5 10
Non-alcoholic beverages (excluding 
milk, fruit and vegetable juice, water and 
stimulants)
Soft drinks 14.1.4 Soya milk; prepackaged ND mg/kg 5 10
Fruit and vegetable juices Fruit juice 14.1.2.1 Apple juice; prepackaged ND mg/kg 5 10
Fruit and vegetable juices Fruit juice 14.1.2.1 Apple juice; prepackaged ND mg/kg 5 10
Fruit and vegetable juices Fruit juice 14.1.2.1 Apple juice; prepackaged ND mg/kg 5 10
Fruit and vegetable juices Fruit juice 14.1.2.1 Grape juice; prepackaged ND mg/kg 5 10
Fruit and vegetable juices Fruit juice 14.1.2.1 Mixed fruit juice; 
prepackaged
ND mg/kg 5 10
Fruit and vegetable juices Fruit juice 14.1.2.1 Pineapple juice; prepack-
aged
ND mg/kg 5 10
Fruit and vegetable juices Fruit juice 14.1.2.1 Pear and lemon juice; 
prepackaged
ND mg/kg 5 10
Fruit and vegetable juices Fruit juice 14.1.2.1 Grape juice; prepackaged ND mg/kg 5 10
Fruit and vegetable juices Fruit juice 14.1.2.1 Apple and mango juice; 
prepackaged
ND mg/kg 5 10
Fruit and vegetable juices Fruit juice 14.1.2.1 Dark grape juice; 
prepackaged
ND mg/kg 5 10
Fruit and vegetable juices Fruit juice 14.1.2.1 Orange juice; prepack-
aged
ND mg/kg 5 10
Fruit and vegetable juices Fruit juice 14.1.2.1 Apple juice; prepackaged ND mg/kg 5 10
Fruit and vegetable juices Fruit juice 14.1.2.1 Orange juice; prepack-
aged
ND mg/kg 5 10
Fruit and vegetable juices Fruit juice 14.1.2.1 Mixed fruit juice; 
prepackaged
ND mg/kg 5 10
Fruit and vegetable juices Fruit juice 14.1.2.1 Blackcurrant juice with 
aloe vera; prepackaged
140 mg/kg 5 10
Fruit and vegetable juices Fruit juice 14.1.2.1 Orange juice with aloe 
vera; prepackaged
100 mg/kg 5 10
Non-alcoholic beverages (excluding 
milk, fruit and vegetable juice, water and 
stimulants)
Soft drinks 14.1.4 Soya milk; prepackaged ND mg/kg 5 10
Appendix 1
GeMs/food search results: individual records from China (Hong Kong special Administrative 
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Food category Food name Food code Local food name Result Units LOD LOQ
Non-alcoholic beverages (excluding 
milk, fruit and vegetable juice, water and 
stimulants)
Soft drinks 14.1.4 Soya milk; prepackaged ND mg/kg 5 10
Non-alcoholic beverages (excluding 
milk, fruit and vegetable juice, water and 
stimulants)
Soft drinks 14.1.4 Soya milk with sesame; 
prepackaged
ND mg/kg 5 10
Fruit and vegetable juices Fruit juice 14.1.2.1 Apple juice; prepackaged 170 mg/kg 5 10
Non-alcoholic beverages (excluding 
milk, fruit and vegetable juice, water and 
stimulants)
Soft drinks 14.1.4 Soya milk; prepackaged ND mg/kg 5 10
Fruit and vegetable juices Fruit juice 14.1.2.1 Mixed vegetable juice; 
prepackaged
ND mg/kg 5 10
Fruit and vegetable juices Fruit juice 14.1.2.1 Apple juice; prepackaged ND mg/kg 5 10
Fruit and vegetable juices Fruit juice 14.1.2.1 Mixed fruit juice; 
prepackaged
ND mg/kg 5 10
Fruit and vegetable juices Fruit juice 14.1.2.1 Orange juice; prepack-
aged
ND mg/kg 5 10
Fruit and vegetable juices Fruit juice 14.1.2.1 Mixed fruit and vegeta-
ble juice; prepackaged
ND mg/kg 5 10
Fruit and vegetable juices Fruit juice 14.1.2.1 Apple juice; prepackaged ND mg/kg 5 10
Fruit and vegetable juices Fruit juice 14.1.2.1 Grape juice; prepackaged ND mg/kg 5 10
Fruit and vegetable juices Fruit juice 14.1.2.1 Grape juice; prepackaged ND mg/kg 5 10
Fruit and vegetable juices Fruit juice 14.1.2.1 Grape juice; prepackaged ND mg/kg 5 10
Fruit and vegetable juices Fruit juice 14.1.2.1 Grape juice; prepackaged ND mg/kg 5 10
Fruit and vegetable juices Fruit juice 14.1.2.1 White grape juice; 
prepackaged
ND mg/kg 5 10
Fruit and vegetable juices Fruit juice 14.1.2.1 Mixed fruit juice; 
prepackaged
ND mg/kg 5 10
Fruit and vegetable juices Fruit nectar 14.1.3.1 Guava nectar; prepack-
aged
ND mg/kg 5 10
Fruit and vegetable juices Fruit juice 14.1.2.1 Grape juice; prepackaged ND mg/kg 5 10
Fruit and vegetable juices Fruit juice 14.1.2.1 Grape juice; prepackaged ND mg/kg 5 10
Non-alcoholic beverages (excluding 
milk, fruit and vegetable juice, water and 
stimulants)
Soft drinks 14.1.4 Flavoured carbonated 
drink
ND mg/kg 5 10
Fruit and vegetable juices Fruit juice 14.1.2.1 Red grape juice; 
prepackaged
ND mg/kg 5 10
Fruit and vegetable juices Fruit juice 14.1.2.1 Carrot and lemon juice; 
prepackaged
ND mg/kg 5 10
Non-alcoholic beverages (excluding 
milk, fruit and vegetable juice, water and 
stimulants)
Soft drinks 14.1.4 Flavoured carbonated 
drink
ND mg/kg 5 10
Fruit and vegetable juices Fruit juice 14.1.2.1 Carbonated red grape 
juice
ND mg/kg 5 10
Non-alcoholic beverages (excluding 
milk, fruit and vegetable juice, water and 
stimulants)
Soft drinks 14.1.4 Apple drink; prepack-
aged
ND mg/kg 5 10
16
W
H
O
 F
oo
d 
Ad
di
tiv
es
 S
er
ie
s N
o.
 7
1,
  2
01
5
Safety evaluation of certain food additives and contaminants   Eightieth  JECFA
Food category Food name Food code Local food name Result Units LOD LOQ
Non-alcoholic beverages (excluding 
milk, fruit and vegetable juice, water and 
stimulants)
Soft drinks 14.1.4 Orange and apple drink; 
prepackaged
ND mg/kg 5 10
Non-alcoholic beverages (excluding 
milk, fruit and vegetable juice, water and 
stimulants)
Soft drinks 14.1.4 Orange drink; prepack-
aged
ND mg/kg 5 10
Fruit and vegetable juices Fruit juice 14.1.2.1 Pear juice; prepackaged ND mg/kg 5 10
Fruit and vegetable juices Fruit juice 14.1.2.1 Tomato juice; prepack-
aged
ND mg/kg 5 10
Fruit and vegetable juices Fruit juice 14.1.2.1 Pineapple juice; prepack-
aged
ND mg/kg 5 10
Fruit and vegetable juices Fruit juice 14.1.2.1 Mixed fruit juice; 
prepackaged
ND mg/kg 5 10
Non-alcoholic beverages (excluding 
milk, fruit and vegetable juice, water and 
stimulants)
Soft drinks 14.1.4 Carbonated apple drink; 
prepackaged
ND mg/kg 5 10
Non-alcoholic beverages (excluding 
milk, fruit and vegetable juice, water and 
stimulants)
Soft drinks 14.1.4 Carbonated grapefruit 
drink; prepackaged
ND mg/kg 5 10
Non-alcoholic beverages (excluding 
milk, fruit and vegetable juice, water and 
stimulants)
Soft drinks 14.1.4 Carbonated orange 
drink; prepackaged
ND mg/kg 5 10
Non-alcoholic beverages (excluding 
milk, fruit and vegetable juice, water and 
stimulants)
Soft drinks 14.1.4 Carbonated peach drink; 
prepackaged
ND mg/kg 5 10
Non-alcoholic beverages (excluding 
milk, fruit and vegetable juice, water and 
stimulants)
Soft drinks 14.1.4 Flavoured carbonated 
drink
140 mg/kg 5 10
Non-alcoholic beverages (excluding 
milk, fruit and vegetable juice, water and 
stimulants)
Soft drinks 14.1.4 Flavoured carbonated 
drink
140 mg/kg 5 10
Non-alcoholic beverages (excluding 
milk, fruit and vegetable juice, water and 
stimulants)
Soft drinks 14.1.4 Flavoured carbonated 
light drink
56 mg/kg 5 10
Non-alcoholic beverages (excluding 
milk, fruit and vegetable juice, water and 
stimulants)
Soft drinks 14.1.4 Flavoured carbonated 
drink
120 mg/kg 5 10
Non-alcoholic beverages (excluding 
milk, fruit and vegetable juice, water and 
stimulants)
Soft drinks 14.1.4 Flavoured carbonated 
drink
130 mg/kg 5 10
Non-alcoholic beverages (excluding 
milk, fruit and vegetable juice, water and 
stimulants)
Soft drinks 14.1.4 Flavoured carbonated 
drink
130 mg/kg 5 10
Non-alcoholic beverages (excluding 
milk, fruit and vegetable juice, water and 
stimulants)
Soft drinks 14.1.4 Flavoured carbonated 
drink
130 mg/kg 5 10
Non-alcoholic beverages (excluding 
milk, fruit and vegetable juice, water and 
stimulants)
Soft drinks 14.1.4 Flavoured carbonated 
light drink
130 mg/kg 5 10
Appendix 1 (continued)
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Food category Food name Food code Local food name Result Units LOD LOQ
Fruit and vegetable juices Fruit juice 14.1.2.1 Apple juice; prepackaged ND mg/kg 5 10
Fruit and vegetable juices Fruit juice 14.1.2.1 Apple juice; prepackaged ND mg/kg 5 10
Fruit and vegetable juices Fruit juice 14.1.2.1 Dark grape juice; 
prepackaged
ND mg/kg 5 10
Fruit and vegetable juices Fruit juice 14.1.2.1 Red grape juice; 
prepackaged
ND mg/kg 5 10
Non-alcoholic beverages (excluding 
milk, fruit and vegetable juice, water and 
stimulants)
Soft drinks 14.1.4 Flavoured carbonated 
drink (caffeine free)
ND mg/kg 5 10
Non-alcoholic beverages (excluding 
milk, fruit and vegetable juice, water and 
stimulants)
Soft drinks 14.1.4 Glucose drink; prepack-
aged
ND mg/kg 5 10
Non-alcoholic beverages (excluding 
milk, fruit and vegetable juice, water and 
stimulants)
Soft drinks 14.1.4 Flavoured carbonated 
drink
ND mg/kg 5 10
Non-alcoholic beverages (excluding 
milk, fruit and vegetable juice, water and 
stimulants)
Soft drinks 14.1.4 Flavoured carbonated 
energy drink 
150 mg/kg 5 10
Non-alcoholic beverages (excluding 
milk, fruit and vegetable juice, water and 
stimulants)
Soft drinks 14.1.4 Flavoured carbonated 
drink
150 mg/kg 5 10
Non-alcoholic beverages (excluding 
milk, fruit and vegetable juice, water and 
stimulants)
Soft drinks 14.1.4 Flavoured carbonated 
drink
150 mg/kg 5 10
Non-alcoholic beverages (excluding 
milk, fruit and vegetable juice, water and 
stimulants)
Soft drinks 14.1.4 Flavoured carbonated 
drink
150 mg/kg 5 10
Non-alcoholic beverages (excluding 
milk, fruit and vegetable juice, water and 
stimulants)
Soft drinks 14.1.4 Flavoured carbonated 
drink
150 mg/kg 5 10
Non-alcoholic beverages (excluding 
milk, fruit and vegetable juice, water and 
stimulants)
Soft drinks 14.1.4 Lemon lime carbonated 
drink
ND mg/kg 5 10
Fruit and vegetable juices Fruit juice 14.1.2.1 Tomato juice; prepack-
aged
ND mg/kg 5 10
Fruit and vegetable juices Fruit juice 14.1.2.1 Tomato juice; prepack-
aged
ND mg/kg 5 10
Fruit and vegetable juices Fruit juice 14.1.2.1 Orange and red grape-
fruit juice; prepackaged
ND mg/kg 5 10
Fruit and vegetable juices Fruit juice 14.1.2.1 Mixed fruit juice; 
prepackaged
ND mg/kg 5 10
Fruit and vegetable juices Fruit juice 14.1.2.1 Mixed fruit juice; 
prepackaged
ND mg/kg 5 10
Fruit and vegetable juices Fruit nectar 14.1.3.1 Mango nectar; pre-
packaged
ND mg/kg 5 10
Fruit and vegetable juices Fruit juice 14.1.2.1 Orange juice; prepack-
aged
ND mg/kg 5 10
Fruit and vegetable juices Fruit juice 14.1.2.1 Mixed fruit juice; 
prepackaged
ND mg/kg 5 10
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Food category Food name Food code Local food name Result Units LOD LOQ
Non-alcoholic beverages (excluding 
milk, fruit and vegetable juice, water and 
stimulants)
Soft drinks 14.1.4 Soya milk; prepackaged ND mg/kg 5 10
Non-alcoholic beverages (excluding 
milk, fruit and vegetable juice, water and 
stimulants)
Soft drinks 14.1.4 Soya milk; prepackaged ND mg/kg 5 10
Non-alcoholic beverages (excluding 
milk, fruit and vegetable juice, water and 
stimulants)
Soft drinks 14.1.4 Soya milk; prepackaged ND mg/kg 5 10
Non-alcoholic beverages (excluding 
milk, fruit and vegetable juice, water and 
stimulants)
Soft drinks 14.1.4 Malted soya milk; 
prepackaged
ND mg/kg 5 10
Non-alcoholic beverages (excluding 
milk, fruit and vegetable juice, water and 
stimulants)
Soft drinks 14.1.4 Soya milk; prepackaged ND mg/kg 5 10
Non-alcoholic beverages (excluding 
milk, fruit and vegetable juice, water and 
stimulants)
Soft drinks 14.1.4 Soya milk; prepackaged ND mg/kg 5 10
Non-alcoholic beverages (excluding 
milk, fruit and vegetable juice, water and 
stimulants)
Soft drinks 14.1.4 Soya milk; prepackaged ND mg/kg 5 10
Non-alcoholic beverages (excluding 
milk, fruit and vegetable juice, water and 
stimulants)
Soft drinks 14.1.4 Chocolate flavoured soya 
milk; prepackaged
ND mg/kg 5 10
Non-alcoholic beverages (excluding 
milk, fruit and vegetable juice, water and 
stimulants)
Soft drinks 14.1.4 Flavoured carbonated 
drink
ND mg/kg 5 10
Non-alcoholic beverages (excluding 
milk, fruit and vegetable juice, water and 
stimulants)
Soft drinks 14.1.4 Flavoured carbonated 
drink 
ND mg/kg 5 10
Non-alcoholic beverages (excluding 
milk, fruit and vegetable juice, water and 
stimulants)
Soft drinks 14.1.4 Soya milk; prepackaged ND mg/kg 5 10
Non-alcoholic beverages (excluding 
milk, fruit and vegetable juice, water and 
stimulants)
Soft drinks 14.1.4 Black soya milk; 
prepackaged
ND mg/kg 5 10
Non-alcoholic beverages (excluding 
milk, fruit and vegetable juice, water and 
stimulants)
Soft drinks 14.1.4 Grape juice drink; 
prepackaged
ND mg/kg 5 10
Non-alcoholic beverages (excluding 
milk, fruit and vegetable juice, water and 
stimulants)
Soft drinks 14.1.4 Melon flavoured soya 
milk; prepackaged
ND mg/kg 5 10
Non-alcoholic beverages (excluding 
milk, fruit and vegetable juice, water and 
stimulants)
Soft drinks 14.1.4 Melon flavoured soya 
milk; prepackaged
ND mg/kg 5 10
Non-alcoholic beverages (excluding 
milk, fruit and vegetable juice, water and 
stimulants)
Soft drinks 14.1.4 Soya milk; prepackaged ND mg/kg 5 10
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Food category Food name Food code Local food name Result Units LOD LOQ
Non-alcoholic beverages (excluding 
milk, fruit and vegetable juice, water and 
stimulants)
Soft drinks 14.1.4 Soya milk; prepackaged ND mg/kg 5 10
Non-alcoholic beverages (excluding 
milk, fruit and vegetable juice, water and 
stimulants)
Soft drinks 14.1.4 Soya milk; prepackaged ND mg/kg 5 10
Non-alcoholic beverages (excluding 
milk, fruit and vegetable juice, water and 
stimulants)
Soft drinks 14.1.4 Soya milk; prepackaged ND mg/kg 5 10
Fruit and vegetable juices Fruit juice 14.1.2.1 Orange juice; prepack-
aged
ND mg/kg 5 10
Fruit and vegetable juices Fruit juice 14.1.2.1 Mixed fruit juice; 
prepackaged
ND mg/kg 5 10
Fruit and vegetable juices Fruit juice 14.1.2.1 Mulberry juice; 
prepackaged
ND mg/kg 5 10
Non-alcoholic beverages (excluding 
milk, fruit and vegetable juice, water and 
stimulants)
Soft drinks 14.1.4 Flavoured carbonated 
light drink 
150 mg/kg 5 10
Non-alcoholic beverages (excluding 
milk, fruit and vegetable juice, water and 
stimulants)
Soft drinks 14.1.4 Flavoured carbonated 
light drink
150 mg/kg 5 10
Non-alcoholic beverages (excluding 
milk, fruit and vegetable juice, water and 
stimulants)
Soft drinks 14.1.4 Flavoured carbonated 
drink
150 mg/kg 5 10
Non-alcoholic beverages (excluding 
milk, fruit and vegetable juice, water and 
stimulants)
Soft drinks 14.1.4 Flavoured carbonated 
drink
150 mg/kg 5 10
Non-alcoholic beverages (excluding 
milk, fruit and vegetable juice, water and 
stimulants)
Soft drinks 14.1.4 Flavoured carbonated 
light drink 
140 mg/kg 5 10
Non-alcoholic beverages (excluding 
milk, fruit and vegetable juice, water and 
stimulants)
Soft drinks 14.1.4 Flavoured carbonated 
energy drink 
150 mg/kg 5 10
Non-alcoholic beverages (excluding 
milk, fruit and vegetable juice, water and 
stimulants)
Soft drinks 14.1.4 Flavoured carbonated 
energy drink 
150 mg/kg 5 10
Non-alcoholic beverages (excluding 
milk, fruit and vegetable juice, water and 
stimulants)
Soft drinks 14.1.4 Flavoured carbonated 
drink
140 mg/kg 5 10
Non-alcoholic beverages (excluding 
milk, fruit and vegetable juice, water and 
stimulants)
Soft drinks 14.1.4 Flavoured carbonated 
drink
140 mg/kg 5 10
Non-alcoholic beverages (excluding 
milk, fruit and vegetable juice, water and 
stimulants)
Soft drinks 14.1.4 Flavoured carbonated 
drink
130 mg/kg 5 10
Non-alcoholic beverages (excluding 
milk, fruit and vegetable juice, water and 
stimulants)
Soft drinks 14.1.4 Flavoured carbonated 
drink
130 mg/kg 5 10
Non-alcoholic beverages (excluding 
milk, fruit and vegetable juice, water and 
stimulants)
Soft drinks 14.1.4 Flavoured carbonated 
drink
ND mg/kg 5 10
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Food category Food name Food code Local food name Result Units LOD LOQ
Fruit and vegetable juices Fruit juice 14.1.2.1 Kiwifruit juice; prepack-
aged
ND mg/kg 5 10
Fruit and vegetable juices Fruit juice 14.1.2.1 Strawberry juice; 
prepackaged
ND mg/kg 5 10
Non-alcoholic beverages (excluding 
milk, fruit and vegetable juice, water and 
stimulants)
Soft drinks 14.1.4 Malted soya milk; 
prepackaged
ND mg/kg 5 10
Non-alcoholic beverages (excluding 
milk, fruit and vegetable juice, water and 
stimulants)
Soft drinks 14.1.4 Soya milk; prepackaged ND mg/kg 5 10
Non-alcoholic beverages (excluding 
milk, fruit and vegetable juice, water and 
stimulants)
Soft drinks 14.1.4 Soya milk; prepackaged ND mg/kg 5 10
Fruit and vegetable juices Fruit juice 14.1.2.1 Fruit and vegetable juice; 
prepackaged
ND mg/kg 5 10
Fruit and vegetable juices Fruit juice 14.1.2.1 Tomato juice; prepack-
aged
ND mg/kg 5 10
Non-alcoholic beverages (excluding 
milk, fruit and vegetable juice, water and 
stimulants)
Soft drinks 14.1.4 Soya milk; prepackaged ND mg/kg 5 10
Fruit and vegetable juices Fruit juice 14.1.2.1 Cranberry juice; 
prepackaged
51 mg/kg 5 10
Fruit and vegetable juices Fruit juice 14.1.2.1 Grape juice; prepackaged ND mg/kg 5 10
Non-alcoholic beverages (excluding 
milk, fruit and vegetable juice, water and 
stimulants)
Soft drinks 14.1.4 Flavoured carbonated 
drink
140 mg/kg 5 10
Non-alcoholic beverages (excluding 
milk, fruit and vegetable juice, water and 
stimulants)
Soft drinks 14.1.4 Flavoured carbonated 
drink
ND mg/kg 5 10
Fruit and vegetable juices Fruit juice 14.1.2.1 Mixed fruit juice; 
prepackaged
ND mg/kg 5 10
Fruit and vegetable juices Fruit juice 14.1.2.1 Fruit and vegetable juice 
drink; prepackaged
ND mg/kg 5 10
Fruit and vegetable juices Fruit juice 14.1.2.1 Pineapple juice drink; 
prepackaged
ND mg/kg 5 10
Non-alcoholic beverages (excluding 
milk, fruit and vegetable juice, water and 
stimulants)
Soft drinks 14.1.4 Lemon drink; prepack-
aged
ND mg/kg 5 10
Non-alcoholic beverages (excluding 
milk, fruit and vegetable juice, water and 
stimulants)
Soft drinks 14.1.4 Flavoured carbonated 
drink
ND mg/kg 5 10
Fruit and vegetable juices Fruit juice 14.1.2.1 Mixed vegetable juice; 
prepackaged
ND mg/kg 5 10
Fruit and vegetable juices Fruit juice 14.1.2.1 Mixed fruit juice; 
prepackaged
ND mg/kg 5 10
Fruit and vegetable juices Fruit juice 14.1.2.1 Pomelo juice; prepack-
aged
ND mg/kg 5 10
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Food category Food name Food code Local food name Result Units LOD LOQ
Fruit and vegetable juices Fruit juice 14.1.2.1 Chinese pear juice; 
prepackaged
ND mg/kg 5 10
Fruit and vegetable juices Fruit juice 14.1.2.1 Orange juice; prepack-
aged
ND mg/kg 5 10
Fruit and vegetable juices Fruit juice 14.1.2.1 Red and white grape 
juice drink; prepackaged
ND mg/kg 5 10
Total 14.1.2.1 68 Mean-LB 15.31 
208.2a
Mean-UB 24.57 
14.1.3.1 2 Mean-LB   0.00 
–
Mean-UB 10.00 
14.1.4 74 Mean-LB 46.57 
 137.84a
Mean-UB 53.19 
Total 144 Mean-LB 31.16 
 149.57a
Mean-UB 39.08 
LB: lower bound; LOD: limit of detection; LOQ: limit of quantification; ND: not detected; UB: upper bound
a Average excluding non-detects. 
Cluster  Age class
Consumers onlya
Country Mean-L Mean-H P95 max-L P95 max-H
5 General population Brazil 0.35 0.87 0.95 2.38
6 Other children Greece 0.34 0.86 0.63 2.08
7 Adolescents France 0.24 0.61 0.74 1.87
7 Adults Finland 0.30 0.76 0.85 2.13
7 Adults France 0.19 0.48 0.67 1.69
7 Adults United Kingdom 0.24 0.60 0.73 1.84
7 Elderly Finland 0.24 0.62 0.80 2.03
7 Elderly France 0.09 0.23 0.45 0.66
7 Other children Finland 0.51 1.28 0.51 6.51
7 Other children France 0.40 1.00 1.31 3.29
7 Toddlers Finland 0.82 2.07 2.89 7.28
7 Very elderly France 0.09 0.24 0.36 0.91
8 Adolescents Germany 0.56 1.42 1.66 4.17
8 Adolescents Spain 0.44 1.10 1.18 2.98
8 Adults Germany 0.47 1.18 1.46 3.68
8 Adults Spain 0.34 0.87 1.01 2.55
8 Elderly Germany 0.29 0.74 0.83 2.09
8 Other children Germany 0.73 1.84 2.68 6.75
8 Other children Spain 0.48 1.20 1.79 4.50
8 Toddlers Germany 0.94 2.38 6.32 15.92
8 Very elderly Germany 0.31 0.77 0.76 1.90
9 Children China 0.35 0.89 0.85 2.13
Appendix 2
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Cluster  Age class
Consumers onlya
Country Mean-L Mean-H P95 max-L P95 max-H
9 Children Philippines 0.23 0.58 0.66 1.67
9 General population China 0.15 0.39 0.53 1.34
9 General population Thailand 0.03 0.18 – –
10 Adolescents Cyprus 0.24 0.61 0.69 1.73
10 Adolescents Italy 0.27 0.67 0.63 1.59
10 Adolescents Latvia 0.33 0.83 0.91 2.30
10 Adults Italy 0.16 0.41 0.38 0.96
10 Adults Latvia 0.21 0.54 0.67 1.69
10 Children Japan 0.96 2.43 2.72 6.86
10 Children Republic of Korea 0.51 1.28 1.04 2.62
10 Elderly Italy 0.12 0.30 0.30 0.76
10 General population Japan 0.29 0.74 0.98 2.48
10 General population Republic of Korea 0.36 0.89 0.91 2.30
10 Infants Bulgaria 1.33 3.36 – –
10 Other children Bulgaria 0.79 1.98 1.93 4.86
10 Other children Italy 0.28 0.70 0.55 1.39
10 Other children Latvia 0.48 1.22 1.22 3.07
10 Toddlers Bulgaria 0.71 1.78 1.91 4.81
10 Toddlers Italy 0.32 0.82 – –
10 Very elderly Italy 0.13 0.33 0.34 0.85
11 Adolescents Belgium 0.70 1.77 1.72 4.34
11 Adults Belgium 0.57 1.43 1.65 4.16
11 Adults Netherlands 0.56 1.41 1.43 3.60
11 Elderly Belgium 0.28 0.70 0.79 1.98
11 Other children Belgium 0.92 2.32 2.77 6.97
11 Other children Netherlands 0.49 1.24 2.69 6.77
11 Toddlers Belgium 1.31 3.29 – –
11 Toddlers Netherlands 0.53 1.33 3.63 9.14
11 Very elderly Belgium 0.27 0.67 0.87 2.20
13 Adult women Burkina Faso 0.58 1.47 1.45 3.64
13 Children Burkina Faso 1.09 2.74 1.66 4.18
15 Adolescents Czech Republic 0.67 1.69 1.81 4.55
15 Adolescents Denmark 0.49 1.23 1.24 3.12
15 Adolescents Sweden 0.57 1.44 1.37 3.45
15 Adults Czech Republic 0.40 1.00 1.10 2.78
15 Adults Denmark 0.27 0.68 0.85 2.15
15 Adults Hungary 0.27 0.69 0.72 1.81
15 Adults Ireland 0.22 0.55 0.71 1.78
15 Adults Sweden 0.27 0.68 0.81 2.03
15 Elderly Denmark 0.14 0.35 0.58 1.45
15 Elderly Hungary 0.17 0.42 0.41 1.03
15 Other children Czech Republic 0.87 2.18 2.39 6.03
15 Other children Denmark 0.56 1.41 1.34 3.37
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Cluster  Age class
Consumers onlya
Country Mean-L Mean-H P95 max-L P95 max-H
15 Other children Sweden 0.82 2.05 1.91 4.81
15 Very elderly Denmark 0.08 0.20 0.19 0.48
15 Very elderly Hungary 0.19 0.48 0.57 1.43
16 Adult women Uganda 0.22 0.55 0.27 0.68
 Toddlers USAb 1.47 3.70 3.31 8.33
 Children USAb 0.90 2.27 1.97 4.97
 Adolescents – f USAb 0.62 1.57 1.27 3.20
 Adolescents – m USAb 0.70 1.77 1.34 3.37
 Adults – f USAb 0.56 1.40 1.14 2.87
 Adults – m USAb 0.66 1.67 1.32 3.33
 Toddlers Mexicob 0.70 1.76 1.65 4.15
 Children Mexicob 0.65 1.65 1.33 3.35
 Adolescents – f Mexicob 0.47 1.19 1.01 2.56
 Adolescents – m Mexicob 0.52 1.31 1.06 2.67
 Adults – f Mexicob 0.32 0.80 0.70 1.76
 Adults – m Mexicob 0.41 1.02 0.86 2.16
 Young children (1–5 years) South Africac 1.63 4.10 4.10 10.90
 Children South Africac 1.23 2.74 3.10 6.90
 10+ years South Africac 0.60 1.83 1.50 4.60
–: not applicable owing to the small number of consumers; f: female; H: high; L: low; m: male; max: maximum; P95: 95th percentile
α Mean-L, P95-L: based on low benzoate concentration (83 mg/L); mean-H, P95-H: based on high benzoate concentration (209 mg/L). 
b Based on consumption figures from the submitted data. 
c Based on the highest consumption figures of beverages from the submitted data.
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1.  explanation
At the request of the Codex Committee on Food Additives at its Forty-sixth Session 
(FAO/WHO, 2014), the Committee evaluated the safety of lipase (triacylglycerol 
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lipase; Enzyme Commission No. 3.1.1.3) from Fusarium heterosporum expressed in 
Ogataea polymorpha, which it had not previously considered. Ogataea polymorpha 
was recently renamed from Hansenula polymorpha based on genetic analyses (Suh 
& Zhou, 2010). Lipase hydrolyses ester bonds in the 1- and 3-positions of fatty 
acids in triglycerides. The enzyme also has activity towards sn-1 ester bonds in 
other lipid components, including diacyl-phospholipids and diacyl-galactolipids. 
In this report, the expression “lipase” refers to the lipase enzyme and its amino 
acid sequence, the expression “lipase liquid enzyme concentrate” refers to the test 
material used in the toxicity studies evaluated, and the expression “lipase enzyme 
preparation” refers to the preparation formulated for commercial use. The lipase 
enzyme preparation is used as a processing aid in the manufacture of bakery 
products, pasta and noodles, in egg yolk and in the degumming of edible oil.
1.1 Genetic background
The host microorganism, Ogataea polymorpha, was recently renamed from 
Hansenula polymorpha based on genetic analyses (Suh & Zhou, 2010). Therefore, 
the name H. polymorpha still appears in many references. Ogataea polymorpha is 
a non-pathogenic and non-toxigenic yeast commonly used in commercial food 
enzyme production. In a previous evaluation by the Committee, it was determined 
to be the safe host microorganism for the production of hexose oxidase (Annex 
1, reference 174).
 A uracil auxotroph of the wild-type O. polymorpha strain ATCC 34438, 
designated as RB11, was further genetically modified via plasmid transformation 
to produce a lipase originating from F. heterosporum. The transformation vector 
was created from a modified Escherichia coli pBR322 in which the genes encoding 
ampicillin resistance (Apr) and tetracycline resistance (TCr) had been removed. 
The synthetic lipase gene, containing a codon sequence optimized for maximum 
production in O. polymorpha of the native F. heterosporum lipase, combined with 
a promoter and a terminator from native O. polymorpha, was inserted into the 
vector. The Saccharomyces cerevisiae oritidine-5ʹ-phosphate decarboxylase gene 
(URA3) was also inserted into the vector as a selectable marker. The resulting 
vector was used to transform the host strain RB11 to obtain the lipase production 
strain O. polymorpha GICC03251. The genetic construction was verified by 
Southern blot analysis to confirm that only the intended genetic modification 
to the O. polymorpha strain had been made. The production strain is stable with 
respect to the introduced DNA.
1.2 Chemical and technical considerations
Lipase is produced by submerged straight-batch or fed-batch pure culture 
fermentation of a genetically modified strain of O. polymorpha containing a 
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synthetic gene that encodes the same amino acid sequence as the native lipase 
gene from F. heterosporum. The fermentation broth carrying the enzyme is 
separated from the biomass by filtration and/or centrifugation. The liquid filtrate 
containing the enzyme is then concentrated by ultrafiltration, followed by polish 
filtration. Food-grade preservatives are added to the enzyme concentrate before 
spray-drying or agglomeration, and the product is formulated to the desired 
activity with food-grade ingredients. The lipase enzyme preparation conforms to 
the General Specifications and Considerations for Enzyme Preparations Used in 
Food Processing (http://www.fao.org/ag/agn/jecfa-additives/docs/enzymes_en.htm). 
 Lipase activity is measured in titratable phospholipase units (TIPU). One 
TIPU is defined as the amount of enzyme liberating 1 μmol free fatty acid from 
a lecithin substrate per minute under the assay conditions. The mean activity of 
lipase from three batches of the lipase enzyme concentrate was approximately 
14 000 TIPU/g. The mean total organic solids (TOS) content of these three batches 
was 15%. TOS includes the enzyme of interest and residues of organic materials, 
such as proteins, peptides and carbohydrates, derived from the production 
organism during the manufacturing process. The final commercial formulations 
can vary widely in activity and TOS content, depending on the use. The lipase 
enzyme preparation is used at concentrations up to 220 mg TOS/kg raw material, 
depending on the proposed food application. Lipase is expected to be inactivated 
in food or removed from the oil.
2. Biological data
2.1 Assessment of potential allergenicity
Lipase from F. heterosporum is a triacylglycerol lipase with a known amino acid 
sequence and a molecular weight of approximately 30 kDa. It was evaluated 
for potential allergenicity using the bioinformatics criteria recommended by 
FAO/WHO (2001, 2009), but modified at the present meeting. The amino acid 
sequence of lipase was compared with the amino acid sequences of known 
allergens in the AllergenOnline database (http://www.allergenonline.org/index.
shtml) and in the Allermatch database (http://www.allermatch.org). A search for 
matches with greater than 35% identity over a window of 80 amino acids and a 
search for sequence identity of eight contiguous amino acids produced no match. 
Additionally, a full-length FASTA sequence search found two matches: Pha a 5 
from Phalaris aquatica (identity 28.33% in 120 amino acid stretches) and Art v 
2 from Artemisia vulgaris (identity 35.0% in 40 amino acid stretches). However, 
these two matches are identified as pollen allergens, not food allergens. 
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 Based on these data, the Committee considered that dietary exposure to 
lipase from F. heterosporum is not anticipated to pose a risk of allergenicity. 
2.2 Toxicological studies
Toxicological studies of lipase have been performed using either a lipase liquid 
enzyme concentrate (with TOS of 6.69% and protein content of 0.4%) or its 
freeze-dried powdered form (with TOS of 90.1% and protein content of 6.2%).
2.2.1 Acute toxicity 
A good laboratory practice (GLP)–compliant acute oral toxicity study was 
performed in female Sprague-Dawley: Hsd:SD: Tu rats (Madetoja, 2005a). The 
test material was the freeze-dried powdered form of the lipase liquid enzyme 
concentrate suspended in sterile water at a concentration of 133 mg/mL. Ten 
millilitres of the test material was administered orally by gavage to rats that had 
been fasted overnight. In the sighting study, one female rat was administered 
a single dose of the test material at 1.33 g/kg body weight (bw) (equivalent to 
1200 mg TOS/kg bw) and was observed for clinical signs for 14 days. With a 
lack of toxicity in the sighting study, the same single dose of the test material 
was administered to four additional female rats in the main study, followed by a 
14-day observation period. At the end of the study, all the animals were weighed 
and terminated. A gross necropsy was performed, and all macroscopic signs were 
recorded.
 No abnormal clinical signs were observed during the study, and all 
animals survived in good condition during the whole experiment. The body 
weight gains were normal in all animals during the observation period. No 
treatment-related macroscopic findings were noted at necropsy. Therefore, under 
these experimental conditions, oral administration of the freeze-dried powdered 
form of lipase liquid enzyme concentrate at 1.33 g/kg bw (equivalent to 1200 mg 
TOS/kg bw) to female rats did not result in acute toxicity (Madetoja, 2005a).
2.2.2 Short-term studies of toxicity
A GLP-compliant 13-week repeated-dose oral toxicity study in SPF Hsd: Sprague-
Dawley rats was performed according to Organisation for Economic Co-operation 
and Development (OECD) test guideline 408 (Madetoja, 2005b). In this study, the 
lipase liquid enzyme concentrate was given to four groups of rats (10 of each sex 
per group) by gavage at a dose of 0 (sterile water), 67, 201 or 669 mg TOS/kg bw 
per day in a constant volume of 10 mL/kg bw. The animals were fed ad libitum 
and had free access to water. The general well-being of the animals and clinical 
signs were observed daily. A necropsy was performed at the end of the study.
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 All animals survived in good condition during the whole study. No 
abnormal treatment-related clinical signs, including changes in the eyes, were 
observed. Statistically significant differences in feed and water consumption 
were observed between the treated group and the control group. However, these 
changes are considered to be of no biological significance, as no changes in body 
weight or body weight gain were observed.
 At necropsy, isolated incidences of macroscopic findings were noted (i.e. 
enlarged lymph nodes, hyperaemia in small intestine, erosion of stomach mucus). 
However, these occurrences were identified within the background values specific 
for rats of this strain and age. Additionally, none of these findings was dose related 
or could be attributed to exposure to the test material. 
 The total serum bilirubin level was statistically significantly increased 
in the two highest dose groups in both male and female animals at study 
termination. However, the values were still within the historical control range. No 
histopathological changes were identified in the liver. 
 No treatment-related effects on organ weights or urine analysis were 
noted. Macroscopic findings were minor and are considered to be of little 
biological significance. Microscopic examination of the liver and kidneys did not 
reveal any functional changes. The microscopic findings were considered to be 
incidental findings for animals of this strain and age. It was concluded that there 
were no observed treatment-related signs of clinical or systemic toxicity. 
 A no-observed-adverse-effect level (NOAEL) of 669 mg TOS/kg bw per 
day, the highest dose tested, was identified (Madetoja, 2005b). 
2.2.3 Long-term studies of toxicity and carcinogenicity
No information was available. 
2.2.4 Genotoxicity
The freeze-dried powdered form of the lipase enzyme concentrate, dissolved in 
water, was tested for genotoxicity using the bacterial reverse mutation test (Ames 
assay) and the in vitro chromosomal aberration assay. Both studies were GLP 
compliant and were conducted in accordance with the respective OECD test 
guideline (471 and 473, respectively). The results of these studies were negative 
(Table 1), indicating that the lipase enzyme preparation was unlikely to be 
genotoxic.
2.2.5 Reproductive and developmental toxicity
No information was available. 
32
W
H
O
 F
oo
d 
Ad
di
tiv
es
 S
er
ie
s N
o.
 7
1,
  2
01
5
Safety evaluation of certain food additives and contaminants   Eightieth  JECFA
2.3 Observations in humans 
No information was available. 
3. Dietary exposure 
3.1 Introduction
The Committee evaluated one submission received from DuPont Industrial 
Biosciences, a manufacturer of the lipase enzyme preparation.
 The lipase enzyme preparation is used internationally, being approved 
for use in Australia, Brazil, Denmark, France, Mexico and New Zealand, and is 
generally recognized as safe for use in food processing in the USA. The lipase 
enzyme preparation is used across a number of food products, and therefore an 
upper-bounding dietary exposure assessment approach was taken. A theoretical 
“worst-case” dietary exposure estimate was made, assuming that 100% of food 
products in which lipase could be used would be manufactured using the product 
at its maximum proposed use levels and that 100% would remain in the final food 
products. 
End-point Test system Concentration Result Reference
In vitro
Reverse mutationa Salmonella typhimurium TA97, TA98, TA100 
and TA1535 and Escherichia coli WP2uvrA
10–5 000 µg/plate ±S9b Negative Marhan (2005a)
Chromosomal 
aberrationsc
Human lymphocytes 500–2 000 μg/mL ±S9b Negative Marhan (2005b)
Table 1
Genotoxicity of lipase from F. heterosporum expressed in O. polymorpha 
S9: 9000 × g supernatant fraction from rat liver homogenate
a The test was performed by the standard plate incorporation method. The positive controls used without S9 mix were N-ethyl-N-nitro-nitrosoguanidine (20 µg/plate) 
for TA97 and E. coli WP2uvrA; 2-nitrofluorene (10 µg/plate) for TA98; and sodium azide (5 µg/plate) for TA100 and TA1535. The positive controls used with S9 mix were 
2-aminoanthracene (10 µg/plate) for TA97, TA98 and TA100 and E. coli WP2uvrA; and cyclophosphamide (100 µg/plate) for TA1535. A preliminary dose range–finding test 
was carried out using TA100, with and without S9, for doses up to 5000 μg/plate. In the main study, each of the five strains was tested using five doses of the test material, 
ranging from 10 to 5000 μg/plate, with and without S9. All tests were repeated twice in two independent assays; each was performed in triplicate. The positive control 
substances produced marked increases over the concurrent negative control values, and the test substance was not toxic to the test bacteria. There was no significant 
increase in the number of induced revertant colonies in any strain at any dose in the tests both with and without metabolic activation.
b The S9 mix, which acts as an exogenous metabolic activation system, was prepared from the liver of male Wistar rats induced with a single intraperitoneal injection of 
Aroclor 1254 (500 mg/kg bw) 5 days before S9 preparation. 
c Positive controls used in the chromosomal aberration assay were thiopeta (1 μg/mL) and cyclophosphamide (100 μg/mL), with and without S9 mix. The result was con-
sidered positive if the test substance increased the average percentage of aberrant cells to more than twice that of the negative control value (water) and a dose–response 
relationship was observed. In a dose range–finding test (1000–5000 μg/mL), cell toxicity was observed at doses of 3000 μg/mL and above. Therefore, the two main tests 
were carried out with the test material at 500, 1000 and 2000 μg/mL. Cells were treated for 4 hours (with a 24-hour incubation time) in the first main test and 48 hours 
in the repeated main test. Two slides from each culture were prepared, and 50 well spread metaphases on each slide were examined. The negative and positive controls 
worked properly in all tests. The test material did not produce an increase in the frequency of aberrant cells more than twice the control values at any dose. 
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 The Committee concluded that a tiered approach to assessing potential 
dietary exposure to lipase was not necessary, as the upper-bounding exposure 
estimate was evaluated.
3.2 Dietary exposure assessment
Three broad uses were considered individually to arrive at a total dietary exposure 
estimate.
3.2.1 Bakery products, pasta and noodles
The lipase enzyme preparation is used to modify lipids used in flour/cereals for the 
production of bakery products, pasta and noodles. The sponsor used information 
on the consumption of flour from wheat, rye, corn, oat and barley in the USA to 
prepare its estimate of the dietary exposure from this use. Per capita consumption 
of these cereals was 79.2 kg/person per year (217 g/person per day, 3.6 g/kg bw 
per day for a 60 kg individual) in 2012 (USDA, 2012). If it is assumed that the 
lipase enzyme preparation is applied at the highest suggested rate of 44 mg TOS/
kg flour, the estimated dietary exposure is 0.16 mg TOS/kg bw per day. 
 Reference to the 17 consumption cluster diets of the Global Environment 
Monitoring System – Food Contamination Monitoring and Assessment 
Programme (GEMS/Food) (WHO, 2012) reveals that cluster G06 (including a 
number of Middle Eastern countries) has the highest apparent consumption of 
total cereal grains and flour, at 479.2 g/day (cluster G10, which includes the USA, 
has an apparent consumption of 260 g/day). If the lipase enzyme preparation is 
applied at the highest suggested rate of 44 mg TOS/kg flour, the dietary exposure 
for consumption of 479.2 g/day would be 21.1 mg TOS/day, or 0.35 mg TOS/kg 
bw per day for a 60 kg individual. 
3.2.2 Egg yolks
The lipase enzyme preparation is used in the modification of egg yolk lipids at 
a maximum rate of 220 mg TOS/kg egg. To estimate the contribution from egg 
yolks, the consumption of eggs by the population of the USA was used (USDA, 
2012). If an egg consumption of 14.6 kg/person per year (40 g/person per day, or 
0.67 g/kg bw per day for a 60 kg individual) is assumed and the maximum rate of 
220 mg TOS/kg egg is used, dietary exposure to lipase enzyme preparation would 
be 0.15 mg TOS/kg bw per day.
 Reference to the 17 GEMS/Food cluster diets (WHO, 2012) reveals that 
cluster G11 (Belgium and the Netherlands) has the highest apparent consumption 
of eggs, at 42.1 g/day (cluster G10, which includes the USA, has an apparent 
consumption of 17.6 g/day). The Committee concluded that the use of the cluster 
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diet information for cluster G11 would not give a dietary exposure estimate 
significantly different from that provided by the sponsor.
3.2.3 Degumming food oils
The lipase enzyme preparation is used as a degumming agent in the manufacture 
of food oils. The maximum intended use level of the lipase enzyme preparation 
is 22 mg TOS/kg crude oil. The sponsor used food oil consumption, as dairy fat, 
from the USA (USDA, 2012). If it is assumed that oil consumption is 13.4 g/
day (0.22 g/kg bw per day for a 60 kg individual) and that the lipase enzyme 
preparation is used at the maximum intended use level, dietary exposure would 
be estimated to be 0.005 mg TOS/kg bw per day.
 Reference to the 17 GEMS/Food cluster diets (WHO, 2012) reveals 
that cluster G08 (Austria, Germany, Poland and Spain) has the highest apparent 
consumption of total milk, mammalian and plant fats, at 89.8 g/day (cluster G10, 
which includes the USA, has the highest plant fat consumption, at 59.9 g/day, 
and cluster G15, primarily European countries, has the highest consumption of 
mammalian fat, at 14.1 g/day). If it is conservatively assumed that all fats would be 
degummed using the lipase enzyme preparation at its highest intended use level, 
dietary exposure as high as 0.03 mg TOS/kg bw per day could be estimated.
3.2.4 Assessment of total dietary exposure
The combination of the maximum dietary exposure from each of the three uses 
of lipase (0.35 + 0.15 + 0.03 mg TOS/kg bw per day) results in a potential total 
dietary exposure of 0.53 mg TOS/kg bw per day. This conservative estimate 
assumes maximum use concentrations, 100% market penetration for the 
production of products using the lipase enzyme preparation and the presence 
of the enzyme following the production processes. The Committee noted that 
under these conditions, the major contribution to total dietary exposure to lipase 
enzyme preparation would be from the consumption of bakery products, pasta 
and noodles.
4. Comments
4.1 Assessment of potential allergenicity
Lipase from F. heterosporum was evaluated for potential allergenicity using the 
bioinformatics criteria recommended by FAO/WHO (2001, 2009), but modified 
at the present meeting. The amino acid sequence of lipase from F. heterosporum 
was compared with the amino acid sequences of known allergens in publicly 
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available databases. A search for matches with greater than 35% identity over a 
window of 80 amino acids and a search for sequence identity of eight contiguous 
amino acids produced no match. Therefore, the Committee considered that 
dietary exposure to lipase from F. heterosporum is not anticipated to pose a risk 
of allergenicity. 
4.2 Toxicological studies
An acute oral toxicity study using a freeze-dried powdered form of a lipase liquid 
enzyme concentrate demonstrated no sign of toxicity at 1.33 g/kg bw in rats 
(Madetoja, 2005a). In a 13-week oral toxicity study in rats, no treatment-related 
adverse effects were observed when the lipase liquid enzyme concentrate was 
administered by gavage at doses up to 669 mg TOS/kg bw per day (Madetoja, 
2005b). The results from an in vitro bacterial reverse mutation assay (Marhan, 
2005a) and an in vitro chromosomal aberration assay in human lymphocytes 
(Marhan, 2005b) using the powdered form of the lipase enzyme concentrate were 
both negative. The Committee concluded that the lipase enzyme preparation is 
unlikely to be genotoxic. 
4.3 Assessment of dietary exposure
An estimate of the theoretical dietary exposure to this lipase enzyme preparation 
was made by the Committee based on the level of TOS in the lipase enzyme 
preparation and its maximum use levels in bakery products, pasta and noodles 
(44 mg TOS/kg flour) and egg yolk (220 mg TOS/kg egg) and in the degumming 
of edible oil (22 mg TOS/kg crude oil). The combination of these maximum levels 
with per capita food consumption data from the USA (supplied by the sponsor) 
or from the GEMS/Food cluster diets results in a potential total dietary exposure 
of 0.5 mg TOS/kg bw per day for a 60 kg individual. The Committee noted that 
the enzyme will be inactivated in baking and cooking steps and will be removed 
from the refined oil. 
5. evaluation 
No treatment-related adverse effects were seen at the highest dose tested (669 
mg TOS/kg bw per day) in the 13-week study of oral toxicity in rats (Madetoja, 
2005b). A comparison of the dietary exposure estimate of 0.5 mg TOS/kg bw 
per day with the highest dose tested of 669 mg TOS/kg bw per day results in a 
margin of exposure of at least 1300. The Committee established an acceptable 
daily intake (ADI) “not specified” for lipase from F. heterosporum expressed in O. 
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polymorpha when used in the applications specified and in accordance with good 
manufacturing practice. 
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1.  explanation
The commercial product called magnesium stearate is composed mainly of 
magnesium salts of stearic and palmitic acids, obtained from edible fats and oils.
 In 2010, at the Forty-second Session of the Codex Committee on Food 
Additives (CCFA) (FAO/WHO, 2010), the deletion of magnesium salts of fatty 
acids from the International Numbering System (INS) had been proposed. 
The International Alliance of Dietary/Food Supplement Associations offered 
technological justification for the use of this additive. CCFA at its Forty-third 
Session in 2011 (FAO/WHO, 2011) assigned the new INS number 470(iii) to 
magnesium stearate and asked the Committee to conduct a safety assessment, 
assess dietary exposure and set specifications for magnesium stearate.
 Magnesium salts of fatty acids, previously included in the INS as number 
470 (salts of fatty acids), have been evaluated by the Committee at its seventeenth, 
twenty-ninth, forty-ninth and seventy-sixth meetings (Annex 1, references 32, 
70, 131 and 211). At the seventeenth meeting (1974), the Committee evaluated 
salts of palmitic and stearic acids and established acceptable daily intakes (ADIs) 
“not limited”,1 with notes that palmitic and stearic acids are normal products of 
the metabolism of fats and that their metabolic fate is well established. Provided 
that the contribution of cations such as magnesium does not add excessively 
to the normal body load, there would be no need to consider the use of these 
substances in any different light to that of dietary fatty acids.
 At its twenty-ninth meeting (1986), the Committee was of the opinion that 
“ADIs for ionizable salts should be based on previously accepted recommendations 
for the constituent cations and anions”. The Committee listed ADIs for a number 
of combinations of cations and anions, including those of magnesium stearate 
and magnesium palmitate (ADI “not specified”). The Committee was concerned 
that dietary exposure resulting from the use of magnesium salts as food additives 
may have a laxative effect. It was also noted that infants are particularly sensitive 
to the sedative effects of magnesium salts and that individuals with chronic renal 
impairment retained 15–30% of administered magnesium, which could cause 
toxicity. The Committee stated that fatty acids are normal constituents of coconut 
oil, butter and other edible oils and that they do not represent a toxicological 
problem. As the Committee had no information on the manufacture or use of 
the food-grade materials at that time, an ADI for magnesium stearate was not 
established. 
 At its forty-ninth meeting (1999), the Committee evaluated the safety of 
palmitic acid and stearic acid when used as flavouring agents and concluded that 
they would not present a safety concern under the proposed conditions of use.
1 This term is no longer used by JECFA. It has the same meaning as ADI “not specified”.
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 At its seventy-sixth meeting (2012), the Committee established an 
ADI “not specified” for a number of magnesium-containing food additives and 
recommended that total dietary exposure to magnesium from food additives 
and other sources in the diet should be assessed. This was in the context of 
the evaluation of magnesium dihydrogen diphosphate, in which the estimated 
chronic dietary exposure to magnesium from the proposed uses was up to twice 
the background exposures from food previously noted by the Committee and 
may be in the region of the minimum laxative effective dose.
 For the present evaluation, a range of published studies together with 
three reports on genotoxicity testing of magnesium stearate were submitted to 
the Committee.
 Magnesium stearate has been permitted for use in the European Union 
(EU, 2008) and is generally recognized as safe (GRAS) in the USA (CFR, 1985; 
FDA SCOGS, 2013). It is also permitted for use in China (NHFPC, 2014), Japan 
(FSC, 2003), and Australia and New Zealand (FSANZ, 2014).
1.1 Chemical and technical considerations
Magnesium stearate is an off-white to white, very fine powder that is greasy to 
the touch and practically insoluble in water. It is used as an anticaking agent, 
emulsifier and binder in food supplement tablets, capsules and powders, 
compressed and granulated mints and candy, chewing gum, herbs and spices, and 
bakery ingredients. According to the industry, the use levels in these categories 
range from 0.05% to 3% by weight.
 The commercial product is manufactured by either a direct process, called 
fusion, in which fatty acids are directly reacted with a magnesium source, such 
as magnesium oxide, to form magnesium salts of the fatty acids; or an indirect 
process, called precipitation, in which a sodium soap is produced by the reaction 
of fatty acids with sodium hydroxide in water and the product is precipitated by 
adding magnesium salts to the soap.
 The final product contains not less than 4.0% and not more than 5.0% 
magnesium, on a dried basis, and the fatty acid fraction contains not less than 
40.0% stearic acid and not less than 90.0% of the sum of stearic acid and palmitic 
acid. Specifications for unsaponifiable matter are set to not more than 2%. In 
addition, the limits for cadmium, lead and nickel are specified.
 According to the data provided by industry, magnesium stearate is a 
stable product for which no decomposition products are expected under normal 
storage conditions.
 Magnesium distearate as such has the chemical formula Mg(C18H35O2)2 
and a molecular weight of 591.27 g/mol. The molecular structure of magnesium 
distearate is shown in Fig. 1.
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Fig. 1
Molecular structure of magnesium distearate
 
Mg2+
 Besides magnesium salts of stearic acid and palmitic acid, other 
magnesium salts with fatty acids, such as lauric acid, myristic acid, pentadecanoic 
acid, margaric acid, oleic acid and arachic acid, may be present in the additive as 
minor components. The composition and distribution of the fatty acid fraction 
of commercial magnesium stearate depend on the vegetable or animal source 
of the fatty acid used as raw material for the production of the additive and the 
fractionation conditions to which the source material was subjected.
2. Biological data
2.1 Biochemical aspects
Magnesium stearate, under the acidic conditions of the stomach, is dissolved 
upon ingestion and separated into magnesium ion (cation) and stearic and 
palmitic acids (anions). The components are not necessarily absorbed in equal 
amounts.
 Magnesium is an essential mineral, acting as a cofactor for many enzyme 
systems. It is involved in energy metabolism, the synthesis of proteins and 
nucleotides, and the metabolism and activation of vitamin D and parathyroid 
hormone. It is a normal constituent of the human body and is ubiquitous in foods, 
where it is commonly bound to phosphates. Recommended Dietary Allowances, 
which are considered to meet the nutrient needs of 97–98% of individuals in 
a population, have been set at 80–420 mg of magnesium per day for different 
age groups by the Institute of Medicine in the USA (Institute of Medicine, 1997; 
Annex 1, reference 211).
 Palmitic and stearic acids and their salts are constituents and products 
of the metabolism of edible oils and fats, for which the metabolic fate is well 
established. Stearic acid is the most poorly absorbed of the common fatty acids 
and is synthesized by the condensation of palmitoyl and acetyl coenzyme A 
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Species Sex Route LD50 (g/kg bw) or LC50 (mg/L) Reference
Rat Unknown Oral LD50 >10 S.B. Penick & Co. (1977) 
Rabbit Unknown Dermal Non-corrosive S.B. Penick & Co. (1977) 
Rabbit Unknown Dermal Non-irritating S.B. Penick & Co. (1977) 
Rabbit Unknown Ocular Non-irritating S.B. Penick & Co. (1977) 
Rat Unknown Inhalation LC50 >2 mg/L S.B. Penick & Co. (1977) 
Table 1
Acute toxicity of magnesium stearate
bw: body weight; LC50: median lethal concentration; LD50: median lethal dose 
in the mitochondria. As palmitic and stearic acids undergo oxidation to give 
acetoacetic acid and ketone bodies, their β-oxidation yields two-carbon units, 
which enter the tricarboxylic acid cycle; the metabolic products are utilized and 
excreted (Cosmetic Ingredient Review, 1987; Annex 1, reference 70). These fatty 
acids are of no toxicological concern and are therefore not further considered in 
this assessment.
2.2 Toxicological studies
2.2.1 Acute toxicity
(a) Magnesium stearate
The oral median lethal dose (LD50) for magnesium stearate (composition 
unknown) in rats was greater than 10 g/kg body weight (bw), indicating that 
magnesium stearate is practically non-toxic. The results of acute toxicity tests for 
magnesium stearate administered to experimental species by different routes are 
summarized in Table 1. 
2.2.2 Short-term studies of toxicity
(a) Magnesium stearate 
(i) Rats
In a 90-day repeated-dose oral toxicity study, a commercial product of magnesium 
stearate was mixed with a semisynthetic diet and given to four groups of Wistar 
rats (20 animals of each sex per group) at a concentration of 0%, 5%, 10% or 20%. 
The test material was prepared according to Pharmacopoeia Nordica 1963, and 
the details of its composition were not available. 
 Decreased body weight gain was observed in males in the high-dose 
group (20%), and urolithiasis was found in eight males and seven females in the 
same group. Four males from the 20% dose group died within the first 2 months; 
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these deaths were related to stone formation in the lower urinary pathways. 
Reduced relative liver weight was seen in males in the 10% and 20% groups, 
and an increased amount of iron was found in the livers of rats of both sexes in 
the 20% group. Nephrocalcinosis was reduced in females in the 20% group. The 
authors concluded that the no-observed-effect level (NOEL), based on reduction 
in relative liver weight, was 5% magnesium stearate in the diet, equivalent to 
2500 mg/kg bw per day, as determined by the authors (Sondergaard, Meyer & 
Würtzen, 1980).
 The Committee concluded that this study was not relevant for the 
evaluation given the high concentration tested, which might lead to dietary 
imbalances, and the lack of information on the composition of the material 
tested.
(b) Magnesium 
(i) Rats 
At its seventy-sixth meeting, the Committee reviewed short-term studies of the 
toxicity of magnesium chloride hexahydrate in its evaluation of magnesium 
dihydrogen diphosphate. Groups of 10 male and 10 female F344 rats were fed 
magnesium chloride hexahydrate at a dietary concentration of 0%, 0.1%, 0.5% or 
2.5% for 90 days. These dietary concentrations were equivalent to 0, 100, 500 and 
2500 mg/kg bw per day, corresponding to, respectively, 0, 12, 60 and 300 mg/kg 
bw per day expressed as magnesium. 
 Transient soft faeces and a sustained increase in water consumption were 
observed in both high-dose males and females, and a slight reduction in body 
weight gain was also noted in the high-dose males. There were no changes in feed 
consumption, organ weights, haematology, biochemistry or histopathology. The 
no-observed-adverse-effect level (NOAEL) was reported to be 0.5% magnesium 
chloride hexahydrate in the diet, equivalent to 60 mg/kg bw per day expressed as 
magnesium (Takizawa et al., 2000).
2.2.3 Long-term studies of toxicity and carcinogenicity
(a) Magnesium stearate
(i) Mice 
Magnesium stearate pellets implanted in the urinary bladders of mice (bred at the 
test institute) for 30 weeks produced a tumour incidence of 5% (2/41 mice, one 
adenoma or papilloma and one carcinoma). This study is not considered relevant 
for the evaluation of the potential cancer risk from ingested stearates (Boyland 
et al., 1964).
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(b) Magnesium 
(i) Mice 
At its seventy-sixth meeting, the Committee reviewed long-term studies of the 
toxicity and carcinogenicity of magnesium chloride hexahydrate in its evaluation 
of magnesium dihydrogen diphosphate. Groups of 50 male and 50 female 
B6C3F1 mice were given magnesium chloride hexahydrate (MgCl2.6H2O) at 
a dose level of 0% (control), 0.5% or 2% in the diet for 96 weeks, after which 
all animals received the control diet for 8 weeks and were then necropsied. The 
dietary concentrations were equivalent to 0, 750 and 3000 mg/kg bw per day, 
corresponding to, respectively, 0, 90 and 360 mg/kg bw per day expressed as 
magnesium. 
 A decrease in body weight was observed in females of the high-dose 
group. Survival rates did not differ between the treatment and control groups for 
males or females. Clinical signs and urinary, haematological and serum clinical 
chemistry parameters showed no treatment-related effects. With the exception of 
a significant decrease in the incidence of liver tumours among males of the high-
dose group, no differences were noted in tumour incidence between the treated 
and control animals. Based on the decreased body weight gain in the high-dose 
females, the NOAEL was 0.5% magnesium chloride hexahydrate in the diet, 
equivalent to 90 mg/kg bw per day expressed as magnesium (Kurata et al., 1989).
2.2.4 Genotoxicity
(a) Magnesium stearate
In a series of in vitro and in vivo assays, no genotoxic potential of magnesium 
stearate was identified. The results of these studies of genotoxicity are summarized 
in Table 2.
2.2.5 Reproductive toxicity
(a) Magnesium stearate
(i) Rabbits
A tablet-coating vehicle containing 5.5% magnesium stearate was tested for 
teratogenicity in rabbits. Other components of this vehicle included polyethylene 
glycol 4000, starch, talcum and silica gel. Female rabbits were given this vehicle 
orally at a dose of 2.5 mg/kg bw 70 hours postcoitus (n = 14) and 192 hours 
postcoitus (n = 13). Fetal anomalies were observed in 9/86 and 11/90 offspring, 
respectively, compared with 12/112 anomalies in offspring from untreated 
control mothers (n = 16). The vehicle did not demonstrate teratogenicity at the 
dose tested in this study (Cosmetic Ingredient Review, 1982). The Committee 
noted that the vehicle tested was composed of many components with unknown 
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bw: body weight; S9: 9000 × g supernatant fraction of liver homogenate from various species; w/v: weight per volume
a Negative control substance: dimethylformamide. Positive control substances without metabolic activation: ethylmethanesulfonate for TA1535 and D4, 2-nitrofluo-
rene for TA1538, quinacrine mustard for TA1537. Positive control substances with metabolic activation: dimethylnitrosamine for TA1535 and D4, 8-aminoquinoline 
for TA1537, 2-aminoanthracene for TA1538. These positive controls produced the expected increase in the number of revertants. In this assay, the test substance 
is considered positive (mutagenic) if it produces at least a doubling of the mean number of revertants per plate in one or more strains compared with the solvent 
control, with or without metabolic activation. 
b  The S9 is the 9000 × g supernatant fraction of liver homogenate from male mice, male rats or male monkeys, without liver enzyme induction. The three S9 fractions, 
acting as an exogenous metabolic activation system, were used in separate experiments.
c  Positive control substances without metabolic activation: 2-(2-furyl)-3-(5-nitro-2-furyl) acrylamide for TA100 and TA98, N-ethyl-N′-nitrosoguanidine for TA1535 and 
WP2uvrA, 9-aminoacridine hydrochloride monohydrate for TA1537. Positive control substance with metabolic activation for all test strains: 2-aminoanthracene. All 
positive control substances produced the expected increase in the number of revertants. In this assay, the test substance is considered positive (mutagenic) if it pro-
duces at least a doubling of the mean number of revertants per plate in one or more strains compared with the solvent control, with or without metabolic activation. 
d  The S9 is the 9000 × g supernatant fraction of liver homogenate from male rats treated with phenobarbital and 5,6-benzoflavone intraperitoneally. The S9 fraction 
acts as an exogenous metabolic activation system.
e  Negative control substance: sodium carboxymethylcellulose. Positive control substance without metabolic activation: mitomycin. Positive control substance with 
metabolic activation: benzo[a]pyrene. All positive controls produced a statistically significant increase in the incidence of cells with chromosomal aberration. In this 
test, the test substance is considered positive (clastogenic) if the frequency of cells with chromosomal aberrations is significantly increased in the test substance 
group compared with the negative control group and if dose dependency or reproducibility was noted.
f  Sampling times were 24, 48 and 72 hours. Negative control substance: sodium carboxymethylcellulose. Positive control substance: mitomycin. The test substance is 
considered positive (clastogenic) if the incidence of micronucleated polychromatic erythrocytes in the test substance group was significantly higher than that in the 
negative control group at a significance level of 5%.
Test system Test object Concentration/dose Results Reference 
In vitro
Reverse  
mutationa
Saccharomyces cerevisiae strain D4; 
Salmonella typhimurium strains 
TA1535, TA1537 and TA1538
1.25–5.0% (w/v) ±S9b Negative Brusick & Weir (1976)
Reverse  
mutationc
S. typhimurium strains TA98, 
TA100, TA1535 and TA1537; 
Escherichia coli WP2uvrA
Range finding:
5–5 000 μg/plate ±S9d
Main: 
156–5 000 μg/plate ±S9d
Negative Saigoh (2001a)
Chromosomal 
aberratione
Chinese hamster lung  
(CHL/IU) cells
Range finding:
24 h treatment:
5–5 000 μg/mL 
Main: 
6 h treatment:
1.56–50 μg/mL −S9;
31.3–1 000 μg/mL +S9d
24 h treatment:
0.313–10 μg/mL −S9
48 h treatment:
0.156–5 μg/mL −S9
Negative Saigoh (2001b)
In vivo
Micronucleus 
formationf
Male ICR mice (CD-1) femoral bone 
marrow
Preliminary:
31.3–2 000 mg/kg bw, oral 
(6 mice/group)
Main:
500–2 000 mg/kg bw, oral 
(6 mice/group)
Negative Saigoh (2001c)
Table 2
results of genotoxicity tests with magnesium stearate 
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proportions and that the percentage of magnesium stearate was only 5.5%. Owing 
to this limitation, the Committee concluded that this study was not relevant for 
the evaluation.
2.3 Observations in humans
2.3.1 Magnesium stearate
No information was available.
2.3.2 Magnesium
Adverse effects such as diarrhoea or other gastrointestinal effects have been 
seen with excessive magnesium intake as a consequence of the use of various 
magnesium salts for pharmacological or medicinal purposes. The United 
Kingdom Expert Group on Vitamins and Minerals reviewed a number of human 
studies on magnesium and concluded that there were insufficient data to establish 
a safe upper level for magnesium. For guidance purposes only, it suggested that 
supplemental magnesium at a dose of 400 mg/day would not be expected to 
result in any significant adverse effects (EVM, 2003). 
 Based on a series of human studies, the European Union’s Scientific 
Committee on Food (SCF) concluded that no laxative effects have been observed 
in adult men and women, including during pregnancy and lactation, at doses 
up to 250 mg/day. This dose was considered to be the NOAEL for magnesium. 
Based on the NOAEL of 250 mg/day and an uncertainty factor of 1.0, the SCF 
established an upper level of 250 mg/day for readily dissociable magnesium 
salts (e.g. chloride, sulfate, aspartate, lactate) and compounds in nutritional 
supplements, in water or added to food and beverages (SCF, 2006). 
 The Institute of Medicine’s Standing Committee on the Scientific 
Evaluation of Dietary Reference Intakes in the USA noted that the primary 
initial and the most sensitive toxic manifestation of excessive magnesium intake 
from non-food sources is diarrhoea. That committee reviewed several studies 
that reported mild diarrhoea and other gastrointestinal symptoms from uses of 
magnesium salts and identified a lowest-observed-adverse-effect level (LOAEL) 
of 360 mg/day for adults. Based on the LOAEL and an uncertainty factor of 
approximately 1.0, an upper level of 350 mg/day for magnesium from non-food 
sources was established (Institute of Medicine, 1997; Annex 1, reference 211).
3. Assessment of dietary exposure
Magnesium stearate is used for diverse purposes, such as an anticaking agent, 
binder, drying agent, emulsifier, foaming agent, hydrophobation agent, lubricant 
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and/or thickener in confectionery (hard candy, pressed mint, mint pastilles), 
chewing gum, food supplements (tablets, capsules, powders), bakery wares 
(rusks, baking powder), herbs and spices. Magnesium stearate is also used in the 
pharmaceutical industry in the production of tablets, capsules and powders.
 The Committee evaluated one submission by a sponsor (APAG, 2014). 
A survey on current food applications of magnesium stearate from 2013 was 
included in the submission and was used as a basis for an assessment of the 
expected dietary exposure to magnesium stearate (Table 3).
 The submission estimated that magnesium stearate will be used in about 
75% of all food supplement tablets and capsules, over 90% of confectionery 
candies and pastilles and up to 30% of chewing gum produced. The usage 
proportion in rusks, baking powder and herbs and spices is not known.
3.1 Assessments based on individual dietary records
An assessment of dietary exposure was performed using the above proposed 
maximum use levels in corresponding food categories and the data set of 
the European Food Safety Authority’s (EFSA) Comprehensive European 
Food Consumption Database (EFSA, 2013) for consumption groups “Other 
confectionery”, “Chewing gum”, “Bakery wares”, “Herbs, spices, seasonings” 
and “Food supplements”. For the consumer groups “Children” (3–9 years) and 
“Adults” (18–64 years), consumption data from 13 and 14 European countries 
were available, respectively. The estimated dietary exposures to magnesium 
stearate (per country) for high-level consumption using the proposed maximum 
use levels were 21–44 mg/kg bw per day for children and 9–83 mg/kg bw per day 
for adults.
 For children, estimates from four countries were higher than 40 mg/kg 
bw per day (Denmark: 44 mg/kg bw per day; United Kingdom: 43 mg/kg bw per 
day; Czech Republic: 42 mg/kg bw per day; Germany: 41 mg/kg bw per day); 
estimates from the majority of the remaining countries were between 25 and 
35 mg/kg bw per day. The predominant source was “Bakery wares” (55–96%), 
followed by “Other confectionery” (2–40%), except for France, where “Other 
confectionery” was the main contributor (73%).
 For adults, the majority of estimates for high-level consumers were in 
the range 10–20 mg/kg bw per day. Germany had the highest estimate, 83 mg/
kg bw per day, followed by the Czech Republic, with 64 mg/kg bw per day, and 
one survey from Spain, with 37 mg/kg bw per day. The predominant source was 
“Bakery wares” (72–96%), followed by “Other confectionery” (1–25%), except 
for Finland, where “Other confectionery” and “Food supplements” were the 
main contributors (58% and 26%, respectively, of an estimated exposure of 18 
mg/kg bw per day).
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GSFA category 
no. GSFA food category Technical functions
Proposed food 
uses
Average 
use level  
(mg/kg)
Maximum 
use level 
(mg/kg) 
05.2 Confectionery including hard and soft 
candy, nougats, etc. other than food 
categories 05.1, 05.3 and 05.4
Anticaking agent, lubricant, 
binder
Hard candy, 
pressed mint 
(05.2.1)
Mint pastille 
(05.2.1)
10 000
5 000
13 000
9 500
05.3 Chewing gum Emulsifier, anticaking agent, 
drying agent
Chewing gum 100–10 000 20 000
07.0 Bakery wares Foaming agent, emulsifier Rusks, baking 
powder
>500 2 500
12.2.1 Herbs and spices Anticaking agent, hydropho-
bation agent
Spices, herbs >500 10 000
13.6 Food supplements Lubricant, anticaking agent, 
emulsifier, thickener
Food supplements: 
(chewable) tablets, 
capsules, powders
13 000 30 000
Table 3
results of survey on use levels and food applications of magnesium stearate
GSFA: Codex General Standard for Food Additives
 In conclusion, the main contributing food category was bakery wares; 
however, the exposure estimate from this category is highly conservative when 
the use of the food additive is restricted to rusks and baking powder.
 Based on the product composition and molecular weights, the dietary 
exposure to the ion components of magnesium stearate would be approximately 
5% for magnesium and 95% for fatty acids (ratio 1:20). Thus, the estimated 
maximum dietary exposure to magnesium stearate of 44 mg/kg bw per day for 
children corresponds to 2 mg magnesium/kg bw per day and 42 mg fatty acids/
kg bw per day. The estimated maximum dietary exposure to magnesium stearate 
of 83 mg/kg bw per day for adults corresponds to 4 mg magnesium/kg bw per day 
(240 mg/day for a 60 kg adult) and 79 mg fatty acids/kg bw per day.
 Regarding magnesium, the Committee has stated previously that the 
background exposure to magnesium from food is 180–480 mg/day (Annex 1, 
reference 70). The conservative estimates for the uses described in the present 
submission would contribute up to an additional 240 mg/day to this background 
exposure to magnesium from food. However, at the seventy-sixth meeting (Annex 
1, reference 70), the Committee also noted that an ADI “not specified” has been 
allocated individually to a number of magnesium-containing food additives and 
recommended that total dietary exposure to magnesium from food additives and 
other sources in the diet should be assessed.
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4. Comments
4.1 Toxicological studies 
The oral LD50 for magnesium stearate of unknown composition administered 
to rats was greater than 10 g/kg bw (S.B. Penick & Co., 1977). The Committee 
reviewed a 90-day study in which rats were fed a diet containing 0%, 5%, 10% or 
20% of a commercial product of magnesium stearate of unknown composition 
(Sondergaard, Meyer & Würtzen, 1980). The Committee concluded that this 
study was not relevant for the evaluation given the high concentrations tested, 
which might lead to dietary imbalances, and the lack of information on the 
composition of the material tested. 
 Magnesium stearate was not genotoxic in bacterial reverse mutation 
assays (Brusick & Weir, 1976; Saigoh, 2001a) and did not induce chromosomal 
aberrations in mammalian cells (Saigoh, 2001b). Magnesium stearate was also 
not genotoxic in an in vivo mouse micronucleus assay (Saigoh, 2001c). 
4.2 Assessment of dietary exposure
An estimate of the theoretical dietary exposure to magnesium stearate was made 
by the Committee based on the proposed maximum use levels. The combination 
of these levels with consumption data using EFSA’s Comprehensive European 
Food Consumption Database (EFSA, 2013) for consumption groups “Other 
confectionery”, “Chewing gum”, “Bakery wares”, “Herbs, spices, seasonings” and 
“Food supplements” results in a potential total dietary exposure to magnesium 
stearate of 44 mg/kg bw per day for children and 83 mg/kg bw per day for adults, 
corresponding to 2 and 4 mg/kg bw per day expressed as magnesium, respectively. 
This would contribute up to an additional 240 mg/day to the background exposure 
to magnesium from food of 180–480 mg/day.
 The Committee noted that the consumption of the food additive may 
lead to an additional dietary exposure to stearic and palmitic acids in the order of 
5 g/day.
5. evaluation
An ADI “not specified” has been established for a number of magnesium salts 
used as food additives. The Committee concluded that there are no differences 
in the evaluation of the toxicity of magnesium stearate compared with other 
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magnesium salts and confirmed the ADI “not specified” for magnesium salts of 
stearic and palmitic acids. However, the Committee was concerned that the use 
of magnesium salts in many food additives may result in combined exposure that 
may lead to a laxative effect. 
5.1 Recommendation
Based on the present dietary exposure assessment, the Committee reiterates its 
earlier recommendation that total dietary exposure to magnesium from food 
additives and other sources in the diet should be assessed. This is important, as 
a large number of magnesium-containing food additives have been evaluated 
individually, but not collectively, in relation to their laxative effects.
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1.  explanation
At the request of the Codex Committee on Food Additives at its Forty-
sixth Session (FAO/WHO, 2014), the Committee evaluated the safety of 
maltotetraohydrolase (glucan 1,4-α-maltotetraohydrolase; Enzyme Commission 
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No. 3.2.1.60) from Pseudomonas stutzeri expressed in Bacillus licheniformis, 
which it had not considered previously. The donor organism was recently 
reclassified from Pseudomonas saccharophila. Maltotetraohydrolase catalyses the 
hydrolysis of 1,4-α-D-glucosidic linkages in amylaceous polysaccharides. The 
reaction removes successive maltotetraose residues from the non-reducing chain 
ends. In this report, the expression “maltotetraohydrolase” refers to the modified 
maltotetraohydrolase enzyme and its amino acid sequence, the expression 
“maltotetraohydrolase liquid enzyme concentrate” refers to the test material 
used in the toxicity studies evaluated, and the expression “maltotetraohydrolase 
enzyme preparation” refers to the preparation formulated for commercial use. 
The maltotetraohydrolase enzyme preparation is commonly used as a processing 
aid in bakery products such as bread, bread buns, tortillas and crackers, as well as 
in the starch processing industry for the manufacture of corn sweeteners, such as 
high-fructose corn syrup (HFCS). 
1.1 Genetic background
Maltotetraohydrolase is produced from a genetically modified strain of B. 
licheniformis, BML347, which is derived from B. licheniformis strain BRA-7. Bacillus 
licheniformis is a Gram-positive bacterium that is widely distributed in nature 
and is considered to be non-pathogenic and non-toxigenic. Bacillus licheniformis 
has a history of use in the production of enzymes used in food processing, 
including enzymes from genetically engineered strains of the organism. Bacillus 
licheniformis strain BRA-7 is also the production strain of pullulanase, which was 
previously evaluated by the Committee (Annex 1, reference 206). 
 The gene donor strain was originally identified as Pseudomonas 
saccharophila and was later reclassified as Pseudomonas stutzeri; thus, the name P. 
saccharophila still appears in most references (DuPont, 2014). 
 Prior to the introduction of the maltotetraohydrolase gene from P. 
stutzeri, the host B. licheniformis strain was genetically modified through a series 
of deletions of genes encoding α-amylase, chloramphenicol acetyltransferase, 
subtilisin, glutamic acid–specific protease and the spoIIAC gene responsible for 
sporulation. The resulting strain was transformed using an expression cassette 
containing the maltotetraohydrolase SAS3 gene, obtained from genetic cloning 
and a series of site-directed mutagenesis events. The maltotetraohydrolase SAS3 
gene encodes a variant of the wild-type P. stutzeri maltotetraohydrolase, with 
the C-terminal starch-binding domain removed, 16 amino acids changed and 
one methionine residue added at the N-terminus of the enzyme. These changes 
improved thermostability, baking performance and fermentation yield. Upon 
transformation, the maltotetraohydrolase expression cassette was integrated 
into the host B. licheniformis strain, and the rest of the plasmid was deleted by 
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recombinant excision. The final production strain was tested and found to be 
genetically stable.
1.2 Chemical and technical considerations
Maltotetraohydrolase is produced by submerged straight-batch or fed-batch 
pure culture fermentation of the genetically modified strain of B. licheniformis. 
The fermentation broth carrying the enzyme is separated from the biomass by 
filtration and/or centrifugation. The liquid filtrate containing the enzyme is then 
concentrated by ultrafiltration, followed by polish filtration. The resulting enzyme 
concentrate is either spray-dried and standardized to the desired activity with 
food-grade ingredients (powdered form) or treated with sodium benzoate and 
potassium sorbate to the desired activity (liquid form). The maltotetraohydrolase 
enzyme preparation conforms to the General Specifications and Considerations 
for Enzyme Preparations Used in Food Processing (http://www.fao.org/ag/agn/
jecfa-additives/docs/enzymes_en.htm). 
 The activity of the maltotetraohydrolase enzyme is measured in betamyl 
units (BMU). One BMU is defined as the activity degrading 0.0351 mmol of 
blocked p-nitrophenyl-α-D-maltoheptaoside per minute in the presence of 
amyloglucosidase and α-glucosidase at 25 °C in a reaction mix for 5 minutes. 
The mean activity of maltotetraohydrolase from three batches of the enzyme 
concentrate prior to formulation was approximately 300 000 BMU/g.
 A typical commercial formulation of the maltotetraohydrolase enzyme 
preparation will contain 32% total organic solids (TOS). TOS includes the enzyme 
of interest and residues of organic materials, such as proteins, peptides and 
carbohydrates, derived from the production organism during the manufacturing 
process. The maltotetraohydrolase enzyme preparation is used at levels up to 
23 mg TOS/kg raw material, depending on the proposed food application. The 
maltotetraohydrolase enzyme is expected to be inactivated during processing.
2. Biological data
2.1 Assessment of potential allergenicity 
The maltotetraohydrolase under evaluation contains 429 amino acids with 
known sequence, and its molecular weight (both theoretical and as determined 
by liquid chromatography–mass spectrometry) is 47.6 kDa. Maltotetraohydrolase 
was evaluated for potential allergenicity using the bioinformatics criteria 
recommended by FAO/WHO (2001, 2009), but modified at the present meeting. 
The amino acid sequence of maltotetraohydrolase was compared with the amino 
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acid sequences of known allergens in the AllergenOnline database (http://www.
allergenonline.org/index.shtml) and in the Allermatch database (http://www.
allermatch.org). A search for matches with greater than 35% identity over a 
window of 80 amino acids and a search for sequence identity of eight contiguous 
amino acids produced no match. 
 Additionally, a full-length FASTA sequence search using E-value <0.1 as 
the cut-off revealed a match with Asp o 21, α-amylase from Aspergillus oryzae 
(TAKA-amylase A), with 23.7% sequence identity in a 325 amino acid stretch. 
TAKA-amylase A is not identified as a food allergen by the Allergen Nomenclature 
Sub-Committee of the World Health Organization/International Union of 
Immunological Societies. Sensitization to TAKA-amylase A is mainly from 
occupational exposure, such as working in a bakery (Green & Beezhold, 2011). 
There have been only four reported cases of allergy to TAKA-amylase A after 
ingestion (Losada et al., 1992; Baur & Czuppon, 1995; Kanny & Moneret-Vautrin, 
1995; Moreno-Ancillo et al., 2004), among which three occurred in occupational 
workers. Furthermore, oral challenge studies conducted among patients with 
documented occupational or other allergy found no cases of allergy to TAKA-
amylase A (Skamstrup Hansen et al., 1999; Bindslev-Jensen et al., 2006). As 
maltotetraohydrolase is also an amylase, amino acid sequence homology among 
these two enzymes is expected. However, based on the crystal structure of TAKA-
amylase A and the sequence alignment result, there are large sequence differences 
in the loop regions, contributing to the low (<35%) homology. In contrast, the 
homologous regions are hydrophobic and do not locate on the enzyme surface 
area and thus are unlikely to be immunoglobulin E epitopes. 
 Based on the facts that there is no match found with 80 and eight amino 
acid searches and that maltotetraohydrolase shares only a low (23.7%) amino 
acid sequence homology with TAKA-amylase A, which is not a food allergen, 
maltotetraohydrolase does not seem to have the characteristics of a potential 
food allergen. Therefore, the Committee considered that dietary exposure to 
maltotetraohydrolase is not anticipated to pose a risk of allergenicity.
2.2 Toxicological studies
The acute and short-term toxicity and genotoxicity of maltotetraohydrolase have 
been tested using a liquid enzyme concentrate (protein content: 78.76 mg/mL; 
TOS: 9.09%; specific gravity: 1.028 mg/mL). This maltotetraohydrolase liquid 
enzyme concentrate was used as the test material in all the toxicological studies 
discussed in this section. 
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2.2.1 Acute toxicity 
A good laboratory practice (GLP)–compliant acute oral toxicity study was 
performed in female Sprague-Dawley CD rats (Genencor, 2009) according 
to Organisation for Economic Co-operation and Development (OECD) test 
guideline 420. In the sighting study, one female rat was administered a single dose 
of maltotetraohydrolase liquid enzyme concentrate by oral gavage at 2 g/kg bw. In 
the absence of toxicity in this sighting study, four additional female rats were given 
the same dose orally in the main study. At the end of a 14-day observation period, 
all the animals were weighed and terminated. A gross necropsy was performed, 
and all macroscopic signs were recorded. 
 No mortality and no overt signs of systemic toxicity were observed during 
the study or at necropsy. It is thus concluded that under the study conditions, 
maltotetraohydrolase liquid enzyme concentrate orally administered to rats at 2 
g/kg bw did not show evidence of acute toxicity (Genencor, 2009).
2.2.2 Short-term studies of toxicity
A GLP-compliant 13-week repeated-dose oral toxicity study in rats was performed 
according to OECD test guideline 408. In this study, four groups of Wistar 
HanTM:HsdRccHanTM:WIST rats (10 of each sex per group) were administered 
maltotetraohydrolase liquid enzyme concentrate by gavage at a dose of 0 (0.9% 
saline), 23.7, 47.4 or 79.0 mg total protein/kg bw in a constant volume of 5 mL/kg 
bw; these doses corresponded to 0, 28.0, 56.0 and 93.4 mg TOS/kg bw, respectively 
(Dhinsa & Brooks, 2008). 
 The animals were fed ad libitum and had free access to water. All animals 
were observed daily for mortality and signs of morbidity. Body weight and feed 
consumption were recorded weekly, and water consumption was recorded twice 
weekly for each cage. Ophthalmologic examination was performed on all animals 
prior to study initiation and in the control and high-dose groups prior to study 
termination. Haematology was conducted on day 90. A functional observational 
battery consisting of detailed clinical observation, reactivity to handling and stimuli, 
motor activity examination and forelimb/hindlimb grip strength as well as clinical 
chemistry were evaluated at study termination, prior to necropsy, on all groups. After 
a thorough macroscopic examination, selected organs were removed, weighed and 
processed for future histopathological examination. Microscopic examination was 
conducted on selected organs from control and high-dose animals. If a questionable 
finding was noted, the microscopic examination was extended to the low- and mid-
dose groups. There were two interim deaths in this study, but both were considered 
to be unrelated to treatment. One low-dose female was killed in extremis on day 68 
as a result of significant morbidity. The other death occurred on day 90 in a mid-
dose female, which did not show any clinical signs prior to death.
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 Among the surviving animals, no abnormal clinical signs were observed 
in functional performance tests. There were no biologically or statistically 
significant differences between the control and treated groups with respect to 
body weight, feed consumption, water consumption, feed efficiency (ratio of body 
weight gain to dietary intake), haematology or ophthalmologic examinations. 
 Females from all treated groups showed higher serum potassium levels 
(i.e. 4.526, 4.469 and 4.433 nmol/L in the low-, mid- and high-dose groups, 
respectively) compared with concurrent controls (3.881 nmol/L). However, as 
these levels were still within the range of historical control values and the increase 
was not related to dose, it was considered to be unrelated to treatment. 
 Females from all treated groups showed lower absolute and relative 
ovary weights when compared with concurrent controls. On review of the 
historical control data, the control values for this parameter were higher than the 
expected ranges for female rats of the age and strain employed. In the absence of 
histopathological findings, these findings were not attributed to treatment. 
 Incidental macroscopic findings were noted (one high-dose male 
displayed small kidneys; one high-dose male exhibited hydronephrosis on the 
right kidney), but were not considered to be treatment related in the absence 
of relevant histopathological changes. Scattered histopathological findings were 
noted, but all morphological changes were those commonly observed in rats of 
the age and strain employed, and there were no differences in severity or incidence 
between the control and treated groups.
 In conclusion, the 13-week rat study did not demonstrate adverse effects 
on clinical chemistry, haematology, functional observational tests or macroscopic 
and histopathological examinations. Under the conditions of this study, a no-
observed-adverse-effect level (NOAEL) of 79.0 mg total protein/kg bw per day 
(corresponding to 93.4 mg TOS/kg bw per day), the highest dose tested, was 
identified (Dhinsa & Brooks, 2008).
2.2.3 Long-term studies of toxicity and carcinogenicity
No information was available. 
2.2.4 Genotoxicity
The maltotetraohydrolase liquid enzyme concentrate was tested for genotoxicity 
using the bacterial reverse mutagenicity test (Ames assay) and the in vitro 
chromosomal aberration assay, conducted in accordance with OECD test 
guidelines 471 and 473, respectively. Both studies were certified for compliance 
with GLP and quality assurance. The results of both studies were negative (Table 
1), indicating that the maltotetraohydrolase enzyme preparation is unlikely to be 
genotoxic.
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2.2.5 Reproductive and developmental toxicity
No information was available. 
2.3 Observations in humans 
No information was available. 
S9: 9000 × g supernatant fraction from rat liver homogenate
a The test was performed by the standard plate incorporation method. The positive controls used for the assays without S9 mix were N-ethyl-N′-nitro-N-nitrosoguan-
idine (3 µg/plate for TA100, 5 µg/plate for TA1535, 2 µg/plate for WP2uvrA); 9-aminoacridine (80 µg/plate for TA1537); and 4-nitroquinoline-1-oxide (0.2 µg/plate 
for TA98). The positive controls used with S9 mix were 2-aminoanthracene (1 µg/plate for TA100, 2 µg/plate for TA1535 and TA1537, 10 µg/plate for WP2uvrA) and 
benzo[a]pyrene (5 µg/plate for TA98). A preliminary dose range–finding test was carried out using TA100 and WP2uvrA, with and without S9, with 11 concentrations 
of the test material (0–5000 μg total protein/plate). In the main study, each of the five strains was tested using five doses of the test material (50, 150, 500, 1500 
and 5000 μg total protein/plate), with and without S9 mix. All tests were repeated in two independent assays; each was performed in triplicate. The positive control 
substances produced marked increases over the concurrent negative control values, and the test substance was not toxic to the test bacteria. There was no significant 
increase in the number of induced revertant colonies in any strain at any dose in the tests both with and without metabolic activation.
b  The S9 mix was prepared from male Sprague-Dawley rats that received three consecutive daily doses of phenobarbitone/p-naphthoflavone (80/100 mg/kg bw per 
day). S9 acted as an exogenous metabolic activation system.
c  A preliminary dose range–finding test was conducted with nine concentrations of the test material (19.53–5000 µg/mL). Two main experiments were subsequently 
conducted, using six concentrations (range shown in table), with only some concentrations selected for metaphase analysis (156.25–625 µg/mL in the 4-hour 
exposure and 156.25–312.5 µg/mL in the 24-hour exposure). Cells were either treated for 4 hours with or without the presence of S9 and followed by a 20-hour 
treatment-free incubation or continuously treated for 24 hours without S9. The average generation time of the cultured cells was approximately 17 hours, measured 
by bromodeoxyuridine incorporation. The negative control used was Eagle’s minimal essential medium. Positive controls were mytomycin C (0.4 and 0.2 µg/mL for ex-
periment 1 and experiment 2, respectively) in the absence of S9; and cyclophosphamide (5 µg/mL) in the presence of S9. Two slides from each culture were prepared, 
and 50 well spread metaphases on each slide were examined. The result was considered positive if the test substance markedly increased the average percentage of 
aberrant cells (excluding gaps) compared with the negative control value. A dose–response relationship was required only if the increase was moderate. The negative 
and positive controls worked properly in all tests. Maltotetraohydrolase liquid enzyme concentrate did not produce an increase in the frequency of aberrant cells more 
than twice the control values at any dose. 
End-point Test system Concentration Results Reference 
In vitro
Reverse  
mutationa
Salmonella typhimurium TA98, 
TA100, TA1535 and TA1537 and 
Escherichia coli WP2uvrA
50–5 000 μg/plate  ±S9b Negative Bowles (2008)
Chromosomal 
aberrationsc
Human lymphocytes 1st experiment:
4 h exposure: 
19.5–625 µg/mL ±S9b
2nd experiment: 
4 h exposure: 
19.5–625 µg/mL +S9b
24 h exposure: 
19.5–312.5 µg/mL −S9b
Negative Morris (2008)
Table 1
Genotoxicity of maltotetraohydrolase from Pseudomonas stutzeri expressed in Bacillus 
licheniformis
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3. Dietary exposure 
3.1 Introduction
The Committee evaluated one submission received from DuPont Industrial 
Biosciences, a manufacturer of the maltotetraohydrolase enzyme preparation.
 The maltotetraohydrolase enzyme preparation is used internationally, 
being approved for use in Australia, Canada, Denmark, France and New 
Zealand, and is generally recognized as safe for use in food processing in the 
USA. The enzyme is not expected to remain in downstream products, such as 
HFCS, following purification processes used in their manufacture, but would be 
present and inactivated in bakery products. The maltotetraohydrolase enzyme 
preparation is used across a number of food products, and therefore an upper-
bounding dietary exposure assessment approach was taken. A theoretical “worst-
case” dietary exposure estimate was made, assuming that 100% of food products 
in which maltotetraohydrolase enzyme preparation could be used would be 
manufactured using the product and that 100% would remain in the final food 
products. 
 The Committee concluded that a tiered approach to assessing potential 
dietary exposure to the maltotetraohydrolase enzyme preparation was not 
necessary, as the upper-bounding exposure estimate was evaluated.
3.2 Dietary exposure assessment
Two broad uses of maltotetraohydrolase enzyme preparation were nominated in 
the submission (manufacture of starch for sweeteners and baking). These were 
considered individually to arrive at a total dietary exposure estimate.
3.2.1 Starch production
The maltotetraohydrolase enzyme preparation is used to prepare starch for the 
production of HFCS. The Committee considered that the consumption of HFCS 
was likely to be higher for the population of the USA than elsewhere; therefore, 
it was assumed that HFCS consumption figures for the USA were sufficient to 
cover all possible use scenarios. For the USA, per capita consumption of HFCS was 
20.9 kg/person per year (57.3 g/person per day, 0.96 g/kg bw per day for a 60 kg 
individual) in 2012 (USDA, 2012). Reference to the 17 consumption cluster diets 
of the Global Environment Monitoring System – Food Contamination Monitoring 
and Assessment Programme (GEMS/Food) (WHO, 2012) confirms that cluster 
G10, which includes the USA, has the highest apparent consumption of total sugars, 
at 130 g/day; however, as total sugars also includes other products, the USDA (2012) 
figure for HFCS consumption was used in the dietary exposure estimate. 
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 If maltotetraohydrolase enzyme preparation is applied at the highest 
suggested rate of 20 mg TOS/kg starch, which is transformed quantitatively to 
HFCS, the dietary exposure would be 0.019 mg TOS/kg bw per day. 
3.2.2 Bakery products
The maltotetraohydrolase enzyme preparation is used in the baking industry at 
the maximum rate of 23 mg TOS/kg flour. To estimate the contribution to dietary 
exposure from flour, the consumption of total flour for the population of the USA 
was used (USDA, 2012). If a consumption of flour of 79.2 kg/year (3.6 g/kg bw per 
day for a 60 kg individual) is assumed and the maximum rate of 23 mg TOS/kg 
flour is used, the dietary exposure to maltotetraohydrolase enzyme preparation 
would be 0.083 mg TOS/kg bw per day.
3.2.3 Assessment of total dietary exposure
The summation of the maximum dietary exposures from each of the two uses 
of maltotetraohydrolase enzyme preparation (0.019 + 0.083 mg TOS/kg bw 
per day) results in a potential total dietary exposure of 0.1 mg TOS/kg bw per 
day for a 60 kg individual. This estimate assumes maximum use levels, 100% 
market penetration for the production of HFCS and bakery products and the 
presence of the maltotetraohydrolase enzyme following the production process. 
The Committee noted that under these conditions, the major contributor to 
total dietary exposure to maltotetraohydrolase enzyme preparation would be the 
consumption of bakery products.
4. Comments
4.1 Assessment of potential allergenicity
Maltotetraohydrolase was evaluated for potential allergenicity using the 
bioinformatics criteria recommended by FAO/WHO (2001, 2009), but modified 
at the present meeting. The amino acid sequence of the enzyme was compared 
with the amino acid sequences of known allergens in publicly available databases. 
A search for matches with greater than 35% identity over a window of 80 
amino acids and a search for sequence identity of eight contiguous amino acids 
produced no match. Therefore, the Committee considered that dietary exposure 
to maltotetraohydrolase enzyme preparation is not anticipated to pose a risk of 
allergenicity. 
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4.2 Toxicological studies
Maltotetraohydrolase liquid enzyme concentrate administered to rats at 2 g/kg bw 
in an acute oral toxicity study demonstrated no sign of toxicity (Genencor, 2009). 
In a 13-week repeated-dose oral toxicity study in rats, no treatment-related adverse 
effects were observed when the maltotetraohydrolase liquid enzyme concentrate 
was administered by gavage at doses up to 93.4 mg TOS/kg bw per day (Dhinsa & 
Brooks, 2008). The results of an in vitro bacterial reverse mutation assay (Bowles, 
2008) and an in vitro chromosomal aberration assay in human lymphocytes 
(Morris, 2008) using the maltotetraohydrolase liquid enzyme concentrate were 
both negative. The Committee concluded that maltotetraohydrolase enzyme 
preparation is unlikely to be genotoxic.
4.3 Assessment of dietary exposure
An estimate of the theoretical dietary exposure to maltotetraohydrolase enzyme 
preparation was made by the Committee based on the maximum level of TOS in 
the enzyme preparation and its maximum use levels in bakery products (23 mg 
TOS/kg flour) and HFCS production (20 mg TOS/kg starch). The combination 
of these levels with per capita food consumption data from the USA (supplied by 
the sponsor; corroborated with data from the GEMS/Food cluster diets) results in 
a potential dietary exposure of 0.1 mg TOS/kg bw per day for a 60 kg individual. 
The Committee noted that the enzyme will be inactivated in food processing and 
also removed from the HFCS final product during production. 
5. evaluation 
No treatment-related adverse effects were seen at the highest dose tested (93.4 
mg TOS/kg bw per day) in the 13-week study of oral toxicity in rats (Dhinsa & 
Brooks, 2008). A comparison of the dietary exposure estimate of 0.1 mg TOS/kg 
bw per day with the highest dose tested of 93.4 mg TOS/kg bw per day results in a 
margin of exposure of at least 900. The Committee established an acceptable daily 
intake (ADI) “not specified” for maltotetraohydrolase from P. stutzeri expressed 
in B. licheniformis when used in the applications specified and in accordance with 
good manufacturing practice. 
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1.  explanation
At the request of the Codex Committee on Food Additives at its Forty-sixth Session 
(FAO/WHO, 2014), the Committee evaluated the safety of mixed β-glucanase 
(3-(1,3;1,4)-β-D-glucan 3(4) glucanohydrolase; Enzyme Commission No. 3.2.1.6), 
cellulase (4-(1,3;1,4)-β-D-glucan 4-glucanohydrolase; Enzyme Commission No. 
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3.2.1.4) and xylanase (1,4-β-D-xylan xylanohydrolase; Enzyme Commission 
No. 3.2.1.8) from Rasamsonia emersonii. This enzyme preparation has not been 
evaluated previously by the Committee. Rasamsonia emersonii was recently 
renamed from Talaromyces emersonii based on genetic analyses (Houbraken, 
Spierenburg & Frisvad, 2012). The Committee evaluated several other enzyme 
preparations of β-glucanase, cellulase or xylanase at its thirty-first, thirty-fifth, 
thirty-ninth, sixty-first and sixty-third meetings and established an acceptable 
daily intake (ADI) “not specified” for their use in several applications, such as the 
preparation of beer and baking products (Annex 1, references 78, 88, 101, 167 and 
174). An exception was cellulase from Penicillium funiculosum, for which no ADI 
was established, as no safety data were submitted (Annex 1, reference 77). In this 
report, the expression “mixed β-glucanase, cellulase and xylanase liquid enzyme 
concentrate” is used when referring to the material tested in the toxicological 
studies evaluated; the expressions “β-glucanase”, “cellulase” and “xylanase” are 
used when referring to the enzymes and their amino acid sequences; and the 
expression “mixed β-glucanase, cellulase and xylanase enzyme preparation” is 
used when referring to the commercial enzyme product. 
 β-Glucanase is an enzyme that catalyses the hydrolysis of 1,3- or 1,4-β-D-
glucosidic linkages in β-D-glucans. Cellulase is an enzyme that catalyses the 
endo-hydrolysis of 1,4-β-D-glucosidic linkages in cellulose, lichenin and cereal 
β-D-glucans and the hydrolysis of 1,4-linkages in β-D-glucans that also have 
1,3-linkages. Xylanase is an enzyme that catalyses the hydrolysis of 1,4-β-xylosidic 
linkages in xylans. 
 The mixed β-glucanase, cellulase and xylanase enzyme preparation 
is intended to be used as a processing aid in brewing, potable alcohol (spirits) 
production and grain processing. 
1.1 Genetic background
The β-glucanase, cellulase and xylanase enzymes are simultaneously produced 
at high levels from a strain of R. emersonii. Rasamsonia emersonii has been 
taxonomically identified to be from the genus Rasamsonia by the Dutch culture 
collection, the Centraalbureau voor Schimmelcultures. Rasamsonia emersonii is 
a filamentous eukaryotic thermostable fungus that is capable of growing at pH 
3.5–5.5 and 45–50 °C. Rasamsonia emersonii is also referred to in the literature 
as Penicillium emersonii, Geosmithia emersonii and Talaromyces emersonii. 
Rasamsonia emersonii is a non-pathogenic microorganism with a history of use 
in commercial food enzyme production. The R. emersonii production strain has 
been demonstrated to be genetically stable under laboratory conditions, with no 
significant decrease in yield or change in appearance of morphological variants. 
It is derived from the original wild-type strain that has been used for large-scale 
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production of the mixed β-glucanase, cellulase and xylanase enzyme preparation 
since 1985. The production strain is a modification of the wild-type R. emersonii 
strain for increased enzyme production by classical mutagenesis and selection 
for higher enzyme productivity. Data indicate that the production strain does not 
produce mycotoxins under large-scale fermentation conditions, indicating that 
the production strain is non-toxigenic. 
1.2 Chemical and technical considerations
The β-glucanase, cellulase and xylanase enzymes are produced by a controlled 
aerobic submerged fed-batch fermentation of a pure culture of R. emersonii. The 
enzymes are secreted into the fermentation broth and subsequently purified and 
concentrated. The enzyme concentrate is formulated with glycerol and sodium 
benzoate to achieve the desired activity and stability. The mixed β-glucanase, 
cellulase and xylanase enzyme preparation contains commonly used food-grade 
materials and conforms to the General Specifications and Considerations for 
Enzyme Preparations Used in Food Processing (http://www.fao.org/ag/agn/jecfa-
additives/docs/enzymes_en.htm). 
 The β-glucanase and cellulase activity is expressed in beta-glucanase 
fungique (BGF) units, as defined in the specific assay that measures a change 
in viscosity of a glucan substrate solution in the presence of β-glucanase and 
cellulase. The xylanase activity is expressed in xylanase viscosity units (XVU), 
as defined in the specific assay that measures a change in viscosity of a xylan 
substrate solution in the presence of xylanase; however, the method described to 
determine this activity is proprietary and non-transferable. The mean activities 
of β-glucanase and cellulase and of xylanase from three batches of the mixed 
β-glucanase, cellulase and xylanase, prior to formulation, were reported to be 
approximately 500 000 BGF/g and 3800 XVU/g, respectively. 
 A typical commercial formulation of the mixed β-glucanase, cellulase and 
xylanase enzyme preparation will contain 5.4–17% total organic solids (TOS), 
depending on the use. TOS includes the enzymes of interest and residues of 
organic materials, such as proteins, peptides and carbohydrates, derived from the 
production organism during the manufacturing process. The mixed β-glucanase, 
cellulase and xylanase enzyme preparation is used in brewing, potable alcohol 
(spirits) production and grain processing (production of non-alcoholic beverages 
[including soft drinks] and bakery ingredients) to reduce viscosity and improve 
filterability, yield and product consistency; it will be used at levels up to 25.5 
mg TOS/kg raw material. The β-glucanase, cellulase and xylanase enzymes are 
expected to be inactivated during processing.
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2. Biological data
2.1 Assessment of potential allergenicity 
Rasamsonia emersonii is not listed in the World Health Organization/International 
Union of Immunological Societies allergen nomenclature (http://www.allergen.
org/). 
 β-Glucanase, xylanase and cellulase from R. emersonii have commonly 
been found in food, and there are no indications for allergic reactions due to 
their ingestion. In addition, two β-glucanases, a xylanase (xylanase from R. 
emersonii expressed in Aspergillus niger, patent WO 20024926 A1) and a cellulase 
(cellulase from R. emersonii [formerly known as T. emersonii] from R. emersonii) 
have been evaluated for potential allergenicity using the bioinformatics criteria 
recommended by FAO/WHO (2001, 2009), but modified at the present meeting. 
A search for matches with greater than 35% identity over a window of 80 amino 
acids and a search for sequence identity of eight contiguous amino acids using the 
database AllergenOnline (available at http://www.allergenonline.org/, accessed 9 
October 2013 and 27 November 2013) produced no match. Based on these data, 
the Committee concluded that dietary exposure to the β-glucanase, cellulase and 
xylanase enzyme preparation from R. emersonii is not anticipated to pose a risk of 
allergenicity. 
2.2 Toxicological studies 
The toxicological studies were performed with a mixed β-glucanase, cellulase 
and xylanase liquid enzyme concentrate (batch no. OP8017; dry matter content, 
6.2% by weight; TOS content, 5.3% by weight), omitting stabilization and 
standardization. The liquid enzyme concentrate had activities of 92 000 BGF/g 
(β-glucanase and cellulase) and 520 XVU/g (xylanase).
2.2.1 Acute toxicity
No information was available.
2.2.2 Short-term studies of toxicity
In a 14-day range-finding study, groups of five male and five female CD rats were 
given the mixed β-glucanase, cellulase and xylanase liquid enzyme concentrate 
from R. emersonii at a dose equal to 0, 5.3, 26.5 or 133 mg TOS/kg body weight 
(bw) per day by oral gavage (Cooper, 2000a). Clinical signs, body weight, feed 
consumption, feed conversion efficiency, haematology, blood chemistry, weights 
of principal organs and macroscopic pathology were studied in all animals.
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 No treatment-related deaths or clinical signs were observed. Body 
weight, feed consumption and feed conversion efficiency were not adversely 
affected. Final body weights (up to +6%) and body weight gain (up to +11%) were 
slightly higher in treatment groups than in controls. Slightly lower haemoglobin 
concentrations (up to −7%, no dose–response relationship) were noted in all 
treated females, compared with controls. Also, haematocrit and erythrocyte 
counts were lower (up to, respectively, −7% and −8%) in treated females compared 
with controls, reaching significance in the low-dose group (haematocrit and 
erythrocyte counts) and/or the mid-dose group (haematocrit) only. The slightly 
higher alanine aminotransferase activities (+22–24%) seen in the mid-dose group 
(males only) and the high-dose group (both sexes) and the lower cholesterol levels 
(−14–15%) seen in females of the mid- and high-dose groups are considered to be 
of no toxicological concern. In addition, when compared with controls, plasma 
phosphorus concentrations were decreased (up to −16%) in all treatment groups, 
and calcium concentrations were lower (up to –5%) in treated males and females 
of the mid-dose group. Glucose concentrations were increased (up to +32%) in 
treated females and males of the mid-dose group. Potassium concentrations were 
statistically significantly increased in females of the high-dose group. All changes 
were small and not dose related and were therefore not considered to be of 
toxicological relevance. Organ weights were not affected by the treatment. Lower 
absolute and relative uterus and cervix weights were observed for females in the 
high-dose group, but statistical significance was not attained. No macroscopic 
findings related to treatment were observed. In the absence of adverse effects, the 
no-observed-adverse-effect level (NOAEL) for this study was 133 mg TOS/kg bw 
per day, the highest dose tested (Cooper, 2000).
 In the subsequent 90-day study of toxicity, groups of 20 male and 20 
female CD rats were given the mixed β-glucanase, cellulase and xylanase liquid 
enzyme concentrate from R. emersonii at a dose equal to 0, 5.3, 21.2 or 84.8 mg 
TOS/kg bw per day by oral gavage (in water obtained by reverse osmosis). The 
study was designed to meet the requirements of the United States Food and 
Drug Administration Redbook and was certified for compliance with good 
laboratory practice (GLP) and quality assurance (QA) (Cooper, 2000b). All 
animals were evaluated with respect to general clinical observations, body weight, 
feed consumption, feed conversion efficiency, ophthalmoscopic examination, 
haematology, clinical chemistry, weights of principal organs, macroscopic 
examination and histopathology of selected organs (control and high-dose 
groups) and histopathology of all lesions.
 No treatment-related deaths or clinical signs were observed. 
Ophthalmoscopic, macroscopic and microscopic examinations did not reveal any 
abnormalities associated with the treatment. 
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 Body weight gain of males of the high-dose group was slightly lower 
(−6%) than that of controls, and weekly feed consumption by males of the high-
dose group was slightly lower than that of the controls (overall feed intake was 
97% of feed intake of controls), but these effects were not statistically significant.
 When compared with the controls, slightly longer prothrombin times 
(0.7 second longer) were recorded for both sexes of the high-dose group, with 
slightly longer activated partial thromboplastin times (3.6 seconds longer) also 
seen in the females. These slight changes in haematology are considered to be of 
no toxicological relevance.
 Slightly lower aspartate aminotransferase activities were observed in 
females of the high-dose group (71 versus 85 units/L in controls). High levels of 
aspartate aminotransferase activity are markers for liver damage in rats, whereas 
low activity levels are considered to be of no toxicological significance. Glucose 
concentrations were increased in males of the high-dose group (7.54 versus 6.63 
mmol/L in controls). Triglyceride concentrations were higher (up to +28%) in 
treated females, reaching statistical significance only in the low- and mid-dose 
groups. Sodium levels were slightly decreased in females of the high-dose group 
(140 versus 142 mmol/L in controls). As these effects were small and/or lacked 
a dose–response relationship, they were not considered to be toxicologically 
relevant.
 Based on the absence of adverse effects in this study, the NOAEL was 84.8 
mg TOS/kg bw per day, the highest dose tested (Cooper, 2000b).
2.2.3 Long-term studies of toxicity and carcinogenicity
No information was available.
2.2.4 Genotoxicity
The results of two studies of genotoxicity in vitro with the mixed β-glucanase, 
cellulase and xylanase liquid enzyme concentrate are summarized in Table 1. The 
first study followed Organisation for Economic Co-operation and Development 
(OECD) test guideline 471 (Bacterial Reverse Mutation Test, 1997), and the 
second study, OECD test guideline 473 (In Vitro Mammalian Chromosome 
Aberration Test, 1997). Both studies were certified for compliance with GLP and 
QA. Based on the results, the Committee concluded that the mixed β-glucanase, 
cellulase and xylanase enzyme preparation is unlikely to be genotoxic.
2.2.5 Reproductive and developmental toxicity
No information was available.
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2.3 Observations in humans 
No information was available.
3. Dietary exposure
3.1 Introduction
The mixed β-glucanase, cellulase and xylanase enzyme preparation is intended to 
be used as a processing aid in brewing, potable alcohol (spirits) production and 
grain processing (production of non-alcoholic beverages [including soft drinks] 
and bakery ingredients [starch, fibres, flour]). The estimated maximum levels 
in final food products are 3.5 mg TOS/L in beer, 3 mg TOS/L in non-alcoholic 
beverages, 3 mg TOS/kg in bakery ingredients and 0 mg TOS/L in potable alcohol 
(spirits).
 The enzymes are inactivated during the intended processes. In addition 
to the enzymes in question, the mixed β-glucanase, cellulase and xylanase 
enzyme preparation also contains some substances derived from the producing 
microorganism and the fermentation medium.
S9: 9000 × g supernatant fraction from rat liver homogenate
a Two independent experiments were performed, the first using the plate incorporation method and the second using the preincubation assay. The same concentration 
range, with and without S9, was used in both experiments.  
b  In the first experiment, the cells were treated for 3 hours without and with S9 and were harvested 17 hours later. The highest tested concentration induced 16% 
mitotic inhibition in the presence of S9. In the absence of S9, no significant mitotic inhibition was observed. In the second experiment, the cells were exposed contin-
uously for 20 hours without S9 and then harvested. With S9, the cells were treated for 3 hours and harvested 17 hours later. The highest tested concentration induced 
60% mitotic inhibition in the absence of S9. In the presence of S9, no significant mitotic inhibition was observed. In the first experiment, no significant increase in 
chromosomal aberrations was observed. In the second experiment, in the absence of S9, a statistically significant increase in the proportion of cells with chromosom-
al aberrations was observed at 4000 µg/mL when gap-type aberrations were included in the analysis. The percentage of cells with aberrations including gaps was 
10.5% versus 4.0% in controls. In the absence of a statistically significant increase in chromosomal aberrations when gaps were excluded, the results indicated that 
the material tested does not induce chromosomal aberrations.
End-point Test system Concentration Results Reference 
In vitro
Reverse  
mutation
Salmonella typhimurium 
TA98, TA100, TA1535 and 
TA1537 and Escherichia coli 
WP2uvrApKM101
100–10 000 µg/mL, ±S9 Negativea May (1999)
Chromosomal 
aberrations
Human lymphocytes 1st experiment: 1 250, 2 500 or 5 000 µg/mL, ±S9
2nd experiment: 1 000, 3 000 or 4 000 µg/mL, –S9
1 250, 2 500 or 5 000 µg/mL, +S9 
Negativeb Mason (1999)
Table 1
Genotoxicity of the mixed β-glucanase, cellulase and xylanase liquid enzyme concentrate 
in vitro
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 The Committee evaluated one submission by a sponsor (Reuvers, 2014) 
on dietary exposure to the additive using assessments based on individual dietary 
records.
3.2 Assessment of dietary exposure
The estimated daily intake (EDI) was calculated by the sponsor based on the 
estimated levels in the final food products and intake levels of beverages and 
solid food based on per capita food consumption data from the United States 
Department of Agriculture (USDA) (Wilkinson Enns, Goldman & Cook, 1997; 
Wilson et al., 1997). As a “worst-case situation”, the 90th percentile of the intake 
level was taken except for alcoholic beverages, for which the 95th percentile was 
used. The EDI was estimated to be 0.001–0.02 mg TOS/kg bw per day from beer 
and ale using an estimated consumption per person of 360 mL beverage/day, 
0.01–0.04 mg TOS/kg bw per day from non-alcoholic beverages (fruit drinks and 
ades; carbonated soft drinks; 838 mL/day) and 0.008–0.02 mg TOS/kg bw per 
day from grain products (cereal and pasta; quick breads, pancakes, French toast; 
cakes, cookies, pastries, pies; crackers, popcorn and chips; mixtures mainly grain, 
502 g/day). The three estimates sum to 0.02–0.08 mg TOS/kg bw per day, or 1–5 
mg/day for a 60 kg person. This estimate assumes that all cereal grain products, 
including beer and ale, are treated with the mixed β-glucanase, cellulase and 
xylanase enzyme preparation and would therefore be an overestimate.
 Reference to the 17 consumption cluster diets of the Global Environment 
Monitoring System – Food Contamination Monitoring and Assessment 
Programme (GEMS/Food) (WHO, 2012) reveals that clusters G08, G11 and 
G15 (including a number of European countries) have the highest apparent 
consumption of beer (225–260 g/day). Cluster G10, which includes the USA, has 
an apparent consumption of 174 g/day. If the mixed β-glucanase, cellulase and 
xylanase enzyme preparation is present at the highest suggested level of 3.5 mg 
TOS/L beverage, the dietary exposure at the maximum consumption of 260 g/day 
would be 0.9 mg TOS/day (or 0.02 mg TOS/kg bw per day for a 60 kg person). 
 Cluster G02 (including a number of Eastern European/Central Asian 
countries) has the highest apparent consumption of non-alcoholic beverages 
(excluding milk-based beverages, stimulants and water) (75 g/day), followed by 
cluster G15 (including a number of European countries), at 56 g/day, and cluster 
G10, which includes the USA, at 47 g/day. If the mixed β-glucanase, cellulase and 
xylanase enzyme preparation is present at the highest suggested level of 3 mg 
TOS/L beverage, the dietary exposure at the maximum consumption of 75 g/day 
would be 0.2 mg TOS/day (or 0.004 mg TOS/kg bw per day for a 60 kg person). 
The estimate for consumption used here (75 g/day) is significantly lower than the 
estimate used by the sponsor (838 mL/day).
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 Clusters G01, G06 and G09 (including a number of countries from 
Asia, the Middle East and North Africa) have the highest apparent consumption 
of cereals and flour (370–480 g/day). If the mixed β-glucanase, cellulase and 
xylanase enzyme preparation is present at the highest suggested level of 3 mg 
TOS/kg product, the dietary exposure at the maximum consumption of 480 g/day 
would be 1.4 mg TOS/day (or 0.02 mg TOS/kg bw per day for a 60 kg person).
 The three estimates (0.9, 0.2 and 1.4 mg TOS/day) sum to 2.5 mg TOS/
day, or 0.04 mg TOS/kg bw per day for a 60 kg person. This estimate assumes 
that all cereal grain products, including beer and ale, are treated with the enzyme 
mixture and would therefore be an overestimate. The estimate is within the range 
of the EDI calculated by the sponsor using survey data from the USDA.
4. Comments
4.1 Assessment of potential allergenicity
β-Glucanase, xylanase and cellulase from R. emersonii have commonly been 
found in food, and there are no indications for allergic reactions due to their 
ingestion. In addition, two β-glucanases, a xylanase and a cellulase from R. 
emersonii have been evaluated for potential allergenicity using the bioinformatics 
criteria recommended by FAO/WHO (2001, 2009), but modified at the present 
meeting. A search for matches with greater than 35% identity over a window of 
80 amino acids and a search for sequence identity of eight contiguous amino acids 
produced no match. Based on these data, the Committee concluded that dietary 
exposure to the β-glucanase, cellulase and xylanase enzymes from R. emersonii is 
not anticipated to pose a risk of allergenicity. 
4.2 Toxicological studies
In a 13-week study of oral toxicity in rats, no treatment-related adverse effects 
were seen when the mixed β-glucanase, cellulase and xylanase liquid enzyme 
concentrate was administered by gavage at doses up to 84.8 mg TOS/kg bw per 
day (Cooper, 2000). The mixed β-glucanase, cellulase and xylanase liquid enzyme 
concentrate gave negative results in a bacterial reverse mutation assay (May, 1999) 
and an in vitro chromosomal aberration assay (Mason, 1999), and the Committee 
concluded that the mixed β-glucanase, cellulase and xylanase enzyme preparation 
is unlikely to be genotoxic.
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4.3 Assessment of dietary exposure
The Committee estimated the theoretical dietary exposure to the mixed 
β-glucanase, cellulase and xylanase enzyme preparation based on the estimated 
maximum levels in final food products (3.5 mg TOS/L in beer, 3 mg TOS/L 
in non-alcoholic beverages [including soft drinks], 3 mg TOS/kg in bakery 
ingredients [starch, fibres, flour] and 0 mg TOS/L in potable alcohol [spirits]). 
The combination of these maximum levels with per capita food consumption data 
from the USA (supplied by the sponsor) and data from the GEMS/Food cluster 
diets results in a potential dietary exposure of 0.08 mg TOS/kg bw per day for 
a 60 kg person. The Committee noted that the enzymes will be inactivated in 
processed food and that the exposure estimate is conservative.
5. evaluation
No treatment-related adverse effects were seen at the highest dose tested (84.8 
mg TOS/kg bw per day) in the 13-week study of oral toxicity in rats (Cooper, 
2000). A comparison of the dietary exposure estimate of 0.08 mg TOS/kg bw 
per day with the highest dose tested of 84.8 mg TOS/kg bw per day results in 
a margin of exposure of at least 1000. The Committee established an ADI “not 
specified” for the mixed β-glucanase, cellulase and xylanase enzyme preparation 
from R. emersonii, used in the applications specified and in accordance with good 
manufacturing practice. 
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1.  explanation
At the request of the Codex Committee on Food Additives at its Forty-sixth Session 
(FAO/WHO, 2014), the Committee evaluated the safety of mixed β-glucanase 
(3-(1,3;1,4)-β-D-glucan 3(4) glucanohydrolase; Enzyme Commission No. 3.2.1.6) 
and xylanase (1,4-β-D-xylan xylanohydrolase; Enzyme Commission No. 3.2.1.8) 
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from Disporotrichum dimorphosporum. This enzyme preparation has not been 
evaluated previously by the Committee. The Committee evaluated several other 
enzyme preparations of β-glucanase or xylanase at its thirty-first, thirty-fifth, 
thirty-ninth, sixty-first and sixty-third meetings and established an acceptable 
daily intake (ADI) “not specified” for their use in several applications, such as 
the preparation of beer and baking products (Annex 1, references 78, 88, 101, 
167 and 174). In this report, the expression “mixed β-glucanase and xylanase 
liquid enzyme concentrate” is used when referring to the material tested in the 
toxicological studies evaluated; the expressions “β-glucanase” and “xylanase” are 
used when referring to the enzymes and their amino acid sequences; and the 
expression “mixed β-glucanase and xylanase enzyme preparation” is used when 
referring to the commercial enzyme preparation. 
 β-Glucanase is an enzyme that catalyses the hydrolysis of 1,3- or 1,4-β-D-
glucosidic linkages in β-D-glucans. Xylanase is an enzyme that catalyses the 
hydrolysis of 1,4-β-D-xylosidic linkages in xylans.
  The mixed β-glucanase and xylanase enzyme preparation is intended to 
be used as a processing aid in brewing, potable alcohol (spirits) production and 
grain processing. 
1.1 Genetic background
The β-glucanase and xylanase enzymes are simultaneously produced at high 
levels from a strain of D. dimorphosporum. Disporotrichum dimorphosporum has 
been taxonomically identified to be from the genus Sporotrichum by the Dutch 
culture collection, the Centraalbureau voor Schimmelcultures (Stalpers, 1984). 
Disporotrichum dimorphosporum is a saprophyte and a basidiomycete fungus; it is 
capable of growing at pH 3.5–5.5 and 28–32 °C. Disporotrichum dimorphosporum 
is a non-pathogenic microorganism with a history of use in commercial food 
enzyme production.
 The D. dimorphosporum production strain is derived from the original 
wild-type strain that has been used for large-scale production of the mixed 
β-glucanase and xylanase enzyme preparation since 1999 after reisolation and 
subculturing. It has been demonstrated to be genetically stable under laboratory 
conditions, with no significant decrease in yield or change in appearance of 
morphological variants. Data indicate that the production strain does not 
produce mycotoxins under large-scale fermentation conditions, indicating that 
the production strain is non-toxigenic.
1.2 Chemical and technical considerations
The β-glucanase and xylanase enzymes are produced by a controlled aerobic 
submerged fed-batch fermentation of a pure culture of D. dimorphosporum. The 
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enzymes are secreted into the fermentation broth and subsequently purified and 
concentrated. Sodium benzoate and glycerol are added to the liquid enzyme 
concentrate to standardize and stabilize the enzyme preparation. The mixed 
β-glucanase and xylanase enzyme preparation contains commonly used food-
grade materials and conforms to the General Specifications and Considerations 
for Enzyme Preparations Used in Food Processing (http://www.fao.org/ag/agn/
jecfa-additives/docs/enzymes_en.htm). 
 The β-glucanase activity is expressed in beta-glucanase fungique (BGF) 
units, as defined in the specific assay that measures a change in viscosity of a 
glucan substrate solution in the presence of β-glucanase and cellulase. The 
xylanase activity is expressed in xylanase viscosity units (XVU), as defined in the 
specific assay that measures a change in viscosity of a xylan substrate solution 
in the presence of xylanase; however, the method described to determine this 
activity is proprietary and non-transferable. The mean activities of β-glucanase 
and xylanase from three batches of the mixed β-glucanase and xylanase, prior to 
formulation, were reported to be approximately 520 000 BGF/g and 3300 XVU/g, 
respectively. 
 A typical commercial formulation of the mixed β-glucanase and xylanase 
enzyme preparation will contain 11–17% total organic solids (TOS), depending 
on the use. TOS includes the enzymes of interest and residues of organic materials, 
such as proteins, peptides and carbohydrates, derived from the production 
organism during the manufacturing process. 
 The mixed β-glucanase and xylanase enzyme preparation is used in 
brewing, potable alcohol (spirits) production and grain processing (production 
of non-alcoholic beverages [including soft drinks] and bakery ingredients) to 
reduce viscosity and improve filterability, yield and product consistency; it will be 
used at levels up to 36.5 mg TOS/kg raw material. The β-glucanase and xylanase 
enzymes are expected to be inactivated during processing. 
2. Biological data
2.1 Assessment of potential allergenicity 
Disporotrichum dimorphosporum is not listed in the World Health Organization/
International Union of Immunological Societies allergen nomenclature (http://
www.allergen.org/).
 β-Glucanase and xylanase from D. dimorphosporum have commonly 
been found in food, and there are no indications for allergic reactions due to their 
ingestion. As these enzymes are not genetically modified, an assessment of their 
potential allergenicity is not required. 
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2.2 Toxicological studies 
The toxicological studies were performed with a mixed β-glucanase and xylanase 
liquid enzyme concentrate (batch no. 8221; dry matter content, 21.8% by weight; 
TOS content, 19.9% by weight), omitting stabilization and standardization. The 
liquid enzyme concentrate had activities of 38 000 BGF/g (β-glucanase) and 3300 
XVU/g (xylanase). 
2.2.1 Acute toxicity
No information was available. 
2.2.2 Short-term studies of toxicity
In a 14-day range-finding study, groups of five male and five female CD rats were 
given the mixed β-glucanase and xylanase liquid enzyme concentrate at a dose 
equal to 0, 20, 60 or 199 mg TOS/kg body weight (bw) per day by oral gavage 
(Cooper, 1999). Clinical signs, body weight, feed consumption, feed conversion 
efficiency, haematology, blood chemistry, weights of principal organs and 
macroscopic pathology were studied in all animals.
 There were no deaths or clinical signs related to the treatment. Overall 
body weight gain (85–88% of controls), feed consumption (89–95% of controls) 
and feed conversion efficiency (93–97% of controls) were slightly, but not 
statistically significantly, lower in treated females compared with controls. 
 In males in the mid- and high-dose groups, haematological investigations 
revealed slightly increased mean cell haemoglobin concentrations (+3% in 
both groups, statistically significantly different at the middle dose only) and 
neutrophil counts (up to +88%) and slightly decreased mean cell volumes (up 
to −6%), compared with the controls. Other statistically significant changes were 
observed in males in the mid-dose group only. Females in the high-dose group 
had statistically significantly increased haematocrit (+2%) and haemoglobin 
concentrations (+5%), compared with the controls. As the changes observed 
were small and/or not consistent between the sexes, they were considered to 
be of no toxicological relevance. Examination of the blood plasma indicated a 
dose-dependent decrease in cholesterol levels in females (up to −27%), which is 
considered to reflect metabolic adaptation to exposure to the test compound. Other 
changes in biochemical parameters were minor and/or lacked a dose–response 
relationship and were therefore considered to be unrelated to treatment. Small, 
but statistically significant, decreases in absolute heart weight (−12%, females 
only) and absolute lung and bronchus weight (−11%, females; −12%, males) were 
observed in the high-dose group. Absolute and relative uterus and cervix weights 
were increased in all treated females, reaching statistical significance in the mid-
dose group only. This increase was related to fluid distension observed in the 
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uterus of, respectively, one, three and two females of the low-, mid- and high-dose 
groups, a finding commonly encountered in CD rats. In the absence of adverse 
effects, the no-observed-adverse-effect level (NOAEL) in this study was 199 mg/
kg bw per day, the highest dose tested (Cooper, 1999). 
 In the subsequent 13-week study of toxicity, groups of 20 male and 20 
female CD rats were given the mixed β-glucanase and xylanase liquid enzyme 
concentrate at a dose equal to 0, 13, 50 or 199 mg TOS/kg bw per day by oral 
gavage. The study was designed to meet the requirements of the United States 
Food and Drug Administration Redbook and was certified for compliance with 
good laboratory practice (GLP) and quality assurance (QA) (Cooper, 2000). 
 All animals were evaluated with respect to general clinical observations, 
body weight, feed consumption, feed conversion efficiency, ophthalmoscopy (10 
animals/group), haematology, clinical chemistry, weights of principal organs, 
macroscopic examination and histopathology of principal organs (control and 
high-dose groups) and histopathology of all lesions.
 No treatment-related effects on mortality, body weight, feed consumption, 
feed conversion efficiency or ophthalmoscopy were observed. Salivation was 
seen shortly after dosing in several males and females of the high-dose group 
in the last 3 weeks of the treatment period. This finding is associated with the 
dosing procedure and is not considered to be of toxicological relevance. Lower 
incidences of hair loss on the head (in treated males) and on the forelimbs (in 
females of the mid- and high-dose groups) were observed. In females of the high-
dose group, there was a higher incidence of brown staining of the head (eight 
animals compared with three animals in the control group). These signs are not 
considered to be of toxicological relevance. 
 Slightly shorter prothrombin times were recorded for males of the high-
dose group (11.7 versus 12.8 seconds in controls), and slightly lower haematocrit 
values were noted for females (−5% and −3%, respectively, in the mid- and high-
dose groups, compared with controls). Other statistically significant changes in 
haematological parameters were observed in the low- and/or mid-dose groups 
only. As these effects were seen in only one sex and were minor in nature, they 
are considered to be of no toxicological relevance. A dose-dependent decrease in 
alanine aminotransferase activities (up to −20%) was observed in treated females, 
and increased triglyceride concentrations (+53%) were observed in females of 
the high-dose group only. In the absence of other treatment-related findings in 
the liver, these effects were considered to be of no toxicological importance. A 
dose-dependent decrease in urea concentrations (up to −23%) was observed in 
treated females; however, in the absence of other effects on the kidney in these 
animals, this finding was not considered to be of toxicological relevance. In 
treated males, a small decrease in albumin/globulin ratio was observed (up to 
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−6%). Absolute organ weights were not affected by the treatment. Changes in 
relative organ weights comprised marginally higher kidney weights in males of 
the mid- and high-dose groups (+6%) and marginally higher ovary weights in 
females of the high-dose group (+16%), compared with controls. No treatment-
related macroscopic changes were observed. Microscopic changes reported 
included a higher incidence of basophilic tubules in the kidney cortex (12 males 
in the high-dose group compared with five in the controls; with the exception of 
one animal, severity was recorded as minimal or slight). Interstitial inflammatory 
cell infiltration (six animals in the high-dose group compared with two in the 
controls; minimal severity) was seen in the kidneys of high-dose males. Also, 
chronic inflammation of the pancreas (minimal severity) was noted in three high-
dose males, compared with zero control animals. These are common microscopic 
changes seen in rats of this age and strain and are therefore not considered to be 
treatment related. 
 The effects observed in this study were minor and not consistent between 
the sexes and were therefore not considered to be adverse effects. Therefore, the 
NOAEL was 199 mg TOS/kg bw per day, the highest dose tested (Cooper, 2000). 
2.2.3 Long-term studies of toxicity and carcinogenicity
No information was available.
2.2.4 Genotoxicity
The results of three studies of genotoxicity in vitro and in vivo with the mixed 
β-glucanase and xylanase liquid enzyme concentrate are summarized in Table 
1. The first study followed Organisation for Economic Co-operation and 
Development (OECD) test guideline 471 (Bacterial Reverse Mutation Test; 
1997), the second, OECD test guideline 473 (In Vitro Mammalian Chromosome 
Aberration Test; 1997), and the third, OECD test guideline 474 (Mammalian 
Erythrocyte Micronucleus Test; 1997). All three studies were certified for 
compliance with GLP and QA. 
 In the in vitro chromosomal aberration assay (Mason, 1999a), the 
liquid enzyme concentrate did not induce a statistically significant increase in 
chromosomal aberrations in the presence of S9. In the absence of S9, the liquid 
enzyme concentrate induced a statistically significant increase in chromosomal 
aberrations (chromatid-type breaks) after exposure of the cells to the highest 
tested concentration for 20 hours. The author indicated that owing to the nature of 
the material tested, the liquid enzyme concentrate may have caused chromosome 
damage as a result of non-genotoxic mechanisms (Mason, 1999a). The Committee 
noted that the highest concentration caused a mitotic inhibition of 58%. Also, 
the percentage of cells with aberrations was only slightly higher than the upper 
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bw: body weight; M: male; S9: 9000 × g supernatant fraction from rat liver homogenate 
a Two independent experiments were performed using the “treat-and-plate” method. The bacteria were first incubated in liquid culture – that is, with the test sub-
stance in solution, nutrient broth and buffer or S9 mix – for 1 hour. The bacteria were then washed before mixing with top agar and plating on minimal glucose 
agar plates.
b  In the first experiment, the cell cultures were treated for 3 hours without and with S9 and were harvested 17 hours later. The highest tested concentration induced 
15% mitotic inhibition in the absence of S9. In the second experiment, the cells were exposed continuously for 20 hours without S9 and then harvested. With S9, 
the cells were treated for 3 hours and harvested 17 hours later. The highest tested concentration induced 58% mitotic inhibition in the absence of S9. In the first 
experiment, no significant increase in chromosomal aberrations was observed. In the second experiment in the absence of S9, a statistically significant increase in 
chromosomal aberrations was observed at 5000 µg/mL. The percentage of cells with aberrations excluding gaps was 5% at the highest concentration versus 0% in 
the controls (upper 99% confidence limit of historical negative control data was 4.5%), whereas the percentage of cells with aberrations including gaps was 11% at 
the highest concentration versus 2.5% in the controls (upper 99% confidence limit of historical negative control data was 7.85%). 
c Single dose administered by gavage. Animals were examined 24 hours after dosing, and additional examinations were performed 48 hours after dosing in the 
negative control group and the highest-dose group. The Committee noted that no evidence of bone marrow and/or systemic exposure was provided. 
End-point Test system
Route of  
administration Concentration Results Reference 
In vitro
Reverse  
mutation
Salmonella typhimurium TA98, 
TA100, TA1535 and TA1537 and 
Escherichia coli WP2uvrApKM101
– 100–10 000 µg/plate, 
±S9
Negativea May (1999)
Chromosomal 
aberration
Human lymphocytes – 1st experiment: 1 250,  
2 500 or 5 000 µg/mL, 
±S9
2nd experiment: 750,  
3 000 or 5 000 µg/
mL, −S9
1 250, 2 500 or 5 000 µg/
mL, +S9 
Equivocalb Mason (1999a)
In vivo
Micronucleus 
induction
Mouse; M Gavage 500, 1 000 or 2 000 mg/
kg bw
Negativec Mason (1999b)
Table 1
Genotoxicity of mixed β-glucanase and xylanase liquid enzyme concentrate in vitro and in 
vivo
99% confidence limit of the historical negative control data (5.0% versus 4.5%), 
and the level of significance was enhanced by the fact that no aberrations were 
observed in the controls. Therefore, the Committee considered the results of the 
in vitro chromosomal aberration assay to be equivocal. In combination with the 
negative results of the in vitro reverse mutation assay, the Committee did not have 
concerns with respect to the genotoxicity of this enzyme preparation. 
2.2.5 Reproductive and developmental toxicity
No information was available.
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2.3 Observations in humans 
No information was available.
3. Dietary exposure
3.1 Introduction
The mixed β-glucanase and xylanase enzyme preparation is intended to be used 
as a processing aid in brewing, potable alcohol (spirits) production and grain 
processing (production of non-alcoholic beverages [including soft drinks] and 
bakery ingredients). The estimated maximum levels in final food products are 6.2 
mg TOS/L in beer, 28 mg TOS/L in non-alcoholic beverages, 28 mg TOS/kg in 
bakery ingredients and 0 mg TOS/L in potable alcohol (spirits).
 The enzymes are inactivated during the intended processes. In addition 
to the enzyme protein in question, the mixed enzyme preparation also contains 
some substances derived from the producing microorganism and the fermentation 
medium.
 The Committee evaluated one submission by a sponsor (Reuvers, 2014) 
on dietary exposure to the additive using assessments based on individual dietary 
records.
3.2 Assessment of dietary exposure
The estimated daily intake (EDI) was calculated by the sponsor based on the 
estimated levels in the final food products and the intake levels of beverages and 
solid food based on per capita food consumption data from the United States 
Department of Agriculture (USDA) (Wilkinson Enns, Goldman & Cook, 1997; 
Wilson et al., 1997). As a “worst-case situation”, the 90th percentile of the intake 
level was taken except for alcoholic beverages, for which the 95th percentile was 
used. The EDI was estimated to be 0.004–0.04 mg TOS/kg bw per day from beer 
and ale using an estimated consumption per person of 360 mL beverage/day, 
0.04–0.39 mg TOS/kg bw per day from non-alcoholic beverages (fruit drinks 
and ades; carbonated soft drinks; 838 mL/day) and 0.02–0.24 mg TOS/kg bw per 
day from grain products (cereal and pasta; quick breads, pancakes, French toast; 
cakes, cookies, pastries, pies; crackers, popcorn and chips; mixtures mainly grain; 
502 g/day). The three estimates sum to 0.06–0.7 mg TOS/kg bw per day, or 4–40 
mg/day for a 60 kg person. This estimate assumes that all cereal grain products, 
including beer and ale, are treated with the mixed β-glucanase and xylanase 
enzyme preparation and is therefore an overestimate.
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 Reference to the 17 consumption cluster diets of the Global Environment 
Monitoring System – Food Contamination Monitoring and Assessment 
Programme (GEMS/Food) (WHO, 2012) reveals that clusters G08, G11 and 
G15 (including a number of European countries) have the highest apparent 
consumption of beer (225–260 g/day). Cluster G10, which includes the USA, has 
an apparent consumption of 174 g/day. If the mixed β-glucanase and xylanase 
enzyme preparation is present at the highest suggested level of 6.2 mg TOS/L 
beverage, the dietary exposure at the maximum consumption of 260 g/day would 
be 1.6 mg TOS/day (or 0.03 mg TOS/kg bw per day for a 60 kg person).
 Cluster G02 (including a number of Eastern European/Central Asian 
countries) has the highest apparent consumption of non-alcoholic beverages 
(excluding milk-based beverages, stimulants and water) (75 g/day), followed 
by cluster G15 (including a number of European countries), at 56 g/day, and 
cluster G10, which includes the USA, at 47 g/day. If the mixed β-glucanase and 
xylanase enzyme preparation is present at the highest suggested level of 28 mg 
TOS/L beverage, the dietary exposure at the maximum consumption of 75 g/day 
would be 2.1 mg TOS/day (or 0.04 mg TOS/kg bw per day for a 60 kg person). 
The estimate for consumption used here (75 g/day) is significantly lower than the 
estimate used by the sponsor (838 mL/day).
 Clusters G01, G06 and G09 (including a number of countries from Asia, 
the Middle East and North Africa) have the highest apparent consumption of 
cereals and flour (370–480 g/day). If the mixed β-glucanase and xylanase enzyme 
preparation is present at the highest suggested level of 28 mg TOS/kg product, 
the dietary exposure at the maximum consumption of 480 g/day would be 13 mg 
TOS/day (or 0.2 mg TOS/kg bw per day for a 60 kg person).
 The three estimates (1.6, 2.1 and 13 mg TOS/day) sum to 17 mg TOS/
day, or 0.3 mg TOS/kg bw per day for a 60 kg person. This estimate assumes 
that all cereal grain products, including beer and ale, are treated with the 
mixed β-glucanase and xylanase enzyme preparation and would therefore be 
an overestimate. The estimate is within the range of the EDI calculated by the 
sponsor using survey data from the USDA.
4. Comments
4.1 Assessment of potential allergenicity
β-Glucanase and xylanase from D. dimorphosporum have commonly been found 
in food, and there are no indications for allergic reactions due to their ingestion. 
As these enzymes are not products of genetic modification, an assessment of their 
potential allergenicity was not required. 
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4.2 Toxicological studies
In a 13-week study of oral toxicity in rats, no treatment-related adverse effects 
were seen when the mixed β-glucanase and xylanase liquid enzyme concentrate 
was administered by gavage at doses up to 199 mg TOS/kg bw per day (Cooper, 
1999). The mixed β-glucanase and xylanase liquid enzyme concentrate was 
not genotoxic in a bacterial reverse mutation assay (May, 1999). In an in vitro 
chromosomal aberration assay (Mason, 1999a), the liquid enzyme concentrate 
induced a small, but statistically significant, increase in chromosomal aberrations 
(chromatid-type breaks) after exposure of the cells to the highest concentration 
tested for 20 hours, in the absence of S9 only. However, as the effect was small, a 
mitotic inhibition of 58% was observed at the highest concentration tested and 
the level of statistical significance was related to the fact that no aberrations were 
observed in the controls, the Committee considered these results not to be of 
toxicological relevance. In combination with the negative results of the in vitro 
reverse mutation assay, the Committee did not have concerns with respect to the 
genotoxicity of the mixed β-glucanase and xylanase enzyme preparation. 
4.3 Assessment of dietary exposure
The Committee estimated the theoretical dietary exposure to the mixed 
β-glucanase and xylanase enzyme preparation based on the estimated maximum 
levels in final food products (6.2 mg TOS/L in beer, 28 mg TOS/L in non-alcoholic 
beverages [including soft drinks], 28 mg TOS/kg in bakery ingredients [starch, 
fibres, flour] and 0 mg TOS/L in potable alcohol [spirits]). The combination of 
these maximum levels with per capita food consumption data from the USA 
(supplied by the sponsor) and data from the GEMS/Food consumption cluster 
diets results in a potential dietary exposure of 0.7 mg TOS/kg bw per day for 
a 60 kg person. The Committee noted that the enzymes will be inactivated in 
processed food and that the exposure estimate is conservative.
5. evaluation
No treatment-related adverse effects were seen at the highest dose tested (199 mg 
TOS/kg bw per day) in the 13-week study of oral toxicity in rats (Cooper, 1999). 
A comparison of the dietary exposure estimate of 0.7 mg TOS/kg bw per day with 
the highest dose tested of 199 mg TOS/kg bw per day gives a margin of exposure 
of at least 280. The Committee established an ADI “not specified” for the mixed 
β-glucanase and xylanase enzyme preparation from D. dimorphosporum, used in 
the applications specified and in accordance with good manufacturing practice. 
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1.  explanation
At the request of the Codex Committee on Food Additives at its Forty-sixth 
Session (FAO/WHO, 2014), the Committee evaluated the safety of polyvinyl 
alcohol (PVA) – polyethylene glycol (PEG) graft copolymer, which it had not 
evaluated previously. The individual components of the copolymer have been 
evaluated previously by the Committee. The use of PVA as a coating, binder, 
sealing and surface finishing agent in food products such as dairy-based desserts, 
confectionery, cereal products and food supplements was evaluated at the sixty-
first meeting of the Committee, and the Committee established an acceptable 
daily intake (ADI) of 50 mg/kg body weight (bw) for PVA (Annex 1, reference 
167). At the twenty-third meeting, the Committee established an ADI of 10 mg/
kg bw for polyethylene glycols (Annex 1, reference 51).
 PVA-PEG graft copolymer is a synthetic branched graft copolymer 
primarily intended for use in aqueous film coatings in the preparation 
and formulation of food supplements. It is currently approved for use for 
pharmaceutical applications in several regions, including the European Union, 
the USA and Japan. Recently, PVA-PEG graft copolymer was authorized as an 
additive for use in solid food supplements in the European Union, based on the 
evaluation by the European Food Safety Authority (EFSA, 2013). 
1.1 Chemical and technical considerations 
Graft copolymers are a form of copolymer where the side-chains are structurally 
different from the main chain. PVA-PEG graft copolymer is a synthetic, branched 
graft copolymer consisting of side-chains of PVA on a main chain of PEG. It 
consists of approximately 75% vinyl alcohol units (-CH2CH2(OH)-) and 25% 
ethylene glycol units (-CH2CH2O-). 
 PVA-PEG graft copolymer is a white to pale yellow free-flowing powder. 
It is manufactured by grafting polyvinyl acetate side-chains onto a PEG backbone 
that has an average molecular weight of 6000 Da. The polyvinyl acetate side-
chains are then hydrolysed to form PVA side-chains. Based on the manufacturing 
conditions, PVA-PEG graft copolymer has an average of 2–3 PVA side-chains per 
PEG backbone. It has a weight-average molecular weight ranging from 40 000 to 
50 000 Da. In the specifications, maximum limits have been set for a number of 
impurities, including vinyl acetate (20 mg/kg) and ethylene glycol and diethylene 
glycol (400 mg/kg, singly or in combination).
 The predominant use in food supplements is that of glazing agent or, 
more specifically, as an aqueous film coating for food supplement tablets at a use 
level of up to 5% (weight per weight [w/w]). PVA-PEG graft copolymer also has 
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minor uses in food supplements as a stabilizer and binder for tablets at a use level 
of up to 10% (w/w). 
2. Biological data
2.1 Biochemical aspects 
2.1.1 Absorption, distribution, metabolism and elimination 
The toxicokinetic properties of 14C-labelled PVA-PEG graft copolymer (specific 
activity 65.8 MBq/g) were investigated in groups of four male and four female 
Wistar rats following administration of a single oral dose of 10 or 1000 mg/kg bw 
by gavage (Leibold & Hoffmann, 2001; published by Heuschmid et al., 2013a). The 
study design was in accordance with European Commission Directive 87/302/
EEC, Organisation for Economic Co-operation and Development (OECD) test 
guideline 417 (Toxicokinetics; 1984) and United States Environmental Protection 
Agency (USEPA) Office of Prevention, Pesticides and Toxic Substances 
(OPPTS) Health Effects Test Guideline OPPTS 870.7485 (Metabolism and 
Pharmacokinetics; 1998). The study was certified for compliance with good 
laboratory practice (GLP) and quality assurance (QA). 
 The excretion of radioactivity in faeces, urine and exhaled air (the latter 
in two males only) was monitored for up to 168 hours post-dosing, and the 
excretion of radioactivity in bile was monitored for up to 48 hours post-dosing. 
Cumulative values for the excretion of radioactivity for each route as percentages 
of the administered dose are presented in Table 1. 
Table 1
Mean cumulative excretion of radioactive material following administration of single oral 
doses of 14C-labelled PVA-PeG graft copolymer to male and female rats
bw: body weight; ND: not determined
Dose  
(mg/kg bw)
Mean cumulative excretion of radioactive material (% of administered dose)
Faeces Urine Bile Exhaled air
Males Females Males Females Males Females Males Females
48 h
     10 100.05 103.45 0.50 0.45 0.02 0.02 ND ND
     1 000 100.76 105.27 0.27 0.22 0.01 0.02 ND ND
168 h
     10 100.14 103.63 0.53 0.47 ND ND 0.15 ND
     1 000 101.30 105.35 0.31 0.23 ND ND 0.11 ND
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 Following administration of a single oral dose of 10 mg/kg bw of 
14C-labelled PVA-PEG graft copolymer, the cumulative amount of radioactivity 
recovered in the faeces of males and females at 48 and 168 hours post-dosing was 
approximately 100%. The total excretion of radioactivity via urine was negligible 
(range 0.45–0.53%). Excretion of 14CO2 via exhaled air (determined in two males 
only) was also negligible (0.15%). Limited amounts of remaining radioactivity were 
detected in the carcass (i.e. 0.02% in males and in females), and the concentration 
of radioactivity was below 0.1 µg equivalent (Eq)/g in all organs and tissues. Mean 
total recoveries of radioactivity were 101% in males and 104% in females. 
 At the high dose of 1000 mg/kg bw of 14C-labelled PVA-PEG graft 
copolymer, the same pattern was observed. The cumulative amount of radioactivity 
recovered in the faeces of males and females at 48 and 168 hours post-dosing 
was approximately 100%. The total excretion of radioactivity via urine was 
negligible (range 0.22–0.31%). Excretion of 14CO2 via exhaled air (determined 
in two males only) was also negligible (0.11%). Limited amounts of remaining 
radioactivity were detected in the carcass (i.e. 0.13–0.16%), and the concentration 
of radioactivity was below 1 µg Eq/g in all organs and tissues (except the liver, 
with a concentration of 1.31 µg Eq/g). Mean total recoveries of radioactivity were 
102% in males and 106% in females. 
 In bile duct–cannulated rats, cumulative biliary excretion of 14C-labelled 
PVA-PEG graft copolymer 48 hours post-dosing was 0.01–0.02% of the 
administered radioactivity in males and females of the 10 and 1000 mg/kg bw 
dose groups. 
 Overall, based on the excretion data, the oral bioavailability of 
14C-labelled PVA-PEG graft copolymer was calculated to be less than 1% (Leibold 
& Hoffmann, 2001). 
2.2 Toxicological studies
2.2.1 Acute toxicity
In a study of acute oral toxicity, three male and three female rats were given PVA-
PEG graft copolymer (batch no. ZK 1440/236-1) at a single oral dose of 2000 
mg/kg bw by gavage (Wiemann & Hellwig, 2000a). The study was certified for 
compliance with QA and GLP and was performed in accordance with OECD 
test guideline 423 (Acute Oral Toxicity – Acute Toxic Class Method; 1996) and 
USEPA Health Effects Test Guideline OPPTS 870.1100 (Acute Oral Toxicity; 
1998). With the exception of two male rats with diffuse reddish discoloration and 
oedema of the lungs, no other abnormalities were noted at necropsy. The oral 
median lethal dose (LD50 value) in this study was greater than 2000 mg/kg bw 
(Wiemann & Hellwig, 2000a). 
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 PVA-PEG graft copolymer was not corrosive and did not lead to skin or 
eye irritation in New Zealand White rabbits (Wiemann & Hellwig, 2000b,c). 
2.2.2 Short-term studies of toxicity
(a) Rats
In a 90-day oral toxicity study, groups of 10 male and 10 female Wistar rats 
were administered PVA-PEG graft copolymer (batch no. ZK 1440/236-1, purity 
>98.8%) at a concentration of 0 (vehicle control), 600, 3000 or 15 000 mg/L in 
the drinking-water, equal to, respectively, 0, 60, 300 and 1610 mg/kg bw per day 
for males and 0, 80, 370 and 2190 mg/kg bw per day for females. The study was 
designed according to OECD test guideline 408 (Repeated Dose 90-Day Oral 
Toxicity Study in Rodents; 1998) and was certified for compliance with GLP and 
QA. Observations included clinical signs, body weight, feed consumption, water 
consumption, a functional observational battery, motor activity, ophthalmoscopy, 
haematology, clinical chemistry, urine analysis, organ weights, and macroscopic 
and microscopic pathology (Mellert et al., 2001; published by Heuschmid et al., 
2013b). 
 There were no deaths or treatment-related clinical observations. 
No treatment-related effects were observed regarding feed consumption, 
feed efficiency, body weight (gain) and ophthalmoscopy or in the functional 
observational battery. No treatment-related changes in haematological and 
clinical chemistry parameters or urine analyses were noted. In males and females 
of the high-dose group, water consumption was higher (range 5–31% in males 
and 16–37% in females) than in controls throughout the study, reaching statistical 
significance on several days. Regarding the overall motor activity (summation of 
12 time intervals), no significant deviations were seen. There were significantly 
decreased values in males of the mid- and high-dose groups at interval 10, but 
these isolated findings were not considered to be treatment related. A statistically 
significant increase (+10%) in absolute liver weight was observed in males of 
the low-dose group only. Mean relative brain weights of males of the low- and 
high-dose groups were 6% lower than in controls, but these can be attributed to 
the slightly, but not statistically significantly, higher mean body weights in these 
groups. These findings on organ weights were not considered to be treatment 
related. No treatment-related gross lesions or microscopic findings were noted. 
 The only treatment-related effect observed was an increase in water 
consumption in high-dose males and females. The reason for this increase is not 
known. In the absence of other treatment-related findings, this is not considered 
to be an adverse effect. The no-observed-adverse-effect level (NOAEL) in this 
study was therefore 1610 mg/kg bw per day, the highest dose tested (Mellert et al., 
2001). 
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(b) Dogs
In an oral study of toxicity, groups of five male and five female Beagle dogs 
were given PVA-PEG graft copolymer (batch no. 99/401-2; purity >99%) for 
about 9 months. PVA-PEG graft copolymer was dissolved in drinking-water 
at a concentration of 0 (vehicle control), 3000, 10 000 or 30 000 mg/L. Control 
and test drinking-water solutions (400 mL) were added to 400 g feed and mixed 
into a paste. These concentrations were equal to mean intakes of, respectively, 0, 
80, 260 and 780 mg/kg bw per day for males and 0, 80, 270 and 810 mg/kg bw 
per day for females. The study was designed following European Commission 
Directive 87/392/EEC and OECD test guideline 452 (Chronic Toxicity Studies; 
1981). The study was certified for compliance with GLP and QA. Observations 
included clinical signs, body weight, feed consumption, ophthalmoscopy, 
haematology, clinical chemistry, urine analysis, organ weights, and macroscopic 
and microscopic pathology (Kaspers et al., 2002; published by Heuschmid et al., 
2013b). 
 No animals died during the treatment period. Incidental clinical 
observations included a single case of diarrhoea in one female of the high-dose 
group on study day 56 and a palpable mass in the neck region of one female of 
the mid-dose group (from study day 279 onwards). Two females of the high-dose 
group had soft faeces between days 121 and 160. Owing to the incidental and/
or transient nature of these findings, these were considered not to be substance 
related. Ophthalmological examinations did not reveal any deviations, except 
for slight cataract in both eyes in one control female. Feed consumption, body 
weight and feed efficiency were not affected by treatment. Several statistically 
significant differences were observed in haematology (white blood cells, activated 
partial thromboplastin time), clinical chemistry (aspartate aminotransferase, 
magnesium) and urine analysis (squamous cells in sediment). However, these 
were all small and/or occurred in the low- and/or mid-dose groups only and were 
therefore not considered to be of toxicological relevance. 
 In female dogs, the mean absolute weight of the ovaries was significantly 
increased in all dose groups (1450, 1508 and 1760 mg, respectively, in the low-, 
mid- and high-dose groups versus 906 mg in controls). The corresponding 
relative ovary weights were also increased, but these values did not reach statistical 
significance. Heuschmid et al. (2013b) reported that the absolute ovary weights of 
the three treatment groups were within the historical control range of the testing 
facility (range: 979–2258 mg; mean: 1378 mg), whereas the value of the control 
group was below the historical control range. Historical control data were not 
included in the report of Kaspers et al. (2002). The authors attributed the change 
in ovary weights to the different states of the sexual cycle in control and treated 
dogs. Based on histopathological investigations, all control dogs were in the 
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resting phase of the sexual cycle, whereas three low-dose, two mid-dose and four 
high-dose female dogs were in the active phase of the sexual cycle. The change in 
ovary weights was considered not to be treatment related. The Committee agreed 
with this view, given the lack of other histopathological findings in the ovaries in 
the dog study and the lack of adverse effects on reproductive organs in the 90-day 
toxicity study in rats and the reproductive toxicity study in rats. 
 In male dogs, absolute mean thyroid gland weight was significantly 
increased (+31%) in the low-dose group only. In the absence of similar changes 
at higher dose levels, this was considered to be an incidental finding. A few gross 
lesions (e.g. erosion/ulcer in glandular stomach, focus in lungs, urinary bladder, 
epididymides and prostate gland, cyst in pituitary and thyroid glands, and oedema 
in adipose tissue) were reported sporadically in all groups, including controls. With 
two exceptions (erosion/ulcer in the glandular stomach of two high-dose males 
and focus in the prostate of one high-dose male), these gross lesions occurred 
only, or at the same incidence, in control and/or mid-dose animals. The gross 
lesions were considered to be incidental and not substance related. Although no 
explanation for the occurrence of erosion/ulcer in the glandular stomach of the 
two high-dose males was provided, given that only two males were affected and 
in the absence of similar findings in females, this finding was not considered to be 
treatment related. 
 Histopathological examination showed chronic lymphocytic thyro-
adenitis (thyroiditis) in two high-dose males. This type of chronic thyroiditis has 
been reported at an incidence of up to 20% in dogs (Fritz, Zeman & Zelle, 1970) 
and occurred in only one sex; therefore, it was considered not to be treatment 
related. Other microscopic findings noted were single observations, occurred in 
all or almost all groups at comparable incidences and graded severity, including 
control animals, and/or showed no dose–response relationship and therefore 
were considered to be unrelated to treatment.
 In the absence of treatment-related adverse effects, the NOAEL was 780 
mg/kg bw per day, the highest dose tested (Kaspers et al., 2002).
2.2.3 Long-term studies of toxicity and carcinogenicity
No long-term studies of toxicity and carcinogenicity were available for PVA-PEG 
graft copolymer. 
2.2.4 Genotoxicity
The results of two studies of genotoxicity in vitro (a bacterial reverse mutation assay 
and a gene mutation assay) and one study of genotoxicity in vivo (a micronucleus 
assay) with PVA-PEG graft copolymer are summarized in Table 2. All three 
studies were certified for compliance with GLP and QA. The first study followed 
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bw: body weight; M: male; S9: 9000 × g supernatant fraction from rat liver homogenate 
a Two independent experiments were performed. The first experiment was performed using the plate incorporation method, and the second experiment was per-
formed using the preincubation method. A slight decrease in the number of revertants and a slight reduction in bacterial growth were occasionally observed from 
2500 µg/mL onwards. 
b  Two independent experiments were performed. Cells were exposed for 4 hours in the absence and presence of S9 (except in the second experiment, in which cells 
were exposed for 24 hours in the absence of S9), followed by an expression phase of 30–48 hours and a selection period of approximately 10 days. After an exposure 
period of 24 hours, relative total growth was decreased at 2500 µg/mL (−55%) and 5000 µg/mL (−37%). 
c  Two doses were administered intraperitoneally at 0 and 24 hours. Examinations were 24 hours after the last dosing (i.e. at 48 hours). No increases in group mean 
micronuclei were observed. The Committee noted that intraperitoneal administration is not a relevant route for human exposure to PVA-PEG graft copolymer.
End-point Test system
Route of  
administration Concentration Results Reference 
In vitro
Reverse  
mutation
Salmonella typhimurium TA98, 
TA100, TA1535 and TA1537 and 
Escherichia coli WP2uvrA
– 20–5 000 µg/plate, ±S9 Negativea Engelhardt & 
Hoffmann (2000)
Gene mutation Mouse lymphoma L5178Y 
TK+/− cells
– First experiment:
312.5–5 000 µg/mL, ±S9
Second experiment: 
79–5 000 µg/mL, −S9
312.5–5 000 µg/mL, +S9
Negativeb Engelhardt & 
Hildebrand 
(2000a)
In vivo
Micronucleus 
induction
Mouse; M Intraperitoneal 500, 1 000 and 2 000 mg/
kg bw
Negativec Engelhardt & 
Hildebrand 
(2000b)
Table 2
Genotoxicity of PVA-PeG graft copolymer in vitro and in vivo
OECD test guideline 471 (Bacterial Reverse Mutation Test; 1997) (Engelhardt & 
Hoffman, 2000), the gene mutation assay was conducted according to OECD test 
guideline 476 (In Vitro Mammalian Cell Gene Mutation Test; 1997) (Engelhardt 
& Hildebrand, 2000a) and the micronucleus test followed OECD test guideline 
474 (Mammalian Erythrocyte Micronucleus Test; 1997). The genotoxicity studies 
were performed with batch no. ZK 1440/236-1 (purity about 98.8%). Based on the 
results of these tests, PVA-PEG graft copolymer is unlikely to be genotoxic.
2.2.5 Reproductive and developmental toxicity
(a) Reproductive toxicity
In a two-generation reproductive toxicity study performed in accordance with 
the International Conference on Harmonisation of Technical Requirements for 
Registration of Pharmaceuticals for Human Use (ICH) Harmonized Tripartite 
Guideline S5A (Detection of Toxicity to Reproduction for Medicinal Products, 
dated 24 June 1993) and ICH Harmonized Tripartite Guideline S5B (Detection 
of Toxicity to Reproduction for Medicinal Products, Addendum to the Parent 
Guideline: Toxicity to Male Fertility, dated 29 November 1995), Wistar rats (25 
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of each sex per group for the F0 and the F1 generations) received PVA-PEG graft 
copolymer (batch no. Abl. Nr. 61-7156; purity >99%) by gavage at a dose of 0, 100, 
300 or 1000 mg/kg bw per day. F0 males were treated over a 4-week premating 
period, and F0 females were treated over a 2-week period before mating and 
throughout the mating period. The females were also treated during gestation 
and lactation of the F1 pups up to postnatal day (PND) 21. The F1 litters were 
not culled. After weaning at PND 21, 25 weanling rats of each sex per dose were 
selected for producing the F2 generation. The remaining weanlings were killed 
and checked for macroscopic anomalies. After weaning, the F1 parental rats were 
raised without treatment. The F0 and F1 parental males were killed after mating. 
The F0 females were killed after weaning of the F1 pups. The F1 parental females 
were killed on gestation days (GDs) 15–17. Mortality and clinical signs were 
recorded daily. Body weights of parental rats were recorded twice weekly during 
the premating and mating phases. In addition, females were weighed daily during 
gestation and lactation. Feed consumption was recorded weekly. Premating 
estrous cycle, fertility and mating indices of males and females, sperm parameters 
and gestation duration were determined. In F1 females, the numbers of corpora 
lutea, live and dead fetuses, dead implantations, and early and late resorptions 
were recorded. All litters from the F0 parents were examined for number of pups, 
sex of pups, number of stillbirths, number of live births and gross anomalies. All 
pups were checked daily for mortality and clinical signs and weighed on PNDs 
0, 4, 7, 10, 14, 17 and 21. Pups that were not selected for breeding were killed 
and necropsied at PND 21. In all F1 pups selected for breeding the F2 generation, 
the days of vaginal opening and preputial separation were recorded. In addition, 
a learning and memory test (water maze) was performed on PNDs 34–36. The 
parental rats were necropsied, and testes, epididymides, prostate, seminal vesicles 
with coagulation glands, ovaries and uterus were weighed. Histopathology was 
not performed (Schneider et al., 2003; published by Heuschmid et al., 2013c). 
 No treatment-related mortality or clinical signs were observed. Body 
weight gain and feed consumption of the parental animals were not affected 
by treatment. The lower body weights early after weaning, but not later in the 
study, in mid- and high-dose F1 pups selected for breeding were attributed to 
the larger F1 litter sizes that were observed at these dose levels. Necropsy and 
organ weight measurements of parental rats revealed no effect of treatment. 
Fertility and reproduction parameters (estrous cycle data, mating behaviour, 
conception, gestation and parturition rates, number of corpora lutea, number 
of implantations and preimplantation losses) in F0 and F1 parental rats were not 
affected by treatment with PVA-PEG graft copolymer. A reduction in the total 
number of spermatids per gram testis in mid-dose males of the F0 parental group 
was within the normal historical control range and, in the absence of a similar 
effect at the high dose or in the mid-dose F1 males, was not considered treatment 
96
W
H
O
 F
oo
d 
Ad
di
tiv
es
 S
er
ie
s N
o.
 7
1,
  2
01
5
Safety evaluation of certain food additives and contaminants   Eightieth  JECFA
related. In high-dose F0 dams, postimplantation losses and total number of 
resorptions were reduced, and the percentage of live fetuses was increased. Litter 
size at the high dose (11.1) was increased compared with controls (9.5). The lower 
body weight at birth (3%) and at PND 21 (9%) of high-dose pups compared with 
control pups was attributed to the increased litter size. A slight delay in preputial 
separation in the high-dose F1 pups (43.0 days versus 42.5 days in controls) was 
within the historical control range and may be related to the lower body weights 
of these pups. PVA-PEG graft copolymer had no influence on the sex ratio or on 
learning and memory of the F1 generation. Furthermore, no effect of PVA-PEG 
graft copolymer on the intrauterine development and survival of the F2 progeny 
was found. Necropsy of parental rats and F1 pups revealed no effect of treatment. 
 The NOAEL for parental, offspring and reproductive toxicity was 1000 
mg/kg bw per day, the highest dose tested (Schneider et al., 2003). 
(b) Developmental toxicity
(i) Rats
In a developmental toxicity study performed in accordance with the ICH Guideline 
on Detection of Toxicity to Reproduction for Medicinal Products (United States 
Food and Drug Administration, dated 22 September 1994), groups of 25 female 
Wistar rats were treated orally, by gavage, with PVA-PEG graft copolymer (batch 
no. ZK 1440/236-1; purity 98.8%) at a dose of 0, 100, 300 or 1000 mg/kg bw per day 
from days 6 through 15 after mating (GD 0 = day on which sperm were detected 
in the vaginal smear). The vehicle was distilled water. The study was certified to 
comply with GLP and QA. Clinical signs and mortality were recorded daily. Body 
weights and feed consumption were measured on GDs 0 (body weights only), 1, 3, 
6, 8, 10, 13, 15, 17 and 20. All females were killed on GD 20 and subjected to gross 
examination. The uterus was examined and weighed, and the numbers of live and 
dead fetuses, corpora lutea, implantations, and early and late resorptions were 
counted. Each fetus was weighed, sexed and examined macroscopically. About 
half of the fetuses from each litter were selected for skeletal examinations, and the 
other half for visceral examinations (Gamer, Schneider & Van Ravenzwaay, 2002; 
published by Heuschmid et al., 2013d). 
 At 0, 100, 300 and 1000 mg/kg bw per day, 23, 25, 21 and 24 females were 
pregnant, respectively. No treatment-related mortality, clinical signs or abortions 
were observed. Body weight gain and feed consumption were not affected by 
treatment. There were no treatment-related differences in the numbers of corpora 
lutea and implantation sites, preimplantation and postimplantation losses, and 
the numbers of resorptions and viable fetuses. External, visceral and skeletal 
examinations revealed no effect of treatment with PVA-PEG graft copolymer. 
No effects were observed on fetal sex ratio, placental weight or fetal weight. 
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Occasional findings of malformations or variations were generally within the 
historical control range or lacked dose dependency and were considered not 
treatment related. 
 The NOAEL for maternal and embryo/fetal toxicity was 1000 mg/kg bw 
per day, the highest dose tested (Gamer, Schneider & Van Ravenzwaay, 2002). 
(ii) Rabbits
In a developmental toxicity study performed in accordance with the ICH 
Guideline on Detection of Toxicity to Reproduction for Medicinal Products 
(United States Food and Drug Administration, dated 22 September 1994), groups 
of 25 artificially inseminated Himalayan rabbits were treated orally, by gavage, 
with PVA-PEG graft copolymer (batch no. ZK 1440/236-1; purity 98.8%) in 
double distilled water at a dose of 0, 100, 300 or 1000 mg/kg bw per day from days 
6 through 19 of gestation (the day after artificial insemination was designated as 
GD 0). The study was certified to comply with GLP and QA. The rabbits were 
checked daily for mortality and clinical signs. Body weight was measured on GDs 
0, 2, 4, 6, 9, 11, 14, 16, 19, 21, 23, 25 and 29. Feed consumption was measured 
daily from GD 1 to GD 29. All females were killed on GD 29. All rabbits of all 
dose groups were examined macroscopically for abnormalities. The uterus was 
examined and weighed, and the numbers of live and dead fetuses, corpora lutea, 
implantations, and early and late resorptions were counted. Each fetus was 
weighed, sexed and examined macroscopically. All fetuses were subjected to 
skeletal and visceral examinations (Schneider, Hellwig & Van Ravenzwaay, 2002; 
published by Heuschmid et al., 2013d). 
 No treatment-related mortality was observed. One high-dose female 
aborted. No treatment-related effects on clinical signs, body weight gain or 
feed consumption were observed. Necropsy of the dams at day 29 revealed no 
treatment-related abnormalities. There were no treatment-related differences 
in the numbers of corpora lutea and implantation sites, preimplantation and 
postimplantation losses, or the numbers of resorptions and viable fetuses. 
External, visceral and skeletal examinations revealed no effect of treatment with 
PVA-PEG graft copolymer. No effects were observed on fetal sex ratio, placental 
weight or fetal weight. Occasional findings of malformations or variations were 
generally within the historical control range or lacked dose dependency and were 
considered not treatment related. 
 The NOAEL for maternal and embryo/fetal toxicity was 1000 mg/kg bw 
per day, the highest dose tested (Schneider, Hellwig & Van Ravenzwaay, 2002). 
98
W
H
O
 F
oo
d 
Ad
di
tiv
es
 S
er
ie
s N
o.
 7
1,
  2
01
5
Safety evaluation of certain food additives and contaminants   Eightieth  JECFA
2.2.6 Special studies
(a) Studies on vinyl acetate (impurity)
The Committee noted that the use of PVA-PEG graft copolymer that complies 
with the proposed specifications could lead to exposure to vinyl acetate. Vinyl 
acetate is considered to be a possible human carcinogen (Group 2B) by the 
International Agency for Research on Cancer (IARC, 1995). Several oral long-
term studies of toxicity and carcinogenicity with vinyl acetate are described in 
the literature (Lijinksy & Reuber, 1983; Lijinsky, 1988; Bogdanffy et al., 1994; 
Maltoni et al., 1997; Minardi et al., 2002; Umeda et al., 2004). The most recent 
study (Umeda et al., 2004) that complies with the relevant OECD test guideline 
is summarized in detail below, and the results are compared with the results of 
the studies by Bogdanffy et al. (1994), Maltoni et al. (1997) and Minardi et al. 
(2002). The studies of Lijinsky & Reuber (1983) and Lijinksy (1988) had several 
limitations (only 20 animals per group and decomposition of vinyl acetate in the 
drinking-water). Therefore, these are not considered further in this evaluation. 
(i) Mice
In a carcinogenicity study, groups of 50 male and 50 female Crj:BDF1 mice were 
administered vinyl acetate in the drinking-water at a concentration of 0, 400, 
2000 or 10 000 mg/L (equal to 0, 40, 200 and 990 mg/kg bw per day for males and 
0, 60, 300 and 1420 mg/kg bw per day for females, respectively) for 104 weeks 
(Umeda et al., 2004). The study was reported to comply with GLP and to be 
performed according to OECD test guideline 453 (Combined Chronic Toxicity/
Carcinogenicity Studies, 1981). The animals were observed daily for clinical signs 
and mortality. Body weight, feed consumption and water consumption were 
measured weekly for the first 13 weeks and every 4 weeks thereafter. Urinary 
parameters were measured in urine samples collected in the last week of the 
study, and haematological and blood biochemical parameters were measured in 
blood samples collected at the end of the administration period. Necropsies and 
histopathological examinations were performed on all animals. 
 Survival rates were comparable among the groups, but several animals 
in the high-dose group died of tumours in the oral cavity, oesophagus, stomach 
or larynx. Terminal body weights were statistically significantly lower in high-
dose males (−30%) and females (−18%). Average water consumption was lower 
(not statistically significantly) in the high-dose group. Mandibular nodules were 
observed in three males and five females of the high-dose group, whereas maxillary 
nodules were observed in three males and one female of the high-dose group. No 
treatment-related effects on the haematology or blood chemistry parameters were 
reported (results of the urine analysis were not reported). In high-dose males, 
statistically significant increases in squamous cell carcinomas and/or papillomas 
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were observed in the oral cavity (17/50 versus 0/50 in controls), oesophagus (7/50 
versus 0/50 in controls) and forestomach (9/50 versus 1/50 in controls). In high-
dose females, a statistically significant increase in squamous cell papillomas and/
or carcinomas was observed in the oral cavity (18/50 versus 0/50 in controls) 
and the forestomach (4/50 versus 0/50). In addition, squamous cell carcinomas of 
the larynx were observed in males of the high-dose group (2/50) and females of 
the mid-dose (1/50) and high-dose (1/50) groups and were not observed in the 
control group. In these tissues, basal cell hyperplasia, squamous cell hyperplasia 
and/or epithelial dysplasia were also observed in several animals. 
 In addition, neoplastic lesions were observed in the tongue, liver, spleen, 
nasal cavity, lung and uterus, but these were not considered to be treatment 
related given the incidences in the control group and/or lack of a dose–response 
relationship. 
(ii) Rats
In a carcinogenicity study, groups of 50 male and 50 female F344/DuCrj rats 
were administered vinyl acetate in the drinking-water at a concentration of 0, 
400, 2000 or 10 000 mg/L (equal to 0, 20, 100 and 440 mg/kg bw per day for 
males and 0, 30, 150 and 580 mg/kg bw per day for females, respectively) for 104 
weeks (Umeda et al., 2004). The study was reported to comply with GLP and to be 
performed according to OECD test guideline 453 (Combined Chronic Toxicity/
Carcinogenicity Studies, 1981). 
 Survival rates were comparable among the groups, but two males in the 
high-dose group died of oral cavity tumours. An oral cavity nodule appeared in 
a low-dose female. Terminal body weights were statistically significantly lower in 
high-dose males (−7%). Average water consumption was lower (not statistically 
significantly) in the high-dose group. Mandibular nodules were observed in 
three males of the high-dose group and a female of the low-dose group, whereas 
a maxillary nodule was observed in one female of the high-dose group. No 
treatment-related effects on the haematology or blood chemistry parameters 
were reported (results of the urine analysis were not reported). Squamous cell 
carcinomas and/or papillomas were observed in the oral cavity (males: incidence 
was 7/50 in the high-dose group versus 0/50 in controls; females: incidences 
were 1/50, 1/50 and 3/50 in the low-, mid- and high-dose groups versus 0/50 
in controls). In one high-dose female, a squamous cell carcinoma was observed 
in the oesophagus. In addition, several neoplastic lesions were observed in the 
pituitary, liver, uterus and thyroid, but these were not considered to be treatment 
related given the incidences in the control group and/or lack of a dose–response 
relationship. 
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(iii) Conclusion
In the study by Umeda et al. (2004), statistically significant increases in the 
incidences of squamous cell carcinomas in the oral cavity, oesophagus and/or 
forestomach were observed at the highest dose tested in male and/or female rats 
and mice (440–990 mg/kg bw per day). 
 In a study using lower dose levels, Bogdanffy et al. (1994) reported 
no neoplastic or non-neoplastic lesions in rats exposed to vinyl acetate via the 
drinking-water at doses up to 200 mg/kg bw per day for males and 300 mg/kg bw 
per day for females for 104 weeks. In contrast, Minardi et al. (2002) and Maltoni 
et al. (1997) found statistically significant increases in tumours after exposure of 
17-week-old rats (Minardi et al., 2002) and mice (Maltoni et al., 1997) and 12-day-
old embryos (offspring) of both species to vinyl acetate at 1000 or 5000 mg/L in 
the drinking-water for 104 and 74 weeks, respectively. The doses were equivalent 
to 50 and 250 mg/kg bw per day for rats and 90 and 450 mg/kg bw per day for 
mice, based on default values for converting drinking-water concentrations into 
doses, as reported by EFSA (2012).
 In summary, in oral studies of long-term toxicity and carcinogenicity in 
rats and mice, statistically significant increases in incidences of tumours, mainly 
in the upper gastrointestinal tract, were observed at dose levels starting from 50–
440 mg/kg bw per day (Maltoni et al., 1997; Minardi et al., 2002; Umeda et al., 
2004).
2.3 Observations in humans
No information was available.
3. Dietary exposure
3.1 Introduction
PVA-PEG graft copolymer is primarily intended for use in aqueous film coatings 
for food supplement products. The copolymer has been globally approved for 
use in the preparation of pharmaceutical products in a number of regions. The 
copolymer can be used for the same applications as cellulosic polymer coating 
systems (e.g. hydroxypropyl methylcellulose–based coating systems). More 
broadly, however, it can be used for all applications for which a water-soluble 
flexible polymer is required. In addition to its use as an instant release coating, 
PVA-PEG graft copolymer can also be used in food supplements as a binder for 
tablets and a stabilizer. 
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 The Committee evaluated one submission by a sponsor of the additive 
(Haber, 2014). In the dossier, the manufacturer assumes that PVA-PEG graft 
copolymer–based film coating formulations are applied to food supplement 
tablets or capsules at 2–4 mg/cm2. The copolymer may comprise 60–100% of the 
dry coating and would typically constitute up to 5% of the weight of the tablet or 
capsule.
 For technical uses other than film coating of tablets or capsules (i.e. 
binder or stabilizer), up to 10% of the weight of the food supplement is typically 
needed.
 According to the chemical specifications from the sponsor, PVA-PEG 
graft copolymer can contain up to 20 mg vinyl acetate per kilogram and up 
to 400 mg ethylene glycols (ethylene glycol and diethylene glycol, singly or in 
combination) per kilogram as impurities.
3.2 Assessment of dietary exposure1 
3.2.1 Assessments based on individual dietary records
Assuming that each tablet weighs 1 g and that all tablets are coated with PVA-
PEG graft copolymer comprising 5% of the weight of the tablet (the maximum 
use level from its primary use as a coating for tablets), each tablet would contain 
50 mg PVA-PEG graft copolymer. The exposure from the stated minor uses as 
stabilizer and binder for tablets at levels up to 10% is expected to be covered by 
the conservative estimates below. 
 Based on data from the dietary supplement questionnaire included 
in the National Health and Nutrition Examination Surveys (NHANES) of the 
National Center for Health Statistics of the USA (CDC, 2006, 2009; USDA, 2009), 
the manufacturer has estimated the consumption of dietary supplements in the 
form of tablets (including pills and capsules) as up to 15 tablets for adults (95th 
percentile for adult women) and up to nine tablets for children (95th percentile 
for children ages 3–11 years).
 Based on data from the United Kingdom Food Standards Agency, EFSA 
(2013) found that the use of food supplements among high consumers (97.5th 
percentile) ranged from two tablets or capsules per day in children (4–18 years 
old) to seven tablets or capsules per day in adults. 
 The dietary exposure to PVA-PEG graft copolymer for high adult 
consumers would be 350–750 mg/day (7–15 tablets × 50 mg/day), i.e. 5.8–13 mg/
kg bw per day for a 60 kg adult, and for children, 100–450 mg/day (2–9 tablets × 
50 mg/day), i.e. 4.3–20 mg/kg bw per day for a 23 kg child.
1 In this section and in sections 4.2 and 5, “dietary exposure” refers to exposure from both food supplements 
and pharmaceutical products. 
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 Assuming that there are similar levels of use and dietary exposure to 
PVA-PEG graft copolymer from both food supplements and pharmaceuticals, 
the Committee concluded that the combined intake from food supplements and 
pharmaceutical products for high consumers could be up to 25 mg/kg bw per day 
for adults and 40 mg/kg bw per day for children.
 If it is assumed that the impurity vinyl acetate is present in PVA-PEG graft 
copolymer at a concentration up to 20 mg/kg, dietary exposure to vinyl acetate 
from both food supplements and pharmaceutical products for high consumers 
could be up to 0.0005 mg/kg bw per day for adults and 0.0008 mg/kg bw per day 
for children.
 If it is assumed that the impurities ethylene glycol and diethylene glycol 
are present in PVA-PEG graft copolymer at a concentration up to 400 mg/kg, singly 
or in combination, dietary exposure to the glycols (singly or in combination) from 
food supplements and pharmaceutical products for high consumers could be up 
to 0.010 mg/kg bw per day for adults and 0.016 mg/kg bw per day for children.
 The theoretical maximum daily dietary exposures estimated here 
are conservative, owing to the assumption that all food supplements and 
pharmaceutical products are coated with PVA-PEG graft copolymer and the fact 
that the exposure estimates are for high consumers of both food supplements and 
pharmaceutical products.
4. Comments
4.1 Toxicological studies 
The toxicokinetic properties of 14C-labelled PVA-PEG graft copolymer were 
investigated in rats following administration of a single oral dose of 10 or 1000 
mg/kg bw by gavage (Leibold & Hoffmann, 2001; published by Heuschmid et 
al., 2013a). The cumulative percentage of radioactivity recovered in the faeces of 
males and females at 48 hours post-dosing was approximately 100%. Excretion via 
urine, exhaled air and bile was negligible at both dose levels. The bioavailability was 
calculated to be less than 1%. No study on toxicokinetics in humans was available, 
but the Committee concluded that in humans, PVA-PEG graft copolymer would 
also be expected to be mainly eliminated via the faeces and that the bioavailability 
of PVA-PEG graft copolymer would be negligible. 
 PVA-PEG graft copolymer had an LD50 of greater than 2000 mg/kg bw in 
an acute oral toxicity study in rats (Wiemann & Hellwig, 2000a). 
 In a 90-day oral toxicity study in rats (Mellert et al., 2001; published 
by Heuschmid et al., 2013b), the only treatment-related effect observed was an 
increase in water consumption in high-dose males and females. In the absence of 
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other treatment-related findings, this was not considered an adverse effect. The 
NOAEL was 1610 mg/kg bw per day, the highest dose tested. 
 In a 9-month oral toxicity study in dogs (Kaspers et al., 2002; published 
by Heuschmid et al., 2013b), an increase in mean absolute ovary weights was 
reported in all female treatment groups. These values were within the historical 
control range of the testing facility (range: 979–2258 mg; mean: 1378 mg), 
whereas the value of the control group was below the historical control range. In 
the absence of changes in the reproductive organs in rats in the above-described 
study and because no effects were seen in the reproductive toxicity study (see 
below), it was concluded that these changes were not treatment related. Therefore, 
the NOAEL was 780 mg/kg bw per day, the highest dose tested. 
 PVA-PEG graft copolymer was tested for genotoxicity in a bacterial 
reverse mutation assay (Engelhardt & Hoffmann, 2000), a gene mutation assay 
in mouse lymphoma L5178Y TK+/− cells (Engelhardt & Hildebrand, 2000a) and 
an in vivo micronucleus assay in mice using intraperitoneal administration 
(Engelhardt & Hildebrand, 2000b). All three tests gave negative results. Therefore, 
the Committee concluded that PVA-PEG graft copolymer is unlikely to be 
genotoxic. 
 PVA-PEG graft copolymer has not been tested in a long-term toxicity and 
carcinogenicity study. Given the negative genotoxicity studies, the lack of adverse 
effects in the short-term studies and the negligible bioavailability of PVA-PEG 
graft copolymer, the Committee did not consider a study of long-term toxicity 
or carcinogenicity to be necessary for the safety evaluation of PVA-PEG graft 
copolymer. 
 In a two-generation reproductive toxicity study in rats (Schneider et al., 
2003; published by Heuschmid et al., 2013c), no treatment-related effects were 
observed. The NOAEL for parental, offspring and reproductive toxicity was 1000 
mg/kg bw per day, the highest dose tested. 
 In two developmental toxicity studies, no treatment-related maternal 
or developmental effects were observed when rats (Gamer, Schneider & Van 
Ravenzwaay, 2002) or rabbits (Schneider, Hellwig & Van Ravenzwaay, 2002) 
were given PVA-PEG graft copolymer at dose levels up to 1000 mg/kg bw per 
day during gestation. In both studies, the NOAELs for maternal toxicity and for 
embryo/fetal toxicity were 1000 mg/kg bw per day, the highest dose tested. 
 The Committee noted that the use of PVA-PEG graft copolymer that 
complies with the proposed specifications could lead to exposure to vinyl 
acetate, ethylene glycol and diethylene glycol. The Committee has not previously 
evaluated the safety of vinyl acetate. In oral long-term studies of the toxicity and 
carcinogenicity of vinyl acetate in rats and mice (Maltoni et al., 1997; Minardi et 
al., 2002; Umeda et al., 2004), statistically significant increases in incidences of 
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tumours, mainly in the upper gastrointestinal tract, were observed at dose levels 
starting from 50 mg/kg bw per day (Minardi et al., 2002). 
 Diethylene glycol was evaluated by the Committee at its twenty-third 
meeting (Annex 1, reference 50). At that meeting, the Committee concluded that 
diethylene glycol was not suitable as a food additive because it produces renal 
damage, calcium oxalate stones and liver damage in a number of species, including 
humans, and is associated with bladder tumours in rats at higher levels. In view 
of the secondary nature of the bladder tumours produced and the relatively high 
levels of the substance required to produce kidney stones or liver damage, the 
Committee concluded that its presence as an impurity in food additives at low 
levels may be tolerated and that this should be evaluated on a case-by-case basis. 
Ethylene glycol has not been evaluated previously by the Committee. The SCF of 
the European Union derived a group tolerable daily intake (TDI) of 0.5 mg/kg bw 
for ethylene glycol and diethylene glycol in 1986 and confirmed it in 2002 (SCF, 
1986, 2002). 
4.2 Assessment of dietary exposure
An estimate of the theoretical dietary exposure to PVA-PEG graft copolymer was 
made by the Committee based on the estimated levels in food supplements (50 
mg PVA-PEG graft copolymer for a 1 g tablet) from its primary use as a coating 
for tablets and the assumption that the exposures to PVA-PEG graft copolymer 
from pharmaceutical products and food supplements are the same. The exposure 
from the stated minor uses as a stabilizer and binder for tablets at levels up to 
10% is expected to be covered by the conservative estimates below. If the levels 
of PVA-PEG graft copolymer in food supplements are combined with high 
consumption data for food supplements from the USA (supplied by the sponsor) 
and from the United Kingdom Food Standards Agency and if exposure to PVA-
PEG graft copolymer from pharmaceutical products is included, potential total 
dietary exposures of 25 mg/kg bw per day for adults and 40 mg/kg bw per day for 
children can be calculated. 
 If it is assumed that the impurity vinyl acetate is present in PVA-PEG graft 
copolymer at a concentration up to 20 mg/kg, dietary exposure to vinyl acetate 
from both food supplements and pharmaceutical products for high consumers 
could be up to 0.0005 mg/kg bw per day for adults and 0.0008 mg/kg bw per day 
for children.
 If it is assumed that the impurities ethylene glycol and diethylene glycol are 
present in PVA-PEG graft copolymer at a concentration up to 400 mg/kg, singly or 
in combination, dietary exposure to the glycols (singly or in combination) from 
both food supplements and pharmaceutical products for high consumers could be 
up to 0.010 mg/kg bw per day for adults and 0.016 mg/kg bw per day for children.
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 The theoretical maximum daily intakes estimated here are conservative, 
owing to the assumption that all food supplements and pharmaceutical products 
are coated with PVA-PEG graft copolymer and the fact that the exposure estimates 
are for high consumers of both food supplements and pharmaceutical products.
5. evaluation
On the basis of the available studies, in which no treatment-related effects were 
seen at the highest doses tested, the Committee considered PVA-PEG graft 
copolymer to be a substance of low oral toxicity in rats, rabbits and dogs. The 
bioavailability of PVA-PEG graft copolymer in rats is negligible, and PVA-PEG 
graft copolymer is unlikely to be genotoxic and is not associated with reproductive 
or developmental toxicity. Therefore, the Committee concluded that calculation 
of a margin of exposure for PVA-PEG graft copolymer would not be meaningful. 
 Based on these data, the Committee would normally establish an ADI 
“not specified”. However, the Committee decided not to establish an ADI “not 
specified” for PVA-PEG graft copolymer in view of the impurities present, 
some of which may also be impurities in other food additives. The Committee 
had concerns that establishing an ADI “not specified” could lead to additional 
uses beyond those considered in the present evaluation and consequently could 
increase exposure to the impurities.
 The use of PVA-PEG graft copolymer that complies with the proposed 
specifications could lead to a dietary exposure to ethylene glycol and diethylene 
glycol from both food supplements and pharmaceutical products up to 0.016 mg/
kg bw per day for children (high consumers). This is 3% of the TDI of 0.5 mg/kg 
bw per day derived by the SCF, and therefore the exposure to ethylene glycol and 
diethylene glycol from the use of PVA-PEG graft copolymer that complies with 
the specifications established at the current meeting is not of safety concern when 
the food additive is used in the applications specified. 
 The use of PVA-PEG graft copolymer that complies with the proposed 
specifications could lead to dietary exposure to vinyl acetate from both food 
supplements and pharmaceutical products up to 0.0008 mg/kg bw per day for 
children. This dietary exposure estimate is at least 62 500 times lower than the 
dose levels at which increases in tumour incidences are observed in oral long-
term studies of toxicity and carcinogenicity in rats and mice. Therefore, the 
exposure to vinyl acetate from the use of PVA-PEG graft copolymer that complies 
with the specifications established at the current meeting is not of safety concern 
when the food additive is used in the applications specified. 
 The Committee concluded that the use of PVA-PEG graft copolymer 
that complies with the specifications established at the current meeting is not of 
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safety concern when the food additive is used as a glazing agent (aqueous film 
coating), stabilizer and binder for tablets in the preparation and formulation of 
food supplements and in accordance with good manufacturing practice. 
5.1 Recommendation
The Committee noted that ethylene glycol and diethylene glycol may also be 
present as impurities in other food additives, such as polyethylene glycols and 
polysorbates, and the total exposure to these compounds from food additives 
may be higher than from PVA-PEG graft copolymer alone. Currently, only the 
specifications monograph for polyethylene glycols contains maximum limits for 
ethylene glycol and diethylene glycol (2500 mg/kg, singly or in combination). The 
Committee recommends setting and/or revising maximum limits for ethylene 
glycol and diethylene glycol that may occur as impurities in food additives at a 
future meeting. 
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report of the Joint FAO/WHO Expert Committee on Food Additives). These specifications were subsequently 
revised and published as Specifications for identity and purity of food additives, Vol. I. Antimicrobial preservatives 
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United Nations, 1963 (out of print). 
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print). 
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Nutrition Meetings Report Series, No. 38A, 1965; WHO/Food Add/24.65 (out of print). 
10. Specifications for identity and purity and toxicological evaluation of food colours. FAO Nutrition Meetings 
Report Series, No. 38B, 1966; WHO/Food Add/66.25. 
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agents. FAO Nutrition Meetings Report Series, No. 44B, 1969; WHO/Food Add/69.31. 
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(Twelfth report of the Joint FAO/WHO Expert Committee on Food Additives). FAO Nutrition Meetings Series, No. 
45, 1969; WHO Technical Report Series, No. 430, 1969. 
18. Specifications for the identity and purity of some antibiotics. FAO Nutrition Meetings Series, No. 45A, 1969; 
WHO/Food Add/69.34. 
19. Specifications for the identity and purity of food additives and their toxicological evaluation: some food colours, 
emulsifiers, stabilizers, anticaking agents, and certain other substances (Thirteenth report of the Joint FAO/
WHO Expert Committee on Food Additives). FAO Nutrition Meetings Series, No. 46, 1970; WHO Technical Report 
Series, No. 445, 1970. 
20. Toxicological evaluation of some food colours, emulsifiers, stabilizers, anticaking agents, and certain other 
substances. FAO Nutrition Meetings Report Series, No. 46A, 1970; WHO/Food Add/70.36. 
21. Specifications for the identity and purity of some food colours, emulsifiers, stabilizers, anticaking agents, and 
certain other food additives. FAO Nutrition Meetings Report Series, No. 46B, 1970; WHO/Food Add/70.37. 
22. Evaluation of food additives: specifications for the identity and purity of food additives and their toxicological 
evaluation: some extraction solvents and certain other substances; and a review of the technological efficacy of 
some antimicrobial agents (Fourteenth report of the Joint FAO/WHO Expert Committee on Food Additives). FAO 
Nutrition Meetings Series, No. 48, 1971; WHO Technical Report Series, No. 462, 1971.
23. Toxicological evaluation of some extraction solvents and certain other substances. FAO Nutrition Meetings 
Report Series, No. 48A, 1971; WHO/Food Add/70.39. 
24. Specifications for the identity and purity of some extraction solvents and certain other substances. FAO Nutrition 
Meetings Report Series, No. 48B, 1971; WHO/Food Add/70.40.
25. A review of the technological efficacy of some antimicrobial agents. FAO Nutrition Meetings Report Series, No. 
48C, 1971; WHO/Food Add/70.41. 
26. Evaluation of food additives: some enzymes, modified starches, and certain other substances: Toxicological 
evaluations and specifications and a review of the technological efficacy of some antioxidants (Fifteenth report 
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of the Joint FAO/WHO Expert Committee on Food Additives). FAO Nutrition Meetings Series, No. 50, 1972; WHO 
Technical Report Series, No. 488, 1972. 
27. Toxicological evaluation of some enzymes, modified starches, and certain other substances. FAO Nutrition 
Meetings Report Series, No. 50A, 1972; WHO Food Additives Series, No. 1, 1972. 
28. Specifications for the identity and purity of some enzymes and certain other substances. FAO Nutrition Meetings 
Report Series, No. 50B, 1972; WHO Food Additives Series, No. 2, 1972. 
29. A review of the technological efficacy of some antioxidants and synergists. FAO Nutrition Meetings Report 
Series, No. 50C, 1972; WHO Food Additives Series, No. 3, 1972. 
30. Evaluation of certain food additives and the contaminants mercury, lead, and cadmium (Sixteenth report of 
the Joint FAO/WHO Expert Committee on Food Additives). FAO Nutrition Meetings Series, No. 51, 1972; WHO 
Technical Report Series, No. 505, 1972, and corrigendum. 
31. Evaluation of mercury, lead, cadmium and the food additives amaranth, diethylpyrocarbamate, and octyl 
gallate. FAO Nutrition Meetings Report Series, No. 51A, 1972; WHO Food Additives Series, No. 4, 1972. 
32. Toxicological evaluation of certain food additives with a review of general principles and of specifications 
(Seventeenth report of the Joint FAO/WHO Expert Committee on Food Additives). FAO Nutrition Meetings Series, 
No. 53, 1974; WHO Technical Report Series, No. 539, 1974, and corrigendum (out of print). 
33. Toxicological evaluation of some food additives including anticaking agents, antimicrobials, antioxidants, 
emulsifiers, and thickening agents. FAO Nutrition Meetings Report Series, No. 53A, 1974; WHO Food Additives 
Series, No. 5, 1974.
34. Specifications for identity and purity of thickening agents, anticaking agents, antimicrobials, antioxidants and 
emulsifiers. FAO Food and Nutrition Paper, No. 4, 1978.
35. Evaluation of certain food additives (Eighteenth report of the Joint FAO/WHO Expert Committee on Food 
Additives). FAO Nutrition Meetings Series, No. 54, 1974; WHO Technical Report Series, No. 557, 1974, and 
corrigendum. 
36. Toxicological evaluation of some food colours, enzymes, flavour enhancers, thickening agents, and certain other 
food additives. FAO Nutrition Meetings Report Series, No. 54A, 1975; WHO Food Additives Series, No. 6, 1975.
37. Specifications for the identity and purity of some food colours, enhancers, thickening agents, and certain food 
additives. FAO Nutrition Meetings Report Series, No. 54B, 1975; WHO Food Additives Series, No. 7, 1975. 
38. Evaluation of certain food additives: some food colours, thickening agents, smoke condensates, and certain 
other substances (Nineteenth report of the Joint FAO/WHO Expert Committee on Food Additives). FAO Nutrition 
Meetings Series, No. 55, 1975; WHO Technical Report Series, No. 576, 1975. 
39. Toxicological evaluation of some food colours, thickening agents, and certain other substances. FAO Nutrition 
Meetings Report Series, No. 55A, 1975; WHO Food Additives Series, No. 8, 1975. 
40. Specifications for the identity and purity of certain food additives. FAO Nutrition Meetings Report Series, No. 
55B, 1976; WHO Food Additives Series, No. 9, 1976. 
41. Evaluation of certain food additives (Twentieth report of the Joint FAO/WHO Expert Committee on Food 
Additives). FAO Food and Nutrition Meetings Series, No. 1, 1976; WHO Technical Report Series, No. 599, 1976. 
42. Toxicological evaluation of certain food additives. WHO Food Additives Series, No. 10, 1976. 
43. Specifications for the identity and purity of some food additives. FAO Food and Nutrition Series, No. 1B, 1977; 
WHO Food Additives Series, No. 11, 1977. 
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44. Evaluation of certain food additives (Twenty-first report of the Joint FAO/WHO Expert Committee on Food 
Additives). WHO Technical Report Series, No. 617, 1978. 
45. Summary of toxicological data of certain food additives. WHO Food Additives Series, No. 12, 1977. 
46. Specifications for identity and purity of some food additives, including antioxidants, food colours, thickeners, 
and others. FAO Nutrition Meetings Report Series, No. 57, 1977.
47. Evaluation of certain food additives and contaminants (Twenty-second report of the Joint FAO/WHO Expert 
Committee on Food Additives). WHO Technical Report Series, No. 631, 1978. 
48. Summary of toxicological data of certain food additives and contaminants. WHO Food Additives Series, No. 13, 
1978. 
49. Specifications for the identity and purity of certain food additives. FAO Food and Nutrition Paper, No. 7, 1978. 
50. Evaluation of certain food additives (Twenty-third report of the Joint FAO/WHO Expert Committee on Food 
Additives). WHO Technical Report Series, No. 648, 1980, and corrigenda. 
51. Toxicological evaluation of certain food additives. WHO Food Additives Series, No. 14, 1980. 
52. Specifications for identity and purity of food colours, flavouring agents, and other food additives. FAO Food and 
Nutrition Paper, No. 12, 1979.
53. Evaluation of certain food additives (Twenty-fourth report of the Joint FAO/WHO Expert Committee on Food 
Additives). WHO Technical Report Series, No. 653, 1980. 
54. Toxicological evaluation of certain food additives. WHO Food Additives Series, No. 15, 1980. 
55. Specifications for identity and purity of food additives (sweetening agents, emulsifying agents, and other food 
additives). FAO Food and Nutrition Paper, No. 17, 1980.
56. Evaluation of certain food additives (Twenty-fifth report of the Joint FAO/WHO Expert Committee on Food 
Additives). WHO Technical Report Series, No. 669, 1981. 
57. Toxicological evaluation of certain food additives. WHO Food Additives Series, No. 16, 1981. 
58. Specifications for identity and purity of food additives (carrier solvents, emulsifiers and stabilizers, enzyme 
preparations, flavouring agents, food colours, sweetening agents, and other food additives). FAO Food and 
Nutrition Paper, No. 19, 1981.
59. Evaluation of certain food additives and contaminants (Twenty-sixth report of the Joint FAO/WHO Expert 
Committee on Food Additives). WHO Technical Report Series, No. 683, 1982. 
60. Toxicological evaluation of certain food additives. WHO Food Additives Series, No. 17, 1982. 
61. Specifications for the identity and purity of certain food additives. FAO Food and Nutrition Paper, No. 25, 1982. 
62. Evaluation of certain food additives and contaminants (Twenty-seventh report of the Joint FAO/WHO Expert 
Committee on Food Additives). WHO Technical Report Series, No. 696, 1983, and corrigenda. 
63. Toxicological evaluation of certain food additives and contaminants. WHO Food Additives Series, No. 18, 1983. 
64. Specifications for the identity and purity of certain food additives. FAO Food and Nutrition Paper, No. 28, 1983. 
65. Guide to specifications – General notices, general methods, identification tests, test solutions, and other 
reference materials. FAO Food and Nutrition Paper, No. 5, Rev. 1, 1983. 
66. Evaluation of certain food additives and contaminants (Twenty-eighth report of the Joint FAO/WHO Expert 
Committee on Food Additives). WHO Technical Report Series, No. 710, 1984, and corrigendum. 
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67. Toxicological evaluation of certain food additives and contaminants. WHO Food Additives Series, No. 19, 1984. 
68. Specifications for the identity and purity of food colours. FAO Food and Nutrition Paper, No. 31/1, 1984. 
69. Specifications for the identity and purity of food additives. FAO Food and Nutrition Paper, No. 31/2, 1984. 
70. Evaluation of certain food additives and contaminants (Twenty-ninth report of the Joint FAO/WHO Expert 
Committee on Food Additives). WHO Technical Report Series, No. 733, 1986, and corrigendum. 
71. Specifications for the identity and purity of certain food additives. FAO Food and Nutrition Paper, No. 34, 1986. 
72. Toxicological evaluation of certain food additives and contaminants. WHO Food Additives Series, No. 20. 
Cambridge University Press, 1987. 
73. Evaluation of certain food additives and contaminants (Thirtieth report of the Joint FAO/WHO Expert Committee 
on Food Additives). WHO Technical Report Series, No. 751, 1987. 
74. Toxicological evaluation of certain food additives and contaminants. WHO Food Additives Series, No. 21. 
Cambridge University Press, 1987. 
75. Specifications for the identity and purity of certain food additives. FAO Food and Nutrition Paper, No. 37, 1986. 
76. Principles for the safety assessment of food additives and contaminants in food. WHO Environmental Health 
Criteria, No. 70. Geneva, World Health Organization, 1987 (out of print). The full text is available electronically 
at www.who.int/pcs.
77. Evaluation of certain food additives and contaminants (Thirty-first report of the Joint FAO/WHO Expert 
Committee on Food Additives). WHO Technical Report Series, No. 759, 1987, and corrigendum. 
78. Toxicological evaluation of certain food additives. WHO Food Additives Series, No. 22. Cambridge University 
Press, 1988. 
79. Specifications for the identity and purity of certain food additives. FAO Food and Nutrition Paper, No. 38, 1988. 
80. Evaluation of certain veterinary drug residues in food (Thirty-second report of the Joint FAO/WHO Expert 
Committee on Food Additives). WHO Technical Report Series, No. 763, 1988. 
81. Toxicological evaluation of certain veterinary drug residues in food. WHO Food Additives Series, No. 23. 
Cambridge University Press, 1988. 
82. Residues of some veterinary drugs in animals and foods. FAO Food and Nutrition Paper, No. 41, 1988. 
83. Evaluation of certain food additives and contaminants (Thirty-third report of the Joint FAO/WHO Expert 
Committee on Food Additives). WHO Technical Report Series, No. 776, 1989. 
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AnneX 2
Abbreviations used in the monographs
ADI acceptable daily intake
ANCNPAS Australian National Children’s Nutrition and Physical Activity Survey
BGF beta-glucanase fungique
BMU betamyl unit
bw body weight
CCFA Codex Committee on Food Additives
CIFOCOss Chronic Individual Food Consumption Data – Summary statistics (FAO/
WHO)
CNS Children’s Nutrition Survey
DNA deoxyribonucleic acid
EDI estimated daily intake
EFSA European Food Safety Authority
Eq equivalent
f female
F0 parental generation
F1 first filial generation
F2 second filial generation
FAO Food and Agriculture Organization of the United Nations
GD gestation day
GEMS/Food Global Environment Monitoring System – Food Contamination Monitor-
ing and Assessment Programme
GLP good laboratory practice
GSFA Codex General Standard for Food Additives
HFCS high-fructose corn syrup
IARC International Agency for Research on Cancer
ICBA International Council of Beverages Associations
ICH International Conference on Harmonisation of Technical Requirements 
for Registration of Pharmaceuticals for Human Use
INS International Numbering System
JECFA Joint FAO/WHO Expert Committee on Food Additives
LB lower bound
LC50 median lethal concentration
LD50 median lethal dose
LOAEL lowest-observed-adverse-effect level
LOD limit of detection
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LOQ limit of quantification
m male
M male
NA not available
nd not detected
ND not detected
NHANES National Health and Nutrition Examination Survey
NOAEL no-observed-adverse-effect level
NOEL no-observed-effect level
OECD Organisation for Economic Co-operation and Development
OPPTS Office of Prevention, Pesticides and Toxic Substances (USEPA)
P50 50th percentile
P95 95th percentile
P97.5 97.5th percentile
PEG polyethylene glycol
PND postnatal day
PVA polyvinyl alcohol
QA quality assurance
S9 9000 × g supernatant fraction of liver homogenate
SAR Special Administrative Region
SCF Scientific Committee on Food (European Union)
TDI tolerable daily intake
TDS Total Diet Study
TIPU titratable phospholipase unit
TOS total organic solids
UB upper bound
USA United States of America
USDA United States Department of Agriculture
USEPA United States Environmental Protection Agency
WHO World Health Organization
w/v weight per volume
w/w weight per weight
XVU xylanase viscosity unit
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AnneX 3
Joint fAo/WHo expert Committee on food Additives1
Rome, 16–25 June 2015
Members
Dr D. Benford, Risk Assessment Unit, Science Evidence and Research Division, Food 
Standards Agency, London, England, United Kingdom
Dr M. DiNovi, Office of Food Additive Safety, Center for Food Safety and Applied Nutrition, 
United States Food and Drug Administration, College Park, MD, USA
Dr M. Feeley, Bureau of Chemical Safety, Food Directorate, Health Canada, Ottawa, Ontario, 
Canada
Dr D. Folmer, Office of Food Additive Safety, Center for Food Safety and Applied Nutrition, 
United States Food and Drug Administration, College Park, MD, USA 
Dr Y. Kawamura, Division of Food Additives, National Institute of Health Sciences, Tokyo, 
Japan
Dr Madduri Veerabhadra Rao, Quality Control Department, Department of the President’s 
Affairs, Al Ain, United Arab Emirates
Dr A. Mattia, Office of Food Additive Safety, Center for Food Safety and Applied Nutrition, 
United States Food and Drug Administration, College Park, MD, USA (Vice-Chairperson)
Mrs I. Meyland, Birkerød, Denmark (Chairperson)
Dr U. Mueller, Food Standards Australia New Zealand, Barton, ACT, Australia (Joint 
Rapporteur)
Dr J. Schlatter, Zurich, Switzerland
Mrs H. Wallin, Helsinki, Finland (Joint Rapporteur)
Professor G.M. Williams, Department of Pathology, New York Medical College, Valhalla, 
NY, USA
Secretariat
Dr A. Agudo, Unit of Nutrition and Cancer, Cancer Epidemiology Research Program, 
Institut Català d’Oncologia, L’Hospitalet de Llobregat, Spain (WHO Expert)
Dr B. Amzal*, LASER, United Kingdom Headquarters, London, England, United Kingdom 
(WHO Expert)
1 Participants marked with an asterisk (*) did not attend the entire meeting.
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Dr J.H. Andersen, National Food Institute, Technical University of Denmark, Søborg, 
Denmark (WHO Expert)
Dr S. Barlow, Brighton, East Sussex, England, United Kingdom (WHO Expert)
Ms A. Bruno, Joint FAO/WHO Food Standards Programme, Food and Agriculture 
Organization of the United Nations, Rome, Italy (Codex Secretariat)
Ms A.S. Bulder, Centre for Nutrition, Prevention and Health Services, National Institute for 
Public Health and the Environment (RIVM), Bilthoven, the Netherlands (WHO Expert)
Dr S. Cahill, Food Safety and Quality Unit, Agriculture and Consumer Protection 
Department, Food and Agriculture Organization of the United Nations, Rome, Italy 
(FAO Secretariat)
Dr R. Cantrill, AOCS, Urbana, IL, USA (FAO Expert)
Mr P. Cressey, Risk and Response Group, ESR (Institute of Environmental Science and 
Research Ltd), Christchurch, New Zealand (FAO Expert)
Dr M. De Nijs, RIKILT Wageningen UR, Wageningen, the Netherlands (FAO Expert)
Dr E. Dessipri, General Chemical State Laboratory, Athens, Greece (FAO Expert)
Dr J.A. Edgar, CSIRO Food and Nutritional Sciences, North Ryde, NSW, Australia (FAO Expert)
Dr V. Fattori, Agriculture and Consumer Protection Department, Food and Agriculture 
Organization of the United Nations, Rome, Italy (FAO Joint Secretary)
Professor H. Håkansson, Institute of Environmental Medicine, Karolinska Institutet, 
Stockholm, Sweden (WHO Expert)
Ms T. Hambridge, Food Data Analysis Section, Food Standards Australia New Zealand, 
Barton, ACT, Australia (WHO Expert)
Dr S.M.F. Jeurissen, Centre for Nutrition, Prevention and Health Services, National Institute 
for Public Health and the Environment (RIVM), Bilthoven, the Netherlands (WHO 
Expert)
Professor F. Kayama, Department of Environmental & Preventive Medicine, School of 
Medicine, Jichi Medical University, Yakushiji, Shimotsuke-shi, Tochigi-ken, Japan (WHO 
Expert)
Mr J. Kim, Department of Food Safety and Zoonoses, World Health Organization, Geneva, 
Switzerland (WHO Secretariat)
Dr J.C. Leblanc, Food Safety and Quality Unit, Agriculture and Consumer Protection 
Department, Food and Agriculture Organization of the United Nations, Rome, Italy 
(FAO Secretariat) 
Dr T. Rawn, Food Research Division, Health Canada, Ottawa, Ontario, Canada (FAO Expert)
Dr K. Schneider, Forschungs- und Beratungsinstitut Gefahrstoffe GmbH (FoBiG), Freiburg, 
Germany (WHO Expert)
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Ms M. Sheffer, Orleans, Ontario, Canada (WHO Technical Editor)
Dr J.R. Srinivasan, Office of Food Additive Safety, Center for Food Safety and Applied 
Nutrition, United States Food and Drug Administration, College Park, MD, USA (FAO 
Expert)
Professor I. Stankovic, Department of Bromatology, Faculty of Pharmacy, University of 
Belgrade, Belgrade, Serbia (FAO Expert)
Dr A. Tritscher, Department of Food Safety and Zoonoses, World Health Organization, 
Geneva, Switzerland (WHO Joint Secretary)
Dr T. Umemura, Division of Pathology, Biological Safety Research Center, National Institute 
of Health Sciences, Tokyo, Japan (WHO Expert)
Professor Dr M. Van den Berg*, Toxicology and Veterinary Pharmacology Division, Institute 
for Risk Assessment Sciences, Utrecht University, Utrecht, the Netherlands (WHO 
Expert)
Dr Y. Wu, China National Center for Food Safety Risk Assessment, Beijing, China (FAO 
Expert)
Dr X. Yang, Guangdong Provincial Center for Disease Control and Prevention, Guangzhou, 
Guangdong Province, China (WHO Expert)
Dr H.J. Yoon, Food Contaminants Division, Food Safety Evaluation Department, Ministry 
of Food and Drug Safety, Cheongwon-gun, Chungcheongbuk-do, Republic of Korea 
(FAO Expert)
Dr Y. Zang, Office of Food Additive Safety, Center for Food Safety and Applied Nutrition, 
United States Food and Drug Administration, College Park, MD, USA (WHO Expert)
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Food additive Specifications
Advantame Ra
Aluminium silicate Wb
Annatto extract (solvent-extracted bixin) Rc
Annatto extract (solvent-extracted norbixin) Rc
Calcium aluminium silicate Wb
Calcium silicate Rd
Glycerol ester of gum rosin Wb
Silicon dioxide, amorphous R, Te
Sodium aluminium silicate R, Tf
R: existing specifications revised; T: tentative specifications; W: tentative specifications withdrawn
a The requested information was received, and the method of assay was revised. The tentative status of the specifications was removed.
b The requested information was not received.
c The specifications were revised to reflect the modification of the method for residual solvents by headspace gas chromatography and to include sample and standard 
preparation information.
d The requested information was received, and the specifications were revised to include information on functional uses, pH, loss on drying, loss on ignition, impurities 
soluble in 0.5 M hydrochloric acid and the assay. The tentative status of the specifications was removed
e Limited information was received. The specifications were revised to include information on pH, loss on drying, loss on ignition, impurities (lead and arsenic) soluble 
in 0.5 M hydrochloric acid and the assay for some forms of silicon dioxide. The tentative status of the specifications was maintained, and information was requested 
in order for the tentative specifications to be revised. 
f Limited information was received. The specifications were revised to include information on Chemical Abstracts Service number, chemical formula, pH, loss on 
drying, loss on ignition and limits on impurities (lead and arsenic) soluble in 0.5 M hydrochloric acid. The tentative status of the specifications was maintained, and 
information was requested in order for the tentative specifications to be revised. 
AnneX 4
toxicological and dietary exposure information and 
information on specifications
Food additives considered for specifications only
Food additives evaluated toxicologically and/or assessed for dietary exposure
Food additive Specifications
Acceptable daily intakes (ADIs) and other toxicological or safety 
recommendations and dietary exposure information
Benzoates: dietary exposure 
assessment
NA Based on the available data set, the Committee noted that there is 
consistency in the average typical range of concentrations for benzoates 
reported to be used or analysed in non-alcoholic (“soft”) beverages (Codex 
General Standard for Food Additives [GSFA] food category 14.1). For 
example, typical reported concentrations from industries ranged from 83 
to 209 mg/L for water-based flavoured drinks (food category 14.1.4), and 
analytically quantified measurements ranged from 63 to 259 mg/L for 
non-alcoholic beverages (food category 14.1). These levels are lower than 
national maximum limits (150–400 mg/L) or limits for GSFA food category 
14.1.4 (600 mg/L). The Committee also noted that most of the reported 
estimates for mean and high percentile per capita benzoate exposure were 
below the upper bound of the ADI of 0–5 mg/kg body weight (bw), ex-
pressed as benzoic acid, despite different methodologies and assumptions 
applied in the preparation of the exposure estimates.
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Food additives evaluated toxicologically and/or assessed for dietary exposure (continued)
Food additive Specifications
Acceptable daily intakes (ADIs) and other toxicological or safety 
recommendations and dietary exposure information
None of the mean exposure estimates for consumers of non-alcoholic 
(“soft”) beverages exceeded the upper bound of the ADI: 0.3–4.1 mg/kg 
bw per day for toddlers and young children, 0.2–2.7 mg/kg bw per day for 
other children, including adolescents, and 0.1–1.7 mg/kg bw per day for 
adults. However, the Committee noted that the 95th percentile exposures 
for the consumers-only group exceeded the upper bound of the ADI in 
some cases: up to 10.9 mg/kg bw per day for toddlers and young children 
and up to 7.0 mg/kg bw per day for other children, including adolescents. 
Additionally, the Committee noted that in some countries, the overall di-
etary exposure to benzoates for toddlers, young children and adolescents 
also exceeds the upper bound of the ADI at the high percentiles. Reduction 
of those exposures exceeding the upper bound of the ADI would require 
consideration of dietary patterns for both beverage and non-beverage 
foods containing benzoates and typical/allowed benzoate use levels in 
those countries.
Lipase from Fusarium heterosporum 
expressed in Ogataea polymorpha
N No treatment-related adverse effects were seen at the highest dose tested 
(669 mg total organic solids [TOS]/kg bw per day) in a 13-week study of 
oral toxicity in rats. A comparison of the dietary exposure estimate of 0.5 
mg TOS/kg bw per day (for a 60 kg individual) with the highest dose tested 
of 669 mg TOS/kg bw per day results in a margin of exposure (MOE) of at 
least 1300. 
The Committee established an ADI “not specified”a for lipase from 
F. heterosporum expressed in O. polymorpha when used in the 
applications specified and in accordance with good manufacturing 
practice. 
Magnesium stearate N The Committee estimated the potential total dietary exposure to magne-
sium stearate based on the proposed maximum use levels: 44 mg/kg bw 
per day for children and 83 mg/kg bw per day for adults, corresponding to 
2 and 4 mg/kg bw per day, expressed as magnesium, respectively. These 
dietary exposures would contribute up to an additional 250 mg/day to the 
background exposure to magnesium from food of 180–480 mg/day. The 
Committee noted that the consumption of the food additive may lead to 
an additional dietary exposure to stearic and palmitic acids in the order of 
5 g/day.
An ADI “not specified”a has previously been established for a number of 
magnesium salts used as food additives. The Committee concluded that 
there are no differences in the evaluation of the toxicity of magnesium stea-
rate compared with other magnesium salts. The Committee confirmed 
the ADI “not specified” for magnesium salts of stearic and palmitic 
acids. However, the Committee was concerned that the use of magnesium 
salts in many food additives may result in combined exposure that could 
lead to a laxative effect. Therefore, the Committee reiterated its previous 
recommendation to undertake an exposure assessment for magnesium 
from use of food additives. 
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Food additive Specifications
Acceptable daily intakes (ADIs) and other toxicological or safety 
recommendations and dietary exposure information
Maltotetraohydrolase from 
Pseudomonas stutzeri expressed in 
Bacillus licheniformis
N No treatment-related adverse effects were seen at the highest dose tested 
(93 mg TOS/kg bw per day) in a 13-week study of oral toxicity in rats. A 
comparison of the dietary exposure estimate of 0.1 mg TOS/kg bw per day 
(for a 60 kg individual) with the highest dose tested of 93 mg TOS/kg bw per 
day results in an MOE of at least 900. 
The Committee established an ADI “not specified”a for malto- 
tetraohydrolase from P. stutzeri expressed in B. licheniformis when 
used in the applications specified and in accordance with good 
manufacturing practice.
Mixed β-glucanase, cellulase and 
xylanase from Rasamsonia emersonii
N, Tb No treatment-related adverse effects were seen at the highest dose tested 
(84.8 mg TOS/kg bw per day) in a 13-week study of oral toxicity in rats. A 
comparison of the dietary exposure estimate of 0.08 mg TOS/kg bw per day 
(for a 60 kg individual) with the highest dose tested of 84.8 mg TOS/kg bw 
per day results in an MOE of at least 1000. 
The Committee established an ADI “not specified”a for the mixed 
β-glucanase, cellulase and xylanase enzyme preparation from R. 
emersonii when used in the applications specified and in accord-
ance with good manufacturing practice. 
Mixed β-glucanase and 
xylanase from Disporotrichum 
dimorphosporum
N, Tb No treatment-related adverse effects were seen at the highest dose tested 
(199 mg TOS/kg bw per day) in a 13-week study of oral toxicity in rats. A 
comparison of the dietary exposure estimate of 0.7 mg TOS/kg bw per day 
(for a 60 kg individual) with the highest dose tested of 199 mg TOS/kg bw 
per day gives an MOE of at least 280.
The Committee established an ADI “not specified”a for the 
mixed β-glucanase and xylanase enzyme preparation from D. 
dimorphosporum when used in the applications specified and in 
accordance with good manufacturing practice. 
Polyvinyl alcohol (PVA) –  
polyethylene glycol (PEG) graft 
copolymer
N On the basis of the available studies, in which no treatment-related effects 
were seen at the highest doses tested, the Committee considered PVA-PEG 
graft copolymer to be a substance of low oral toxicity in rats, rabbits and 
dogs. The bioavailability of PVA-PEG graft copolymer in rats is negligible, 
and PVA-PEG graft copolymer is unlikely to be genotoxic and is not associ-
ated with reproductive or developmental toxicity. Therefore, the Committee 
concluded that calculation of an MOE for PVA-PEG graft copolymer would 
not be meaningful. 
Based on these data, the Committee would normally establish an ADI 
“not specified”. However, the Committee decided not to establish an ADI 
“not specified” for PVA-PEG graft copolymer in view of the impurities 
present, some of which may also be impurities in other food additives. The 
Committee had concerns that establishing an ADI “not specified” could lead 
to additional uses beyond those considered at the current meeting and 
consequently could increase exposure to the impurities.
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Food additives evaluated toxicologically and/or assessed for dietary exposure (continued)
Food additive Specifications
Acceptable daily intakes (ADIs) and other toxicological or safety 
recommendations and dietary exposure information
The use of PVA-PEG graft copolymer that complies with the proposed 
specifications could lead to a dietary exposure to ethylene glycol and 
diethylene glycol from both food supplements and pharmaceutical products 
up to 0.016 mg/kg bw per day for children (high consumers). This is 3% 
of the tolerable daily intake (TDI) of 0.5 mg/kg bw per day derived by the 
Scientific Committee on Food of the European Union, and therefore the 
exposure to ethylene glycol and diethylene glycol from the use of PVA-PEG 
graft copolymer that complies with the specifications established at the 
current meeting is not of safety concern when the food additive is used in 
the applications specified. 
The use of PVA-PEG graft copolymer that complies with the proposed 
specifications could lead to a dietary exposure to vinyl acetate from both 
food supplements and pharmaceutical products up to 0.0008 mg/kg bw per 
day for children. This dietary exposure estimate is at least 62 500 times lower 
than the dose levels at which increases in tumour incidence are observed 
in oral studies of long-term toxicity and carcinogenicity in rats and mice. 
Therefore, the dietary exposure to vinyl acetate from the use of PVA-PEG 
graft copolymer that complies with the specifications established at the 
current meeting is not of safety concern when the food additive is used in 
the applications specified. 
The Committee concluded that the use of PVA-PEG graft copolymer 
that complies with the specifications established at the current 
meeting is not of safety concern when the food additive is used as 
a glazing agent (aqueous film coating), stabilizer and binder for 
tablets in the preparation and formulation of food supplements 
and in accordance with good manufacturing practice. 
N: new specifications; NA: not applicable (dietary exposure assessment only); T: tentative specifications
a ADI “not specified” is used to refer to a food substance of very low toxicity that, on the basis of the available data (chemical, biochemical, toxicological and other) and 
the total dietary exposure to the substance arising from its use at the levels necessary to achieve the desired effects and from its acceptable background levels in food, 
does not, in the opinion of the Committee, represent a hazard to health. For that reason, and for the reasons stated in the individual evaluations, the establishment 
of an ADI expressed in numerical form is not deemed necessary. An additive meeting this criterion must be used within the bounds of good manufacturing practice 
– i.e. it should be technologically efficacious and should be used at the lowest level necessary to achieve this effect, it should not conceal food of inferior quality or 
adulterated food, and it should not create a nutritional imbalance.
b Information is required in order for the tentative specifications to be revised.

This volume contains monographs prepared at the eight-
ieth meeting of the Joint FAO/WHO Expert Committee 
on Food Additives (JECFA), which met in Rome, Italy, 
from 16 to 25 June 2015.
The toxicological and dietary exposure monographs in 
this volume summarize the safety and/or dietary expo-
sure data on seven food additives (benzoates: dietary 
exposure assessment; lipase from Fusarium heterosporum 
expressed in Ogataea polymorpha; magnesium stea-
rate; maltotetraohydrolase from Pseudomonas stutzeri 
expressed in Bacillus licheniformis; mixed β-glucanase, 
cellulase and xylanase from Rasamsonia emersonii; 
mixed β-glucanase and xylanase from Disporotrichum 
dimorphosporum; and polyvinyl alcohol (PVA) – poly-
ethylene glycol (PEG) graft copolymer). Monographs on 
two contaminant groups (non-dioxin-like polychlorinated 
biphenyls and pyrrolizidine alkaloids) discussed at the 
eightieth meeting will be published as separate supple-
ments in the WHO Food Additives series.
This volume and others in the WHO Food Additives series 
contain information that is useful to those who produce 
and use food additives and veterinary drugs and those 
involved with controlling contaminants in food, govern-
ment and food regulatory officers, industrial testing 
laboratories, toxicological laboratories and universities.
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